P0DTC2 (SPIKE_SARS2) Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2)
Spike glycoprotein UniProtKBInterProInteractive Modelling
1273 aa; Sequence (Fasta) ;
2 identical sequences: Severe acute respiratory syndrome coronavirus 2: A0A6G7K2L4, A0A679G9E9
It is possible new templates exist for this target since these models were created.
Available Structures
1958 Experimental Structures
| Description | PDB ID | Oligo-state | Range | Seq id (%) | Ligands | |
|---|---|---|---|---|---|---|
| Neutral Omicron Spike Trimer in complex with ACE2 |
Heteromer Q9BYF1; | 98.18 | 16×NAG; 5×NAG; 34×NAG; | |||
| Cryo-EM structure of the SARS-CoV-2 spike protein (2-up RBD) bound to neutralizing nanobodies P86 |
Heteromer | 99.73 | 17×NAG; 3×NAG; 6×NAG; 30×NAG; | |||
| SARS-CoV-2 Omicron variant spike protein in complex with two XGv347 binding to one close state RBD … |
Heteromer | 98.18 | 15×NAG; 5×NAG; 29×NAG; | |||
| SARS-CoV-2 Omicron variant spike in complex with Fab 9A8 (State 1) |
Heteromer | 98.18 | 1×NAG; 3×NAG; 41×NAG; | |||
| SARS-CoV-2 Omicron variant spike protein with two XGv347 binding to two open state RBDs |
Heteromer | 98.18 | 15×NAG; 5×NAG; 29×NAG; | |||
| SARS-CoV-2 Omicron variant spike protein with three XGv347 Fabs binding to three closed state RBDs |
Heteromer | 98.18 | 16×NAG; 5×NAG; 31×NAG; | |||
| SARS-CoV-2 Omicron variant spike in complex with Fab XGv264 |
Heteromer | 98.18 | 36×NAG; | |||
| SARS-CoV-2 Omicron variant spike in complex with Fab XGv286 |
Heteromer | 98.18 | 12×NAG; 6×NAG; 28×NAG; | |||
| SARS-CoV-2 Omicron variant spike in complex with Fab 9A8 (State 2) |
Heteromer | 98.18 | 16×NAG; 31×NAG; | |||
| SARS-CoV-2 Omicron variant spike protein in complex with Fab XGv265 |
Heteromer | 98.18 | 14×NAG; 5×NAG; 26×NAG; | |||
| SARS-CoV-2 Omicron variant spike protein in complex with Fab XGv289 |
Heteromer | 98.18 | 15×NAG; 5×NAG; 27×NAG; | |||
| SARS-CoV-2 Omicron variant spike in complex with Fab XGv051 |
Heteromer | 98.18 | 15×NAG; 5×NAG; 30×NAG; | |||
| SARS-CoV-2 Omicron variant spike protein in complex with Fab XGv282 |
Heteromer | 98.18 | 16×NAG; 5×NAG; 27×NAG; | |||
| 17b10 fab in complex with full-length SARS-CoV-2 Spike G614 trimer |
Heteromer | 99.91 | 24×NAG; 3×NAG; 5×NAG; 25×NAG; | |||
| Three RBD-down state of SARS-CoV-2 D614G spike in complex with the SP1-77 neutralizing antibody Fab… |
Heteromer | 99.91 | 6×NAG; 24×NAG; 6×NAG; 21×NAG; | |||
| An antibody from single human VH-rearranging mouse neutralizes all SARS-CoV-2 variants through BA.5… |
Heteromer | 99.91 | 16×NAG; 12×NAG; 6×NAG; 23×NAG; | |||
| SARS-CoV-2 spike protein in complex with ACE2, Beta variant, C2B state |
Heteromer Q9BYF1; | 98.64 | ||||
| SARS-CoV-2 spike protein in complex with ACE2, Beta variant, C2A state |
Heteromer Q9BYF1; | 98.64 | ||||
| SARS-CoV-2 spike protein in complex with ACE2, Beta variant, C3 state |
Heteromer Q9BYF1; | 98.64 | ||||
| SARS-CoV-2 spike protein in complex with ACE2, Beta variant, C1 state |
Heteromer Q9BYF1; | 98.64 | ||||
| SARS-CoV-2 Beta spike in complex with two S3H3 Fabs |
Heteromer | 98.64 | ||||
| SARS-CoV-2 Beta spike in complex with two S5D2 Fabs |
Heteromer | 98.64 | ||||
| SARS-CoV-2 Beta spike in complex with three S5D2 Fabs |
Heteromer | 98.64 | ||||
| SARS-CoV-2 Beta spike in complex with one S5D2 Fab |
Heteromer | 98.64 | ||||
| SARS-CoV-2 Beta spike in complex with three S3H3 Fabs |
Heteromer | 98.64 | ||||
| Camel nanobodies 7A3 and 8A2 broadly neutralize SARS-CoV-2 variants |
Heteromer | 99.21 | ||||
| Cryo-EM structure of SARS-CoV-2 spike in complex with antibodies B1-182.1 and A19-61.1 |
Heteromer | 99.82 | 9×NAG; 25×NAG; | |||
| SARS-CoV-2 spike protein complexed with two nanobodies |
Heteromer | 99.53 | 6×NAG; 25×NAG; | |||
| SARS-Cov2 S protein structure in complex with neutralizing monoclonal antibody 034_32 |
Heteromer | 99.45 | 12×NAG; 23×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 spike in complex with neutralizing antibody A23-58.1 that targets t… |
Heteromer | 99.45 | 4×NAG; 15×NAG; 3×NAG; 27×NAG; | |||
| SARS-Cov2 S protein structure in complex with neutralizing monoclonal antibody 002-13 |
Heteromer | 99.45 | 15×NAG; 29×NAG; | |||
| SARS-Cov2 S protein structure in complex with neutralizing monoclonal antibody 002-S21F2 |
Heteromer | 99.53 | 5×NAG; 22×NAG; | |||
| SARS-CoV-2 spike protein trimer (down conformation) bound with a nanobody |
Heteromer | 99.53 | 6×NAG; 25×NAG; | |||
| SARS-CoV-2 spike protein bound with a nanobody |
Heteromer | 99.45 | 5×NAG; 24×NAG; | |||
| SARS-Cov2 S protein structure in complex with neutralizing monoclonal antibody 002-02 |
Heteromer | 99.45 | 14×NAG; 1×NAG; 23×NAG; | |||
| SARS-Cov2 S protein structure in complex with neutralizing monoclonal antibody 002-S21B10 |
Heteromer | 99.53 | 4×NAG; 28×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 spike in complex with neutralizing antibody B1-182.1 that targets t… |
Heteromer | 99.45 | 13×NAG; 1×NAG; 27×NAG; | |||
| OMI-38 FAB IN COMPLEX WITH SARS-COV-2 BETA SPIKE |
Heteromer | 98.64 | 12×NAG; 28×NAG; | |||
| COVOX-222 fab in complex with SARS-CoV-2 beta-Spike glycoprotein |
Heteromer | 98.64 | 12×NAG; 28×NAG; | |||
| SARS-CoV-2 Spike protein in complex with a pan-sarbecovirus nanobody 1-8 |
Heteromer | 99.82 | 4×NAG; 7×NAG; 1×NAG; 7×NAG; 1×NAG; 1×NAG; 1×NAG; 32×NAG; 1×AH2; | |||
| SARS-CoV-2 Spike protein in complex with a pan-sarbecovirus nanobody 2-34 |
Heteromer | 99.82 | ||||
| OMI-2 FAB IN COMPLEX WITH SARS-COV-2 BETA SPIKE GLYCOPROTEIN |
Heteromer | 98.64 | 12×NAG; 30×NAG; | |||
| Beta-43 fab in complex with SARS-CoV-2 beta-Spike glycoprotein |
Heteromer | 98.64 | 12×NAG; 29×NAG; | |||
| OMI-42 FAB IN COMPLEX WITH SARS-COV-2 BETA SPIKE GLYCOPROTEIN |
Heteromer | 98.64 | 12×NAG; 30×NAG; | |||
| Beta-06 fab in complex with SARS-CoV-2 beta-Spike glycoprotein |
Heteromer | 98.55 | 12×NAG; 28×NAG; | |||
| Cryo-EM structure of the SARS-CoV-2 D614G,N501Y,E484K mutant spike protein ectodomain bound to huma… |
Heteromer Q9BYF1; | 99.17 | 18×NAG; 26×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 Alpha (B.1.1.7) spike protein in complex with human ACE2 |
Heteromer Q9BYF1; | 98.69 | 18×NAG; 28×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 Epsilon (B.1.429) spike protein in complex with human ACE2 |
Heteromer Q9BYF1; | 99.23 | 18×NAG; 36×NAG; | |||
| Cryo-EM structure of the SARS-CoV-2 N501Y mutant spike protein ectodomain bound to human ACE2 ectod… |
Heteromer Q9BYF1; | 99.33 | 18×NAG; 32×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 XBB.1.5 spike protein in complex with human ACE2 |
Heteromer Q9BYF1; | 90.0 | 24×NAG; 33×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 Kappa (B.1.617.1) spike protein in complex with human ACE2 |
Heteromer Q9BYF1; | 99.04 | 18×NAG; 26×NAG; | |||
| SARS-CoV-2 Delta S-ACE2-C3 |
Heteromer Q9BYF1; | 99.25 | ||||
| Cryo-EM structure of mink variant Y453F trimeric spike protein bound to one mink ACE2 receptors |
Heteromer A0A7T0Q2W2; | 100 | ||||
| Cryo-EM structure of SARS-CoV-2 Omicron spike protein (S-6P-RRAR) in complex with human ACE2 ectodo… |
Heteromer Q9BYF1; | 98.18 | 22×NAG; 23×NAG; 1×ZN; | |||
| Cryo-EM structure of SARS-CoV-2 Omicron BA.1 spike protein in complex with mouse ACE2 |
Heteromer Q8R0I0; | 98.18 | 18×NAG; 26×NAG; | |||
| SARS-CoV-2 Delta S-ACE2-C1 |
Heteromer Q9BYF1; | 99.25 | ||||
| Cryo-EM structure of SARS-CoV-2 Beta (B.1.351) spike protein in complex with human ACE2 |
Heteromer Q9BYF1; | 98.69 | 18×NAG; 26×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 Omicron Spike protein with human ACE2 receptor, C2 state |
Heteromer Q9BYF1; | 98.18 | ||||
| Cryo-EM structure of SARS-CoV-2 Gamma (P.1) spike protein in complex with human ACE2 |
Heteromer Q9BYF1; | 98.36 | 18×NAG; 42×NAG; | |||
| Cryo-EM structure of the SARS-CoV-2 D614G,N501Y mutant spike protein ectodomain bound to human ACE2… |
Heteromer Q9BYF1; | 99.17 | 18×NAG; 28×NAG; | |||
| Cryo-EM structure of hACE2-bound SARS-CoV-2 Omicron spike protein with L371S, P373S and F375S mutat… |
Heteromer Q9BYF1; | 98.18 | 15×NAG; 33×NAG; 3×ZN; | |||
| Cryo-EM structure of SARS-CoV-2 prototype spike protein in complex with white-tailed deer ACE2 |
Heteromer A0A6J0Z472; | 99.43 | 21×NAG; 23×NAG; 1×ZN; | |||
| Cryo-EM structure of Omicron S-ACE2, C2 state |
Heteromer Q9BYF1; | 98.18 | ||||
| Cryo-EM structure of SARS-CoV-2 Omicron BA.2 spike protein in complex with human ACE2 |
Heteromer Q9BYF1; | 90.0 | 18×NAG; 33×NAG; | |||
| SARS-CoV-2 S-ACE2 complex |
Heteromer Q9BYF1; | 99.81 | 18×NAG; 36×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 XBB.1.5 spike protein in complex with mouse ACE2 (conformation 2) |
Heteromer Q8R0I0; | 90.0 | 20×NAG; 2×NAG; 21×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 Omicron Spike protein with human ACE2 receptor, C3 state |
Heteromer Q9BYF1; | 98.18 | ||||
| SARS-CoV-2 Delta S-ACE2-C2a |
Heteromer Q9BYF1; | 99.25 | ||||
| Cryo-EM structure of the SARS-CoV-2 D614G,N501Y,E484K,K417T mutant spike protein ectodomain bound t… |
Heteromer Q9BYF1; | 99.17 | 18×NAG; 28×NAG; | |||
| Structures of Omicron Spike complexes illuminate broad-spectrum neutralizing antibody development |
Heteromer Q9BYF1; | 98.18 | 14×NAG; 20×NAG; | |||
| Cryo-EM structure of the SARS-CoV-2 D614G mutant spike protein ectodomain bound to human ACE2 ectod… |
Heteromer Q9BYF1; | 99.17 | 18×NAG; 26×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 Omicron BA.2 spike protein in complex with mouse ACE2 |
Heteromer Q8R0I0; | 90.0 | 18×NAG; 25×NAG; | |||
| SARS-CoV-2 Delta S-ACE2-C2b |
Heteromer Q9BYF1; | 99.25 | ||||
| Structures of Omicron Spike complexes illuminate broad-spectrum neutralizing antibody development |
Heteromer Q9BYF1; | 98.18 | 14×NAG; 12×NAG; | |||
| Cryo-EM structure of the SARS-CoV-2 D614G,N501Y,E484K,K417N mutant spike protein ectodomain bound t… |
Heteromer Q9BYF1; | 99.04 | 18×NAG; 42×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 Omicron spike protein with ACE2, C1 state |
Heteromer Q9BYF1; | 98.18 | ||||
| Cryo-EM structure of SARS-CoV-2 Delta (B.1.617.2) spike protein in complex with human ACE2 |
Heteromer Q9BYF1; | 98.41 | 18×NAG; 26×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 Omicron BA.1 spike protein in complex with white-tailed deer ACE2 |
Heteromer A0A6J0Z472; | 98.18 | 17×NAG; 1×NAG; 31×NAG; 1×ZN; | |||
| SARS-CoV-2 Kappa variant spike protein in complex with ACE2, state C2a |
Heteromer Q9BYF1; | 99.34 | ||||
| Cryo-EM structure of the SARS-CoV-2 D614G,L452R mutant spike protein ectodomain bound to human ACE2… |
Heteromer Q9BYF1; | 99.17 | 18×NAG; 28×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 Omicron spike protein (S-6P-RRAR) in complex with human ACE2 ectodo… |
Heteromer Q9BYF1; | 98.18 | 23×NAG; 24×NAG; 2×ZN; | |||
| Furin Site deletion of SARS-CoV-2 spike |
Heteromer | 100.0 | ||||
| Cryo-EM structure of SARS-CoV-2 Omicron spike protein in complex with human ACE2 |
Heteromer Q9BYF1; | 98.18 | 18×NAG; 34×NAG; | |||
| SARS-CoV-2 Omicron BA.1 spike trimer (6P) in complex with 3 YB13-292 Fabs (1 RBD up) |
Heteromer | 98.18 | 12×NAG; 30×NAG; | |||
| Cryo-EM structure of the SARS-CoV-2 N501Y mutant spike protein ectodomain bound to VH ab8 |
Heteromer | 99.33 | 18×NAG; 24×NAG; | |||
| The state 1 complex structure of Omicron spike with Bn03 (1-up RBD, 3 nanobodies) |
Heteromer | 98.18 | 40×NAG; | |||
| Cryo-EM structure of the SARS-CoV-2 N501Y mutant spike protein ectodomain bound to Fab ab1 (class 1) |
Heteromer | 99.33 | 18×NAG; 24×NAG; | |||
| Cryo-EM structure of NTD-directed neutralizing antibody 4-18 in complex with prefusion SARS-CoV-2 s… |
Heteromer | 99.82 | 24×NAG; 30×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 Omicron BA.2 spike protein in complex with Fab 4A8 |
Heteromer | 90.0 | 18×NAG; 21×NAG; | |||
| SARS-CoV-2 Omicron BA.1 spike trimer (6P) in complex with 1 YB9-258 Fab (1 RBD up) |
Heteromer | 98.18 | 12×NAG; 30×NAG; | |||
| SARS-CoV-2 spike/Nb6 complex |
Heteromer | 99.35 | 11×NAG; 39×NAG; | |||
| EM structure of SARS-CoV-2 Spike glycoprotein (all RBD down) in complex with COVOX-159 |
Heteromer | 99.81 | 15×NAG; 24×NAG; | |||
| SARS-CoV-2 Omicron open state spike protein in complex with S3H3 Fab |
Heteromer | 98.18 | ||||
| Cryo-EM structure of SARS-CoV-2 Omicron BA.2 S-trimer in complex with fab L4.65 and L5.34 |
Heteromer | 90.0 | 32×NAG; | |||
| Cryo-EM structure of the SARS-CoV-2 N501Y mutant spike protein ectodomain bound to Fab ab1 (class 2) |
Heteromer | 99.33 | 18×NAG; 24×NAG; | |||
| The state 3 complex structure of Omicron spike with Bn03 (2-up RBD, 5 nanobodies) |
Heteromer | 98.18 | 28×NAG; | |||
| S-3C1-F1 structure, one RBD is up and two RBDs are down, the up RBD binds with a 3C1 fab |
Heteromer | 99.81 | ||||
| Cryo-EM structure of SARS-CoV-2 prototype spike protein in complex with hippopotamus ACE2 |
Heteromer | 99.43 | 12×NAG; 25×NAG; 1×ZN; | |||
| SARS-CoV-2 spike/nanobody mixture complex |
Heteromer | 99.35 | 12×NAG; 45×NAG; | |||
| S-2H2-F1 structure, one RBD is up and two RBDs are down, only up RBD binds with a 2H2 Fab |
Heteromer | 99.81 | ||||
| SARS-CoV-2 spike/Nb3 complex with 1 RBD up and 2 Nb3 |
Heteromer | 99.35 | 11×NAG; 25×NAG; | |||
| P17-H014 Fab cocktail in complex with SARS-CoV-2 spike protein |
Heteromer | 100.0 | 15×NAG; 16×NAG; | |||
| SARS-CoV-2 Omicron BA.1 spike trimer (6P) in complex with 3 YB13-292 Fabs (3 RBD down) |
Heteromer | 98.18 | 12×NAG; 30×NAG; | |||
| SARS-CoV-2 Spike Proteins Trimer in Complex with FC05 and H014 Fabs Cocktail |
Heteromer | 100.0 | 15×NAG; 16×NAG; | |||
| Cryo-EM structure of RBD-directed neutralizing antibody P2B4 in complex with prefusion SARS-CoV-2 s… |
Heteromer | 99.8 | 44×NAG; | |||
| Cryo-EM structure of NTD-directed neutralizing antibody 2-17 Fab in complex with SARS-CoV-2 S2P spi… |
Heteromer | 99.81 | 26×NAG; | |||
| S-2H2-F2 structure, two RBDs are up and one RBD is down, each up RBD binds with a 2H2 Fab. |
Heteromer | 99.81 | ||||
| Cryo-EM structure of SARS-CoV-2 Epsilon (B.1.429) spike protein in complex with VH ab6 |
Heteromer | 99.2 | 18×NAG; 23×NAG; | |||
| SARS-CoV-2 Delta S-8D3 |
Heteromer | 99.25 | ||||
| Cryo-EM structure of SARS-CoV-2 D614G spike protein in complex with VH ab6 |
Heteromer | 99.17 | 18×NAG; 21×NAG; | |||
| Complex of SARS-CoV-2 spike protein and Fab P17 with one RBD in open state and two RBD in closed st… |
Heteromer | 100.0 | 14×NAG; 16×NAG; | |||
| SARS-CoV-2 spike/Nb4 complex with 2 RBDs up and 3 Nb4 bound |
Heteromer | 99.35 | 11×NAG; 25×NAG; | |||
| Cryo-EM structure of NTD-directed neutralizing antibody 5-24 in complex with prefusion SARS-CoV-2 s… |
Heteromer | 99.82 | 16×NAG; 2×NAG; 36×NAG; | |||
| Structure of the SARS-CoV-2 spike glycoprotein in complex with the 87G7 antibody Fab fragment |
Heteromer | 99.43 | 12×NAG; 27×NAG; | |||
| CC6.33 IgG in complex with SARS-CoV-2-6P-Mut7 S protein (non-uniform refinement) |
Heteromer | 99.25 | 5×NAG; 1×NAG; 29×NAG; | |||
| Structure of the SARS-CoV-2 spike glycoprotein in complex with the macrocyclic peptide S1B3inL1 |
Heteromer | 99.44 | 13×NAG; 23×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 S-BQ.1 in complex with antibody O5C2 |
Heteromer | 90.0 | 18×NAG; | |||
| S-2H2-F3b structure, three RBDs are up and each RBD binds with a 2H2 Fab. |
Heteromer | 99.81 | ||||
| SARS-CoV-2 spike/Nb5 complex |
Heteromer | 99.35 | 10×NAG; 33×NAG; | |||
| SARS-CoV-2 spike protein in complex with two S2H5 Fabs on NTD-1 and NTD-3 |
Heteromer | 99.81 | 1×NAG; | |||
| Ultrapotent SARS-CoV-2 neutralizing antibodies with protective efficacy against newly emerged mutat… |
Heteromer | 98.18 | 14×NAG; 10×NAG; | |||
| Cryo-EM structure of NTD-directed non-neutralizing antibody 4-33 in complex with prefusion SARS-CoV… |
Heteromer | 99.82 | 6×NAG; 33×NAG; | |||
| SARS-CoV-2 spike protein and P17 fab complex with one RBD in close state |
Heteromer | 100.0 | 27×NAG; | |||
| SARS-CoV-2 spike protein in complex with one S2H5 Fab |
Heteromer | 99.81 | 1×NAG; | |||
| Cryo-EM structure of neutralizing antibody 1-57 in complex with prefusion SARS-CoV-2 spike glycopro… |
Heteromer | 99.82 | 3×NAG; 18×NAG; 30×NAG; | |||
| SARS-CoV-2 Spike protein in complex with hb27 and fc05 Fab cocktail |
Heteromer | 100.0 | 14×NAG; | |||
| EM structure of SARS-CoV-2 Spike glycoprotein (one RBD up) in complex with COVOX-159 |
Heteromer | 99.81 | 15×NAG; 24×NAG; | |||
| SARS-CoV-2 Spike in complex with IgG 553-15 (S-553-15 trimer) |
Heteromer | 99.72 | 45×NAG; | |||
| Cryo-EM structure of NTD-directed neutralizing antibody LP5 Fab in complex with SARS-CoV-2 S2P spike |
Heteromer | 99.91 | 3×NAG; 3×NAG; 1×NAG; 28×NAG; | |||
| CC6.30 fragment antigen binding in complex with SARS-CoV-2-6P-Mut7 S protein (non-uniform refinemen… |
Heteromer | 99.27 | 10×NAG; 20×NAG; | |||
| S-3C1-F3a structure, two RBDs are up and one RBD is down, each RBD binds with a 3C1 fab. |
Heteromer | 99.81 | ||||
| Cryo-EM structure of NTD-directed neutralizing antibody 1-87 in complex with prefusion SARS-CoV-2 s… |
Heteromer | 99.82 | 17×NAG; 3×NAG; 34×NAG; | |||
| SARS-CoV-2 Spike in complex with IgG 553-60 (2-up trimer) |
Heteromer | 99.72 | 38×NAG; | |||
| The state 2 complex structure of Omicron spike with Bn03 (2-up RBD, 4 nanobodies) |
Heteromer | 98.18 | 36×NAG; | |||
| SARS-CoV-2 Spike in complex with IgG 553-15 (S-553-15 dimer trimer ) |
Heteromer | 99.72 | 90×NAG; | |||
| SARS-CoV-2 Omicron BA.1 spike trimer (6P) in complex with 2 YB9-258 Fabs (2 RBD up) |
Heteromer | 98.18 | 12×NAG; 30×NAG; | |||
| SARS-CoV-2 Omicron BA.1 spike trimer (6P) in complex with 3 YB13-292 Fabs (2 RBD up) |
Heteromer | 98.18 | 12×NAG; 30×NAG; | |||
| S-3C1-F2 structure, two RBDs are up and one RBD is down, the two up RBD bind with a 3C1 fab. |
Heteromer | 99.81 | ||||
| Cryo-EM structure of SARS-CoV-2 Omicron spike protein (S-6P-RRAR) in complex with S309 fab |
Heteromer | 98.18 | 19×NAG; 25×NAG; | |||
| XG005-bound SARS-CoV-2 S |
Heteromer | 99.81 | 45×NAG; | |||
| S-3C1-F3b structure, all the three RBDs are in the up conformation and each of them associates with… |
Heteromer | 99.81 | ||||
| Cryo-EM structure of SARS-CoV-2 XBB.1.5 spike protein in complex with mouse ACE2 (conformation 1) |
Heteromer Q8R0I0; | 90.0 | 19×NAG; 1×NAG; 21×NAG; | |||
| SARS-CoV-2 Spike in complex with IgG 553-60 (1-up trimer) |
Heteromer | 99.72 | 39×NAG; | |||
| SARS-CoV-2 Omicron closed state spike protein in complex with S3H3 Fab |
Heteromer | 98.18 | ||||
| XBB.1.5 spike/Nanosota-3C complex |
Heteromer | 90.0 | 15×NAG; 10×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 Omicron Prototype S-trimer in complex with fab L4.65 and L5.34 |
Heteromer | 99.42 | 3×NAG; | |||
| Omicron Spike bitrimer with 6m6 antibody |
Heteromer | 98.18 | 49×NAG; | |||
| SARS-CoV-2 spike proteins trimer in complex with P17 and FC05 Fabs cocktail |
Heteromer | 100.0 | 15×NAG; 16×NAG; | |||
| Cryo-EM structure of NTD-directed neutralizing antibody 4-8 Fab in complex with SARS-CoV-2 S2P spike |
Heteromer | 99.82 | 28×NAG; | |||
| Structures of Omicron Spike complexes illuminate broad-spectrum neutralizing antibody development |
Heteromer | 98.18 | 14×NAG; 10×NAG; | |||
| S-2H2-F3a structure, two RBDs are up and one RBD is down, each RBD binds with a 2H2 Fab. |
Heteromer | 99.81 | ||||
| SARS-CoV-2 spike/Nb3 complex with 2 RBDs up and 3 Nb3 bound at 2.5 A |
Heteromer | 99.35 | 11×NAG; 25×NAG; | |||
| SARS-CoV-2 spike protein in complex with two S2H5 Fabs on NTD-1 and NTD-2 |
Heteromer | 99.81 | 1×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 Omicron BA.4 S-trimer in complex with fab L4.65 and L5.34 |
Heteromer | 90.0 | 3×NAG; | |||
| Nanobody C5 bound to Spike |
Heteromer | 99.81 | 15×NAG; 36×NAG; | |||
| SARS-CoV-2 S trimer with four-antibody cocktail complex |
Heteromer | 99.81 | 12×NAG; | |||
| SARS-CoV-2 S trimer with three-antibody cocktail complex |
Heteromer | 99.81 | 15×NAG; | |||
| SARS-CoV-2 Kappa variant spike protein in C2b state |
Heteromer Q9BYF1; | 99.34 | ||||
| SARS-CoV-2 Kappa variant spike protein in C3 state |
Heteromer Q9BYF1; | 99.34 | ||||
| VAS5 Spike (1 RBD up) |
Heteromer | 100.0 | 13×NAG; 31×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 S-Gamma variant (P.1) in complex with Angiotensin-converting enzyme… |
Heteromer Q9BYF1; | 98.75 | 30×NAG; 1×NAG; 19×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 S-Delta variant (B.1.617.2) in complex with Angiotensin-converting … |
Heteromer Q9BYF1; | 97.5 | 43×NAG; 14×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 Omicron BA.1 spike protein in complex with mouse ACE2 |
Heteromer Q8R0I0; | 98.15 | 22×NAG; 23×NAG; 1×ZN; | |||
| Cryo-EM structure of SARS-CoV-2 S-Gamma variant (P.1) in complex with Angiotensin-converting enzyme… |
Heteromer Q9BYF1; | 98.75 | 29×NAG; 26×NAG; | |||
| SARS-CoV-2 Spike Glycoprotein with 2 ACE2 Bound |
Heteromer Q9BYF1; | 99.81 | ||||
| Cryo-EM structure of SARS-CoV-2 S-Beta variant (B.1.351) in complex with Angiotensin-converting enz… |
Heteromer Q9BYF1; | 98.45 | 31×NAG; 17×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 S-Delta variant (B.1.617.2) in complex with Angiotensin-converting … |
Heteromer Q9BYF1; | 97.5 | 37×NAG; 15×NAG; | |||
| SARS-CoV-2 Spike Glycoprotein with 3 ACE2 Bound |
Heteromer Q9BYF1; | 99.81 | ||||
| SARS-CoV-2 Spike Glycoprotein with 1 ACE2 Bound |
Heteromer Q9BYF1; | 99.81 | 23×NAG; 1×ZN; | |||
| SARS-CoV-2 Omicron Variant SPIKE trimer complexed with ACE2 |
Heteromer Q9BYF1; | 100.0 | 12×NAG; 21×NAG; 1×CL; 1×ZN; | |||
| Cryo-EM structure of SARS-CoV-2 S-Delta variant (B.1.617.2) in complex with Angiotensin-converting … |
Heteromer Q9BYF1; | 97.5 | 38×NAG; 16×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 S-Kappa variant (B.1.617.1) in complex with Angiotensin-converting … |
Heteromer Q9BYF1; | 99.13 | 31×NAG; 13×NAG; | |||
| SARS-CoV-2 Spike Glycoprotein with 1 ACE2 Bound and 1 RBD Erect in Clockwise Direction |
Heteromer Q9BYF1; | 99.81 | ||||
| SARS-CoV-2 Spike Glycoprotein with 1 ACE2 Bound and 1 RBD Erect in Anticlockwise Direction |
Heteromer Q9BYF1; | 99.81 | ||||
| Cryo-EM structure of SARS-CoV-2 S-Kappa variant (B.1.617.1) in complex with Angiotensin-converting … |
Heteromer Q9BYF1; | 99.13 | 37×NAG; 13×NAG; | |||
| SARS-CoV-2 Kappa variant spike protein in complex wth ACE2, state C1 |
Heteromer Q9BYF1; | 99.43 | ||||
| Cryo-EM structure of SARS-CoV-2 S-Gamma variant (P.1) in complex with Angiotensin-converting enzyme… |
Heteromer Q9BYF1; | 98.75 | 30×NAG; 29×NAG; | |||
| SARS-CoV-2 Spike in complex with PVI.V6-14 Fab |
Heteromer | 99.45 | 15×NAG; 6×NAG; 6×NAG; 3×NAG; 18×NAG; | |||
| SARS-CoV-2 Spike (6P) in complex with 2 R1-32 Fabs |
Heteromer | 99.53 | 6×NAG; 24×NAG; | |||
| SARS-CoV-2 spike in complex with nanobodies E |
Heteromer | 99.81 | 51×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 spike in complex with FSR22, an anti-SARS-CoV-2 DARPin |
Heteromer | 99.44 | 3×NAG; 9×NAG; 6×NAG; 18×NAG; | |||
| SARS-CoV-2 spike trimer (6P) in complex with two H18 Fabs |
Heteromer | 99.53 | 12×NAG; 33×NAG; | |||
| SARS-CoV-2 spike trimer (6P) in complex with three H18 Fabs, head-to-head aggregate (C1 symmetry) |
Heteromer | 99.52 | 24×NAG; 66×NAG; | |||
| SARS-CoV-2 spike trimer (6P) in complex with R1-26 Fab, head-to-head aggregate |
Heteromer | 99.53 | 30×NAG; 60×NAG; | |||
| A potent and broad-spectrum neutralizing nanobody for SARS-CoV-2 viruses including all major Omicro… |
Heteromer | 98.15 | 10×NAG; 28×NAG; | |||
| Cryo-EM structure of the SARS-CoV-2 spike protein bound to neutralizing sybodies (Sb23) |
Heteromer | 99.81 | 9×NAG; 45×NAG; | |||
| The SARS-CoV-2 spike in complex with the 1.10 neutralizing nanobody |
Heteromer | 99.72 | 5×NAG; 33×NAG; | |||
| SARS-CoV-2 Spike trimer in complex with RmAb 9H1 Fab in the class 1 conformation |
Heteromer | 99.81 | 18×NAG; 27×NAG; | |||
| SARS-CoV-2 Spike protein in complex with a pan-sarbecovirus nanobody 1-23 |
Heteromer | 99.82 | ||||
| SARS-CoV-2 spike trimer (6P) in complex with three H18 Fabs |
Heteromer | 99.53 | 12×NAG; 33×NAG; | |||
| SARS-CoV-2 BA.1 Spike trimer in complex with 55A8 Fab and 58G6 Fab in the class 2 conformation |
Heteromer | 98.15 | 15×NAG; 15×NAG; | |||
| SARS-CoV-2 S-6P in complex with 9 Fabs |
Heteromer | 99.53 | ||||
| SARS-CoV-2 Spike (6P) in complex with 1 R1-32 Fab |
Heteromer | 99.53 | 6×NAG; 24×NAG; | |||
| SARS-CoV-2 Spike trimer in complex with RmAb 9H1 Fab in the class 2 conformation |
Heteromer | 99.81 | 17×NAG; 27×NAG; | |||
| SARS-CoV-2 spike trimer (6P) in complex with three H18 Fabs, head-to-head aggregate (C3 symmetry) |
Heteromer | 99.53 | 24×NAG; 66×NAG; | |||
| SARS-CoV-2 spike trimer (6P) in complex with three H18 and three R1-32 Fabs |
Heteromer | 99.53 | 12×NAG; 33×NAG; | |||
| Structure of the SARS-CoV-2 spike glycoprotein in complex with a human single domain antibody n3113… |
Heteromer | 99.81 | 20×NAG; 2×NAG; 21×NAG; | |||
| SARS-CoV-2 Spike protein in complex with a pan-sarbecovirus nanobody 2-65 |
Heteromer | 99.82 | ||||
| SARS CoV2 Spike in the 2-up state in complex with Fab47. |
Heteromer | 99.62 | 7×NAG; 43×NAG; | |||
| CryoEM structure of SARS-CoV-2 spike protein (S-6P, 2-up) in complex with sybodies (Sb45) |
Heteromer | 99.44 | 17×NAG; 30×NAG; | |||
| Cryo-EM structure of the SARS-CoV-2 spike protein bound to neutralizing nanobodies (Ty1) |
Heteromer | 99.81 | 12×NAG; 39×NAG; | |||
| SARS-CoV-2 Spike protein in complex with a pan-sarbecovirus nanobody 2-57 |
Heteromer | 99.82 | 30×NAG; | |||
| SARS-CoV-2 wildtype spike trimer (6P) in complex with 3 YB9-258 Fabs and 3 R1-32 Fabs (3 RBD up) |
Heteromer | 99.53 | 12×NAG; 30×NAG; | |||
| SARS-CoV-2 spike trimer (6P) in complex with two H18 and two R1-32 Fabs |
Heteromer | 99.53 | 12×NAG; 33×NAG; | |||
| SARS-CoV-2 spike trimer (6P) in complex with three H18 and three R1-32 Fabs (one RBD rotated) |
Heteromer | 99.53 | 12×NAG; 33×NAG; | |||
| S protein of SARS-CoV-2 in complex with 2G1 |
Heteromer | 99.55 | 24×NAG; 30×NAG; 3×EIC; | |||
| Trimeric SARS-CoV-2 spike ectodomain bound to P008_056 Fab |
Heteromer | 99.82 | 25×NAG; 2×BLA; 29×NAG; | |||
| SARS-CoV-2 BA.1 Spike trimer in complex with 55A8 Fab in the class 1 conformation |
Heteromer | 98.15 | 14×NAG; 15×NAG; | |||
| SARS Cov2 Spike RBD in complex with Fab47 |
Heteromer | 99.44 | 7×NAG; 45×NAG; | |||
| SARS-CoV-2 Omicron BA.1 Spike glycoprotein in complex with rabbit monoclonal antibody 1H1 Fab in th… |
Heteromer | 98.15 | 15×NAG; 15×NAG; | |||
| SARS-CoV-2 Spike protein in complex with a pan-sarbecovirus nanobody 1-22 |
Heteromer | 99.82 | ||||
| SARS-CoV-2 Omicron BA.1 Spike glycoprotein in complex with rabbit monoclonal antibody 1H1 IgG. |
Heteromer | 98.15 | 15×NAG; 14×NAG; | |||
| Structure of the SARS-CoV-2 spike glycoprotein in complex with a human single domain antibody n3113… |
Heteromer | 99.81 | 16×NAG; 20×NAG; | |||
| SARS-CoV-2 Spike protein in complex with a pan-sarbecovirus nanobody 2-45 |
Heteromer | 99.82 | ||||
| SARS-CoV-2 BA.1 Spike trimer in complex with 55A8 Fab in the class 2 conformation |
Heteromer | 98.15 | 14×NAG; 15×NAG; | |||
| S protein of SARS-CoV-2 in complex with 3711 |
Heteromer | 99.81 | 23×NAG; 3×NAG; 38×NAG; 3×EIC; | |||
| SARS-CoV-2 spike glycoprotein:Fab 3D11 complex |
Heteromer | 99.81 | ||||
| SARS-CoV-2 Spike in complex with neutralizing Fab SARS2-57 (three down conformation) |
Heteromer | 99.54 | 28×NAG; 25×NAG; | |||
| SARS-CoV-2 spike trimer (6P) in complex with two R1-26 Fabs |
Heteromer | 99.53 | 15×NAG; 30×NAG; | |||
| S protein of SARS-CoV-2 in complex with 26434 |
Heteromer | 99.53 | 31×NAG; 24×NAG; | |||
| J08 fragment antigen binding in complex with SARS-CoV-2-6P-Mut2 S protein (conformation 1) |
Heteromer | 99.25 | 9×NAG; 15×NAG; | |||
| SARS-CoV-2 Omicron BA.1 Spike glycoprotein in complex with rabbit monoclonal antibody 1H1 Fab in cl… |
Heteromer | 98.15 | 15×NAG; 14×NAG; | |||
| SARS-CoV-2 spike in complex with the S304 neutralizing antibody Fab fragment |
Heteromer | 99.8 | 12×NAG; 3×NAG; 36×NAG; | |||
| SARS-CoV-2 Spike (6P) in complex with 3 R1-32 Fabs |
Heteromer | 99.53 | 6×NAG; 24×NAG; | |||
| Cryo-EM structure of the SARS-CoV-2 spike glycoprotein bound to Fab H4 |
Heteromer | 99.81 | 4×NAG; 33×NAG; | |||
| SARS-CoV-spike bound to two neutralising nanobodies |
Heteromer | 99.8 | 1×NAG; 42×NAG; | |||
| SARS-CoV-2 Spike (dimers) in complex with six Fu2 nanobodies |
Heteromer | 99.52 | 2×NAG; 46×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 spike in complex with non-neutralizing NTD-directed CV3-13 Fab isol… |
Heteromer | 99.45 | 3×NAG; 36×NAG; | |||
| Beta-26 fab in complex with SARS-CoV-2 beta-Spike glycoprotein |
Heteromer | 98.52 | 13×NAG; 31×NAG; | |||
| The SARS-CoV-2 spike in complex with the 2.15 neutralizing nanobody |
Heteromer | 99.72 | 5×NAG; 33×NAG; | |||
| Structure of the SARS-CoV-2 S 6P trimer in complex with neutralizing antibody N-612-014 |
Heteromer | 100.0 | ||||
| SARS-CoV-2 spike glycoprotein:Fab 5A6 complex I |
Heteromer | 99.81 | 23×NAG; | |||
| The SARS-CoV-2 spike in complex with the 1.29 neutralizing nanobody |
Heteromer | 99.72 | 5×NAG; 33×NAG; | |||
| Structure of the SARS-CoV-2 spike glycoprotein in complex with a human single domain antibody n3113… |
Heteromer | 99.81 | 3×NAG; 12×NAG; 18×NAG; | |||
| J08 fragment antigen binding in complex with SARS-CoV-2-6P-Mut2 S protein (conformation 2) |
Heteromer | 99.25 | 12×NAG; 21×NAG; | |||
| SARS-CoV-2 Spike protein in complex with a pan-sarbecovirus nanobody 2-67 |
Heteromer | 99.82 | 14×NAG; 4×NAG; 2×NAG; 32×NAG; | |||
| Structures of Omicron Spike complexes illuminate broad-spectrum neutralizing antibody development |
Heteromer | 99.81 | 18×NAG; 30×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 spike in complex with K202.B bispecific antibody |
Heteromer | 99.42 | 32×NAG; | |||
| Cryo-EM structure of the SARS-CoV-2 spike protein bound to neutralizing sybodies (Sb23) 2-up confor… |
Heteromer | 99.81 | 8×NAG; 45×NAG; | |||
| SARS Cov2 Spike in 1-up conformation complex with Fab47 |
Heteromer | 99.62 | 8×NAG; 44×NAG; | |||
| SARS-CoV-2 BA.1 Spike trimer in complex with 55A8 Fab and 58G6 Fab in the class 1 conformation |
Heteromer | 98.15 | 14×NAG; 15×NAG; | |||
| SARS-CoV-2 Spike (6P) in complex with 3 R1-32 Fabs and 3 ACE2 |
Heteromer Q9BYF1; | 99.53 | 6×NAG; 36×NAG; 3×ZN; | |||
| Structures of Omicron Spike complexes illuminate broad-spectrum neutralizing antibody development |
Heteromer | 98.94 | 15×NAG; 24×NAG; | |||
| CryoEm structure of SARS-CoV-2 spike protein (S-6P, 1-up) in complex with sybodies (Sb45) |
Heteromer | 99.44 | 19×NAG; 35×NAG; | |||
| S protein of SARS-CoV-2 in complex bound with 4A8 |
Heteromer | 99.81 | 6×NAG; 23×NAG; 25×NAG; | |||
| CryoEM structure of del68-76/del679-688 prefusion-stabilized spike in complex with the Fab of N12-9 |
Heteromer | 100 | 10×NAG; 28×NAG; | |||
| Structures of Omicron Spike complexes illuminate broad-spectrum neutralizing antibody development |
Heteromer | 99.81 | 18×NAG; 30×NAG; | |||
| SARS-CoV-2 spike trimer (6P) in complex with three R1-26 Fabs |
Heteromer | 99.53 | 15×NAG; 30×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 spike in complex with VHH14 |
Heteromer | 99.81 | 38×NAG; | |||
| Cryo-EM structure of NTD-directed neutralizing antibody 5-7 in complex with prefusion SARS-CoV-2 sp… |
Heteromer | 99.81 | 6×NAG; 48×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 spike in complex with VHH21 |
Heteromer | 100.0 | 40×NAG; | |||
| SARS-CoV-2 S (C.37 Lambda variant) plus S309, S2L20, and S2X303 Fabs |
Heteromer | 100.0 | 57×NAG; | |||
| Structure of the SARS-CoV-2 S 6P trimer in complex with the neutralizing antibody Fab fragment, C15… |
Heteromer | 100.0 | 12×NAG; 35×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 Omicron spike in complex with antibodies A19-46.1 and B1-182.1 |
Heteromer | 98.18 | 13×NAG; 15×NAG; | |||
| SARS-CoV-2 S B.1.617.2 delta variant + S2M11 + S2L20 Global Refinement |
Heteromer | 98.42 | 3×NAG; 45×NAG; | |||
| Delta SARS-CoV-2 spike protein in complex with REGN10987 Fab homologue. |
Heteromer | 98.58 | ||||
| SARS-CoV-2 S/S2M11/S2M28 Global Refinement |
Heteromer | 99.42 | 3×NAG; 6×NAG; 45×NAG; | |||
| SARS-CoV-2 Omicron BA.1 spike ectodomain trimer in complex with the S2X324 neutralizing antibody Fa… |
Heteromer | 97.67 | 1×NAG; 48×NAG; | |||
| SARS-CoV-2 S B.1.617.1 kappa variant + S2X303 Global Refinement |
Heteromer | 98.55 | 3×NAG; 51×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 Omicron spike in complex with antibody A19-46.1 |
Heteromer | 98.18 | 14×NAG; 28×NAG; | |||
| SARS-CoV-2 S ectodomain trimer in complex with neutralizing antibody 10-5B |
Heteromer | 99.81 | ||||
| SARS-CoV-2 S B.1.1.529 Omicron variant + S309 + S2L20 Global Refinement |
Heteromer | 98.11 | 1×NAG; 50×NAG; | |||
| SARS-CoV-2 S/S2M11/S2X333 Global Refinement |
Heteromer | 99.42 | 3×NAG; 6×NAG; 45×NAG; | |||
| SD1-3 Fab in complex with SARS-CoV-2 BA.2.12.1 Spike Glycoprotein |
Heteromer | 87.5 | 30×NAG; | |||
| SARS-CoV-2 S B.1.617.1 kappa variant + S309 + S2L20 Global Refinement |
Heteromer | 98.54 | 51×NAG; | |||
| SARS-CoV-2 S + S2L20 |
Heteromer | 99.42 | 9×NAG; 3×NAG; 33×NAG; | |||
| Omicron BA.1 Spike protein with neutralizing NTD specific mAb K501SP6 |
Heteromer | 100.0 | ||||
| Structure of the SARS-CoV-2 Spike trimer with three RBDs up in complex with the Fab fragment of hum… |
Heteromer | 99.81 | 33×NAG; 21×NAG; | |||
| Structure of the SARS-CoV-2 Spike trimer with one RBD down in complex with the Fab fragment of huma… |
Heteromer | 99.81 | 29×NAG; 25×NAG; | |||
| SARS-CoV-2 S/S2M11/S2L28 Global Refinement |
Heteromer | 99.43 | 3×NAG; 9×NAG; 3×NAG; 39×NAG; | |||
| VIR-7229 Fab fragment bound the BA.2.86 spike trimer (global refinement) |
Heteromer | 93.02 | 10×NAG; 29×NAG; | |||
| The global map of Omicron Subvariants Spike with ACE2 |
Heteromer Q9BYF1; | 71.43 | ||||
| The global map of Omicron Subvariants Spike with two antibodies |
Heteromer | 71.43 | ||||
| cryo-EM structure of omicron spike in complex with de novo designed binder, full map |
Heteromer Q9VKJ9; | 98.0 | 18×NAG; 12×NAG; 16×NAG; | |||
| SARS-CoV-2 BA.2 variant spike protein in complex with Fab BD55-5840 |
Heteromer | 100 | ||||
| Stabilised BA.1 SARS-CoV-2 spike with H6 nanobodies in '3 up' RBD conformation |
Heteromer | 97.54 | 12×NAG; 9×NAG; | |||
| Structure of SARS-CoV-2 Omicron BA.1.1.529 Spike trimer with two RBDs down in complex with the Fab … |
Heteromer | 98.0 | 27×NAG; 19×NAG; | |||
| Structure of SARS-CoV-2 Omicron BA.1.1.529 Spike trimer with one RBD down in complex with the Fab f… |
Heteromer | 98.0 | 20×NAG; 23×NAG; | |||
| SARS-CoV-2 S Omicron Spike B.1.1.529 - 3-P2G3 and 1-P5C3 Fabs (Global) |
Heteromer | 98.0 | 14×NAG; 1×NAG; 2×NAG; 26×NAG; | |||
| Stabilised BA.1 SARS-CoV-2 spike with H6 nanobodies in '2 up 1 down' RBD conformation |
Heteromer | 98.0 | 11×NAG; 15×NAG; | |||
| BA.5 spike/Nanosota-9 complex |
Heteromer | 100 | 8×NAG; 20×NAG; | |||
| SARS-CoV-2 Omicron-BA.2 3-RBD down Spike Protein Trimer without the P986-P987 stabilizing mutations… |
Heteromer | 100 | 10×NAG; 27×NAG; | |||
| CryoEM structure of neutralizing nanobody Nb12 in complex with SARS-CoV2 spike |
Heteromer | 99.4 | 5×NAG; 13×NAG; 22×NAG; | |||
| SARS-CoV-2 Delta Spike in complex with Fab of JE-5C |
Heteromer | 98.35 | ||||
| XBB.1.5.10 spike protein in complex with ACE2 |
Heteromer Q9BYF1; | 90.0 | ||||
| XBB.1.5 spike protein in complex with ACE2 |
Heteromer Q9BYF1; | 95.97 | ||||
| XBB.1.5.70 spike protein in complex with ACE2 |
Heteromer Q9BYF1; | 90.0 | ||||
| XBB.1.5 spike protein in complex with BD55-1205 |
Heteromer | 95.97 | ||||
| cryo-EM structure of SARS-CoV-2 spike in complex with Fab 15033-7, three RBDs bound |
Heteromer | 99.42 | 21×NAG; 6×NAG; 18×NAG; | |||
| Beta-50 fab in complex with SARS-CoV-2 beta-Spike glycoprotein |
Heteromer | 99.44 | 1×NAG; 14×NAG; 2×NAG; 25×NAG; | |||
| BA.2(S375) Spike (S6P)/hACE2 complex |
Heteromer Q9BYF1; | 100 | 3×NAG; 51×NAG; | |||
| Structure of the SARS-CoV-2 S 6P trimer in complex with the mouse antibody Fab fragment, M8a-3 |
Heteromer | 100.0 | 3×NAG; 45×NAG; | |||
| S728-1157 IgG in complex with SARS-CoV-2-6P-Mut7 Spike protein (focused refinement) |
Heteromer | 99.03 | 11×NAG; | |||
| Potent neutralizing nanobodies resist convergent circulating variants of SARS-CoV-2 by targeting no… |
Heteromer | 99.39 | ||||
| BA.2-07 FAB IN COMPLEX WITH SARS-COV-2 BA.2.12.1 SPIKE GLYCOPROTEIN |
Heteromer | 100 | 12×NAG; 24×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 Epsilon (B.1.429) spike protein in complex with Fab S2M11 |
Heteromer | 99.12 | 18×NAG; 3×NAG; 30×NAG; | |||
| Structure of the SARS-CoV-2 S 6P trimer in complex with the human neutralizing antibody Fab fragmen… |
Heteromer | 99.42 | 1×NAG; 32×NAG; | |||
| Beta049 fab in complex with SARS-CoV2 beta-Spike glycoprotein, The Beta mAb response underscores th… |
Heteromer | 99.45 | 2×NAG; 14×NAG; 1×NAG; 26×NAG; | |||
| LM18/Nb136 bispecific tetra-nanobody immunoglobulin in complex with SARS-CoV-2-6P-Mut7 S protein (f… |
Heteromer | 99.21 | 13×NAG; | |||
| Cryo-EM Structure of SARS-CoV-2 BA.2 Spike protein in complex with BA7535 |
Heteromer | 83.33 | 12×NAG; 12×NAG; | |||
| Structure of the SARS-CoV-2 S 6P trimer in complex with neutralizing antibody C051 |
Heteromer | 100.0 | 4×NAG; 27×NAG; | |||
| SD1-2 Fab in complex with SARS-CoV-2 BA.2.12.1 Spike Glycoprotein |
Heteromer | 100 | 30×NAG; | |||
| SARS-CoV-2 spike in complex with the S2M11 neutralizing antibody Fab fragment |
Heteromer | 99.81 | 18×NAG; 3×NAG; 30×NAG; | |||
| Structure of the SARS-CoV-2 S 6P trimer in complex with neutralizing antibody C548 |
Heteromer | 100.0 | 5×NAG; 1×NAG; 1×NAG; 1×NAG; 26×NAG; | |||
| BA.2.86 S-trimer in complex with Nab XGv280 |
Heteromer | 75.0 | 54×NAG; | |||
| Omicron spike trimer with 6m6 antibody |
Heteromer | 97.83 | 24×NAG; | |||
| cryo-EM structure of SARS-CoV-2 spike in complex with Fab 15033-7, two RBDs bound |
Heteromer | 99.42 | 7×NAG; 2×NAG; 25×NAG; | |||
| BA.2.86 S-trimer in complex with Nab XG2v046 |
Heteromer | 75.0 | 9×NAG; 4×NAG; 1×NAG; 39×NAG; | |||
| BA.2.86 Spike in complex with bovine ACE2 (bound 1 ACE2) |
Heteromer Q2HJI5; | 75.0 | 17×NAG; 1×ZN; 1×CL; 36×NAG; | |||
| Cryo-EM Structure of Double ACE2-Bound SARS-CoV-2 Trimer Spike at pH 5.5 |
Heteromer Q9BYF1; | 99.8 | 4×NAG; 48×NAG; | |||
| Cryo-EM structure of Triple ACE2-bound SARS-CoV-2 Trimer Spike at pH 5.5 |
Heteromer Q9BYF1; | 99.81 | 6×NAG; 56×NAG; | |||
| Cryo-EM structure of triple ACE2-bound SARS-CoV-2 trimer spike at pH 7.4 |
Heteromer Q9BYF1; | 99.81 | 8×NAG; 55×NAG; | |||
| Cryo-EM structure of double ACE2-bound SARS-CoV-2 trimer Spike at pH 7.4 |
Heteromer Q9BYF1; | 99.8 | 4×NAG; 53×NAG; | |||
| SARS-CoV-2 spike protein in complex with sybodyb#15 in a 1up/1up-out/1down conformation. |
Heteromer | 99.81 | 4×NAG; 8×NAG; 3×NAG; 1×NAG; 19×NAG; | |||
| The state 2 of Omicron Spike with bispecific antibody FD01 |
Heteromer | 97.78 | 23×NAG; | |||
| SARS-CoV-2 spike protein in complex with sybody#15 and sybody#68 in a 3up conformation |
Heteromer | 99.81 | 10×NAG; 4×NAG; 1×NAG; 1×NAG; 29×NAG; | |||
| SARS-CoV-2 Omicron 1-RBD up spike trimer complexed with two XG005 Fab |
Heteromer | 97.67 | ||||
| SARS-CoV-2 Omicron 1-RBD up Spike trimer complexed with three XG005 molecules |
Heteromer | 97.67 | ||||
| The state 1 of Omicron Spike with bispecific antibody FD01 |
Heteromer | 97.78 | 28×NAG; | |||
| The state 3 of Omicron Spike with bispecific antibody FD01 |
Heteromer | 97.78 | 21×NAG; | |||
| SARS-CoV-2 Omicron 2-RBD up Spike trimer complexed with three XG005 molecules |
Heteromer | 97.67 | ||||
| The state 4 of Omicron Spike with bispecific antibody FD01 |
Heteromer | 97.78 | 23×NAG; | |||
| The state 6 of Omicron Spike with bispecific antibody FD01 |
Heteromer | 97.78 | ||||
| SARS-CoV-2 spike protein in complex with sybody#68 in a 2up/1flexible conformation |
Heteromer | 99.42 | 10×NAG; 4×NAG; 1×NAG; 1×NAG; 28×NAG; | |||
| SARS-CoV-2 spike protein in complex with Fab 15033-7, 2-"up"-1-"down" conformation |
Heteromer | 99.41 | 12×NAG; 3×NAG; 16×NAG; | |||
| The state 5 of Omicron Spike with bispecific antibody FD01 |
Heteromer | 97.78 | 18×NAG; | |||
| SARS-CoV-2 spike protein in complex with Fab 15033-7, 3-"up", asymmetric |
Heteromer | 99.42 | 2×NAG; 1×NAG; 7×NAG; | |||
| 3D model of the 3-RBD up single trimeric spike protein of SARS-CoV2 in the presence of synthetic pe… |
Heteromer | 99.81 | 39×NAG; | |||
| SARS-CoV-2 S (Spike Glycoprotein) D614G with Three (3) RBDs Up, Bound to Antibody 2-7 scFv, composi… |
Heteromer | 99.71 | 3×NAG; 45×NAG; | |||
| SARS-CoV-2 spike in complex with LCB1 (2RBDs open) |
Heteromer | 99.39 | 13×NAG; 33×NAG; | |||
| XBB.1.5 spike/Nb5 complex |
Heteromer | 87.5 | 12×NAG; 33×NAG; | |||
| SARS-CoV-2 spike protein in complex with sybody#15 and sybody#68 in a 1up/1up-out/1down conformation |
Heteromer | 99.81 | 11×NAG; 4×NAG; 1×NAG; 19×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 Spike protein in complex with A6 repebody |
Heteromer | 99.42 | 5×NAG; 24×NAG; | |||
| Cryo-EM structure of broadly neutralizing antibody 2-36 in complex with prefusion SARS-CoV-2 spike … |
Heteromer | 99.8 | 16×NAG; 9×NAG; | |||
| CryoEM structure of neutralizing nanobody Nb30 in complex with SARS-CoV2 spike |
Heteromer | 99.42 | 11×NAG; 4×NAG; 1×NAG; 29×NAG; | |||
| Cryo-EM structure of single ACE2-bound SARS-CoV-2 trimer spike at pH 5.5 |
Heteromer Q9BYF1; | 99.8 | 6×NAG; 44×NAG; | |||
| Cryo-EM structure of single ACE2-bound SARS-CoV-2 trimer spike at pH 7.4 |
Heteromer Q9BYF1; | 99.8 | 5×NAG; 46×NAG; | |||
| SARS-CoV-2 S trimer with two RBDs in the open state and complexed with two H014 Fab |
Heteromer | 99.8 | 15×NAG; 30×NAG; | |||
| SARS-CoV-2 S trimer with three RBD in the open state and complexed with three H014 Fab |
Heteromer | 99.81 | 15×NAG; 30×NAG; | |||
| SARS-CoV-2 Spike protein in complex with a pan-sarbecovirus nanobody 2-34 |
Heteromer | 99.81 | 12×NAG; 50×NAG; | |||
| Complex of SARS-CoV-2 spike trimer with its neutralizing antibody HB27 |
Heteromer | 99.8 | 15×NAG; 29×NAG; | |||
| CryoEM structure of SARS-CoV-2 Spike in complex with Nb17 |
Heteromer | 99.29 | ||||
| SARS-CoV-2 S trimer with one RBD in the open state and complexed with one H014 Fab. |
Heteromer | 99.51 | 15×NAG; 30×NAG; | |||
| JN.1 spike/Nanosota-9 complex |
Heteromer | 97.56 | 16×NAG; | |||
| SARS-CoV-2 BA.2.75 S Trimer in complex with ACE2(state1) |
Heteromer Q9BYF1; | 100 | 9×NAG; 1×ZN; 1×CL; 49×NAG; | |||
| SARS-CoV-2 BA.2.75 S Trimer in complex with ACE2(state2) |
Heteromer Q9BYF1; | 100 | 9×NAG; 53×NAG; 2×ZN; 2×CL; | |||
| SARS-CoV-2 BA.2.75 S Trimer in complex with S309 (state1) |
Heteromer | 100 | 9×NAG; 2×NAG; 45×NAG; | |||
| SARS-CoV-2 BA.2.75 S Trimer in complex with S309 (state2) |
Heteromer | 100 | 9×NAG; 3×NAG; 45×NAG; | |||
| SARS-CoV-2 BA.2.75 S Trimer in complex with S309 (state3) |
Heteromer | 100 | 2×NAG; 45×NAG; | |||
| SARS-CoV-2 spike in prefusion state |
Heteromer | 99.75 | 16×NAG; 4×NAG; 7×NAG; 18×NAG; 2×MAN; 3×DMS; | |||
| Structure of the SARS-CoV-2 S 6P trimer in complex with the mouse antibody Fab fragment, M8a-34 |
Heteromer | 100.0 | 42×NAG; | |||
| cryo-EM structure of Omicron BA.5 S protein in complex with XGv289 |
Heteromer | 100 | 18×NAG; 33×NAG; | |||
| SARS-CoV-2 Delta Spike in complex with JM-1A |
Heteromer | 97.5 | ||||
| Structure of the SARS-CoV-2 S 6P trimer in complex with the mouse antibody Fab fragment, M8a-28 |
Heteromer | 100.0 | 39×NAG; | |||
| cryo-EM structure of Omicron BA.5 S protein in complex with XGv282 |
Heteromer | 100 | 18×NAG; 33×NAG; | |||
| cryo-EM structure of Omicron BA.5 S protein in complex with S2L20 |
Heteromer | 100 | 3×NAG; 18×NAG; 30×NAG; | |||
| Structure of the SARS-CoV-2 S 6P trimer in complex with the mouse antibody Fab fragment, M8a-31 |
Heteromer | 100.0 | 3×NAG; 39×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 spike glycoprotein in complex with three F61 Fab |
Heteromer | 99.41 | 24×NAG; | |||
| Potent neutralizing nanobodies resist convergent circulating variants of SARS-CoV-2 by targeting no… |
Heteromer | 99.4 | ||||
| SARS-CoV2 Omicron BA.1 spike in complex with CAB-A17 antibody |
Heteromer | 96.8 | 15×NAG; 22×NAG; | |||
| A potent and broad-spectrum neutralizing nanobody for SARS-CoV-2 viruses including all major Omicro… |
Heteromer | 97.05 | 13×NAG; 24×NAG; | |||
| CRYO-EM STRUCTURE OF SARS-COV-2 SPIKE : H11-H4 Q98R H100E nanobody complex in 2Up1Down conformation |
Heteromer | 99.8 | 20×NAG; 26×NAG; | |||
| A potent and broad-spectrum neutralizing nanobody for SARS-CoV-2 viruses including all major Omicro… |
Heteromer | 97.05 | 12×NAG; 25×NAG; | |||
| Structure of the SARS-CoV-2 S 6P trimer in complex with the mouse antibody Fab fragment, HSW-1 |
Heteromer | 100.0 | 2×NAG; 34×NAG; | |||
| SARS-CoV-2 B.1.1.7 S-ACE2 complex |
Heteromer Q9BYF1; | 100 | 16×NAG; 27×NAG; | |||
| Mink Cluster 5-associated SARS-CoV-2 spike protein(S-GSAS-D614G-delFV) missing the S1 subunit and S… |
Heteromer | 100 | 1×NAG; 27×NAG; | |||
| Delta (B.1.617.2) SARS-CoV-2 variant spike protein (S-GSAS-Delta) in the M1 conformation, D4 |
Heteromer | 99.76 | 12×NAG; 22×NAG; | |||
| Cryo-EM structure of mink variant Y453F trimeric spike protein bound to two mink ACE2 receptors |
Heteromer A0A7T0Q2W2; | 100 | ||||
| SARS-CoV-2 Spike Glycoprotein with one ACE2 Bound |
Heteromer Q9BYF1; | 99.79 | 17×NAG; 36×NAG; | |||
| SARS-CoV-2 Spike Glycoprotein with two ACE2 Bound |
Heteromer Q9BYF1; | 99.8 | 20×NAG; 40×NAG; | |||
| Cryo-EM structure of mink variant Y453F trimeric spike protein bound to one mink ACE2 receptors at … |
Heteromer A0A7T0Q2W2; | 100 | ||||
| SARS-CoV-2 Spike Glycoprotein with three ACE2 Bound |
Heteromer Q9BYF1; | 99.8 | 24×NAG; 42×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 S-UK variant (B.1.1.7) in complex with Angiotensin-converting enzym… |
Heteromer Q9BYF1; | 100.0 | 29×NAG; 26×NAG; | |||
| Structure of the SARS-CoV-2 S 6P trimer in complex with the human neutralizing antibody Fab fragmen… |
Heteromer | 100.0 | 45×NAG; | |||
| SARS-CoV-2 spike glycoprotein trimer complexed with Fab fragment of anti-RBD antibody E7 |
Heteromer | 99.4 | 7×NAG; 14×NAG; | |||
| Structure of the SARS-CoV-2 S 2P trimer in complex with the human neutralizing antibody Fab fragmen… |
Heteromer | 99.8 | 15×NAG; 27×NAG; | |||
| Structure of the SARS-CoV-2 S 6P trimer in complex with the human neutralizing antibody Fab fragmen… |
Heteromer | 99.7 | 1×NAG; 2×NAG; | |||
| EM structure of SARS-CoV-2 Spike glycoprotein (all RBD down) in complex with COVOX-253H55L Fab |
Heteromer | 99.8 | 14×NAG; 1×NAG; 32×NAG; | |||
| Structure of SARS-CoV-2 S protein in complex with Receptor Binding Domain antibody DH1041 |
Heteromer | 99.7 | 11×NAG; 6×NAG; 17×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 2P S ectodomain bound domain-swapped antibody 2G12 from masked 3D r… |
Heteromer | 99.79 | 10×NAG; 1×NAG; 1×NAG; 1×NAG; 32×NAG; | |||
| Structure of the SARS-CoV-2 Omicron BA.1 S 6P trimer in complex with the mouse antibody Fab fragmen… |
Heteromer | 97.62 | 3×NAG; 27×NAG; | |||
| SARS-CoV-2 Spike glycoprotein in complex with a neutralizing antibody EY6A Fab |
Heteromer | 99.8 | 13×NAG; 23×NAG; | |||
| SARS-CoV-2 spike glycoprotein in complex with the ICO-hu23 neutralizing antibody Fab fragment |
Heteromer | 99.8 | 12×NAG; 30×NAG; | |||
| Cryo-EM structure of the SARS-CoV-2 S-6P in complex with 35B5 Fab(3 up RBDs, state2) |
Heteromer | 99.4 | 27×NAG; | |||
| EM structure of SARS-CoV-2 Spike glycoprotein in complex with COVOX-40 Fab |
Heteromer | 99.8 | 11×NAG; 27×NAG; | |||
| SARS-CoV-2 Omicron BA.4 spike trimer (6P) in complex with D1F6 Fab, head-to-head aggregate |
Heteromer | 97.62 | 20×NAG; | |||
| SARS-CoV-2 Spike Protein Trimer bound to DH1043 fab |
Heteromer | 99.8 | ||||
| Cryo-EM structure of the SARS-CoV-2 S-6P in complex with 35B5 Fab(1 out RBD, state3) |
Heteromer | 99.4 | 27×NAG; | |||
| cryoEM structure of SARS-CoV2 Spike trimer in complex with Fab23 |
Heteromer | 99.4 | ||||
| SARS-CoV-2 Spike ectodomain with Fab FI3A |
Heteromer | 99.8 | 11×NAG; 27×NAG; | |||
| Spike protein from SARS-CoV2 with Fab fragment of enhancing antibody 2490 |
Heteromer | 99.47 | ||||
| SARS-CoV-2 Omicron BA.2 spike trimer (6P) in complex with D1F6 Fab, head-to-head aggregate |
Heteromer | 96.46 | 7×NAG; 22×NAG; | |||
| Structure of SARS-CoV-2 Omicron BA.1 Spike complexed with antibody PW5-570 |
Heteromer | 97.62 | ||||
| SARS-CoV-2 Omicron BA.2 spike trimer (6P) in complex with 3 D1F6 Fabs (2 RBD up) |
Heteromer | 96.46 | 18×NAG; 21×NAG; | |||
| EM structure of SARS-CoV-2 Spike glycoprotein in complex with COVOX-316 Fab |
Heteromer | 99.8 | 15×NAG; 3×NAG; 25×NAG; | |||
| Structure of the SARS-CoV-2 S 2P trimer in complex with the human neutralizing antibody Fab fragmen… |
Heteromer | 99.69 | 13×NAG; 1×NAG; 1×NAG; 33×NAG; | |||
| EM structure of SARS-CoV-2 Spike glycoprotein in complex with COVOX-40 Fab |
Heteromer | 99.8 | 11×NAG; 27×NAG; | |||
| SARS-CoV-2 Omicron BA.4 spike trimer (6P) in complex with 3 D1F6 Fabs (1 RBD up) |
Heteromer | 97.62 | 11×NAG; 28×NAG; | |||
| Cryo-EM structure of Antibody 12-19 in complex with prefusion SARS-CoV-2 Spike glycoprotein |
Heteromer | 99.7 | 47×NAG; | |||
| Cryo-EM structure of South African (B.1.351) SARS-CoV-2 spike glycoprotein in complex with three T6… |
Heteromer | 99.4 | 25×NAG; | |||
| SARS CoV2 Spike ectodomain with engineered trimerized VH binder |
Heteromer | 99.8 | ||||
| SARS-CoV-2 Delta Spike in complex with IS-9A |
Heteromer | 99.05 | 4×NAG; 24×NAG; | |||
| SARS-CoV-2 Omicron BA.2 spike trimer (6P) in complex with 3 D1F6 Fabs (1 RBD up) |
Heteromer | 96.45 | 15×NAG; 2×NAG; 24×NAG; | |||
| SARS-CoV-2 Omicron BA.4 spike trimer (6P) in complex with 3 D1F6 Fabs (2 RBD up) |
Heteromer | 97.62 | 12×NAG; 24×NAG; | |||
| SARS-CoV-2 Spike in complex with neutralizing Fab SARS2-38 (three down conformation) |
Heteromer | 99.4 | 15×NAG; 33×NAG; | |||
| Cryo-EM structure of Antibody 12-16 in complex with prefusion SARS-CoV-2 Spike glycoprotein |
Heteromer | 99.71 | 48×NAG; | |||
| Cryo-EM structure of South African (B.1.351) SARS-CoV-2 spike glycoprotein in complex with two T6 F… |
Heteromer | 99.4 | 25×NAG; | |||
| Cryo-EM structure of the Omicron S in complex with 35B5 Fab(1 down- and 2 up RBDs) |
Heteromer | 97.56 | 2×NAG; 27×NAG; | |||
| CRYO-EM STRUCTURE OF SARS-COV-2 SPIKE : H11-B5 nanobody complex |
Heteromer | 99.8 | 20×NAG; 26×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 spike glycoprotein in complex with three D2 Fab |
Heteromer | 99.41 | 32×NAG; | |||
| Cryo-EM structure of the Omicron S in complex with 35B5 Fab(1 down-, 1 up- and 1 invisible RBDs) |
Heteromer | 97.56 | 27×NAG; | |||
| SARS-CoV-2 Spike in complex with Fab of m31A7 |
Heteromer | 99.71 | 2×NAG; 8×NAG; 2×NAG; 4×NAG; 3×NAG; 2×NAG; 1×NAG; 1×NAG; 1×NAG; 19×NAG; | |||
| Beta-53 fab in complex with SARS-CoV-2 beta-Spike glycoprotein |
Heteromer | 99.37 | 2×NAG; 11×NAG; 15×NAG; | |||
| SARS-CoV-2 WT Spike in complex with R15 Fab and P14 Nanobody |
Heteromer | 99.6 | 15×NAG; 33×NAG; | |||
| Cryo-EM structure of prefusion SARS-CoV-2 spike glycoprotein in complex with 910-30 Fab |
Heteromer | 99.8 | 12×NAG; 35×NAG; | |||
| EM structure of SARS-CoV-2 Spike glycoprotein in complex with COVOX-384 Fab |
Heteromer | 99.8 | 15×NAG; 30×NAG; | |||
| SARS-CoV-2 S-trimer (3 RBDs up) bound to TriSb92, fitted into cryo-EM map |
Heteromer | 99.8 | 6×NAG; 39×NAG; | |||
| Spike protein from SARS-CoV2 with Fab fragment of enhancing antibody 8D2 |
Heteromer | 99.47 | ||||
| Structure of the SARS-CoV-2 BA.1 spike with UT28-RD |
Heteromer | 97.56 | 8×NAG; 34×NAG; | |||
| Structure of the SARS-CoV-2 S 2P trimer in complex with the human neutralizing antibody Fab fragmen… |
Heteromer | 99.8 | 28×NAG; | |||
| Structure of the SARS-CoV-2 spike glycoprotein in complex with the 47D11 neutralizing antibody Fab … |
Heteromer | 99.79 | 10×NAG; 3×NAG; 1×NAG; 1×NAG; 1×NAG; 1×MAN; 28×NAG; 3×FUC; 2×MAN; | |||
| J08 fragment antigen binding in complex with SARS-CoV-2-6P-Mut7 S protein (conformation 3) |
Heteromer | 99.19 | 7×NAG; 16×NAG; | |||
| Ultrapotent SARS-CoV-2 neutralizing antibodies with protective efficacy against newly emerged mutat… |
Heteromer | 99.8 | 22×NAG; | |||
| Cryo-EM structure of the SARS-CoV-2 S-6P in complex with 35B5 Fab(1 down RBD, state1) |
Heteromer | 99.4 | 27×NAG; | |||
| Structure of the SARS-CoV-2 S 6P trimer in complex with the human neutralizing antibody Fab fragmen… |
Heteromer | 99.8 | 15×NAG; 30×NAG; | |||
| Structure of the SARS-CoV-2 S 2P trimer in complex with the human neutralizing antibody Fab fragmen… |
Heteromer | 99.69 | 10×NAG; 21×NAG; | |||
| SARS-CoV-2 Spike in complex with neutralizing Fab 2B04 (one up, two down conformation) |
Heteromer | 100.0 | 14×NAG; 21×NAG; 3×NAG; 3×NAG; 3×NAG; | |||
| SARS-CoV-2 Spike protein in complex with the single chain fragment scFv76 |
Heteromer | 99.41 | 12×NAG; 27×NAG; | |||
| SARS-CoV-2 Spike in complex with neutralizing Fab 2H04 (three down conformation) |
Heteromer | 100.0 | 12×NAG; 21×NAG; 3×NAG; 3×NAG; 3×NAG; 3×NAG; | |||
| Structure of the SARS-CoV-2 S 2P trimer in complex with the human neutralizing antibody Fab fragmen… |
Heteromer | 99.8 | 3×NAG; 1×NAG; 1×NAG; 26×NAG; | |||
| Beta-32 fab in complex with SARS-CoV-2 beta-Spike glycoprotein |
Heteromer | 98.83 | 15×NAG; 30×NAG; | |||
| EM structure of SARS-CoV-2 Spike glycoprotein in complex with COVOX-150 Fab |
Heteromer | 99.8 | 11×NAG; 27×NAG; | |||
| Structure of human SARS-CoV-2 spike glycoprotein trimer bound by neutralizing antibody C1C-A3 Fab (… |
Heteromer | 99.35 | 3×NAG; 45×NAG; | |||
| EM structure of SARS-CoV-2 Spike glycoprotein in complex with COVOX-88 Fab |
Heteromer | 99.8 | 15×NAG; 1×NAG; 2×NAG; 30×NAG; | |||
| SARS-Cov2 Omicron varient S protein structure in complex with neutralizing monoclonal antibody 002-… |
Heteromer | 97.62 | 13×NAG; 28×NAG; | |||
| EM structure of SARS-CoV-2 Spike glycoprotein in complex with COVOX-253H165L Fab |
Heteromer | 99.8 | 10×NAG; 1×NAG; 27×NAG; | |||
| Structure of the SARS-CoV-2 S 2P trimer in complex with the human neutralizing antibody Fab fragmen… |
Heteromer | 99.7 | 13×NAG; 34×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 2P S ectodomain bound to two copies of domain-swapped antibody 2G12 |
Heteromer | 99.79 | 8×NAG; 2×NAG; 2×NAG; 2×NAG; 25×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 2P S ectodomain bound to one copy of domain-swapped antibody 2G12 |
Heteromer | 99.79 | 10×NAG; 1×NAG; 1×NAG; 1×NAG; 31×NAG; | |||
| SARS-CoV-2 Spike in complex with neutralizing nanobody Nb6 |
Heteromer | 99.8 | 12×NAG; 30×NAG; | |||
| SARS-CoV-2 Spike in complex with neutralizing nanobody mNb6 |
Heteromer | 99.8 | 18×NAG; 27×NAG; | |||
| SARS-CoV-2 spike + IMCAS-123 |
Heteromer | 99.8 | 2×NAG; 15×NAG; | |||
| Ultrapotent SARS-CoV-2 neutralizing antibodies with protective efficacy against newly emerged mutat… |
Heteromer | 99.8 | 20×NAG; | |||
| Cryo-EM Structure of SARS-CoV-2 Spike : H11-D4 Nanobody Complex |
Heteromer | 99.8 | 20×NAG; 26×NAG; | |||
| EM structure of SARS-CoV-2 Spike glycoprotein (one RBD up) in complex with COVOX-253H55L Fab |
Heteromer | 99.8 | 10×NAG; 1×NAG; 27×NAG; | |||
| SARS-CoV-2 BA.1 variants S ectodomain trimer in complex with neutralizing antibody 10-5B and 6-2C |
Heteromer | 97.44 | 3×NAG; | |||
| Potent neutralizing nanobodies resist convergent circulating variants of SARS-CoV-2 by targeting no… |
Heteromer | 99.39 | ||||
| CRYO-EM STRUCTURE OF SARS-COV-2 SPIKE : H11-H4 Q98R H100E nanobody complex in 1Up2Down conformation |
Heteromer | 99.8 | 20×NAG; 26×NAG; | |||
| Complex structure of BD-218 and Spike protein |
Heteromer | 99.42 | 2×NAG; 32×NAG; | |||
| CRYO-EM STRUCTURE OF SARS-COV-2 SPIKE : H11 nanobody complex |
Heteromer | 99.8 | 19×NAG; 28×NAG; | |||
| CRYO-EM STRUCTURE OF SARS-COV-2 SPIKE : H11-H6 nanobody complex |
Heteromer | 99.8 | 20×NAG; 26×NAG; | |||
| Structure of the SARS-CoV-2 spike glycoprotein in complex with the C105 neutralizing antibody Fab f… |
Heteromer | 99.69 | 9×NAG; 1×NAG; 2×NAG; 1×NAG; 30×NAG; | |||
| Structure of the SARS-CoV-2 spike glycoprotein in complex with the C105 neutralizing antibody Fab f… |
Heteromer | 99.69 | 9×NAG; 3×NAG; 3×NAG; 24×NAG; | |||
| Structure of SARS-CoV-2 S protein in complex with N-terminal domain antibody DH1052 |
Heteromer | 99.79 | 14×NAG; 31×NAG; | |||
| Structure of SARS-CoV-2 S protein in complex with N-terminal domain antibody DH1050.1 |
Heteromer | 99.8 | 15×NAG; 33×NAG; | |||
| Structure of SARS-CoV-2 S protein in complex with Receptor Binding Domain antibody DH1047 |
Heteromer | 99.38 | 13×NAG; 2×NAG; 24×NAG; | |||
| CryoEM structure of SARS-CoV-2 S protein in complex with Receptor Binding Domain antibody DH1042 |
Heteromer | 99.7 | 1×NAG; 12×NAG; 33×NAG; | |||
| CRYO-EM STRUCTURE OF SARS-COV-2 SPIKE : H11-A10 nanobody complex |
Heteromer | 99.8 | 20×NAG; 26×NAG; | |||
| H11-H4 bound to Spike |
Heteromer | 99.8 | 20×NAG; 26×NAG; | |||
| Structure of the SARS-CoV-2 S 2P trimer in complex with the human neutralizing antibody Fab fragmen… |
Heteromer | 99.8 | 28×NAG; | |||
| Structure of the SARS-CoV-2 S 2P trimer in complex with the human neutralizing antibody Fab fragmen… |
Heteromer | 99.8 | 23×NAG; | |||
| Trypsin-digested S protein of SARS-CoV-2 bound with PD of ACE2 in the conformation 2 (2 up RBD and … |
Heteromer Q9BYF1; | 99.8 | 32×NAG; 29×NAG; | |||
| Furin Cleaved Alpha Variant SARS-CoV-2 Spike in complex with 3 ACE2 |
Heteromer Q9BYF1; | 100.0 | 3×NAG; 48×NAG; 3×ZN; | |||
| S-ECD (Omicron BA.3) in complex with three PD of ACE2 |
Heteromer Q9BYF1; | 100.0 | 38×NAG; 28×NAG; | |||
| SARS-CoV-2 Omicron BA.2 Variant Spike Trimer with three human ACE2 Bound |
Heteromer Q9BYF1; | 97.08 | 39×NAG; 3×CL; 3×ZN; | |||
| S-ECD (Omicron BF.7) in complex with PD of ACE2 |
Heteromer Q9BYF1; | 97.5 | 38×NAG; 28×NAG; | |||
| SARS-CoV-2 Omicron BA.1 Variant Spike Trimer with two mouse ACE2 Bound |
Heteromer Q8R0I0; | 97.62 | 39×NAG; 2×ZN; | |||
| S-ECD (Omicron XBB.1) in complex with PD of ACE2 |
Heteromer Q9BYF1; | 98.0 | 38×NAG; 28×NAG; | |||
| cryo-EM structure of D614 spike in complex with de novo designed binder |
Heteromer Q9VKJ9; | 99.7 | 7×NAG; 32×NAG; | |||
| S protein of SARS-CoV-2 bound with PD of ACE2 in the conformation 3 (2 up RBD and 1 PD bound) |
Heteromer Q9BYF1; | 99.8 | 27×NAG; 28×NAG; | |||
| SARS-CoV-2 Omicron BA.2 Variant Spike Trimer with one mouse ACE2 Bound |
Heteromer Q8R0I0; | 97.08 | 34×NAG; 1×ZN; | |||
| Trypsin-digested S protein of SARS-CoV-2 bound with PD of ACE2 in the conformation 1 (1 up RBD and … |
Heteromer Q9BYF1; | 99.8 | 27×NAG; 28×NAG; | |||
| S-ECD (Omicron BA.3) in complex with two PD of ACE2 |
Heteromer Q9BYF1; | 100.0 | 33×NAG; 27×NAG; | |||
| Conformation 1 of S-ACE2-B0AT1 ternary complex |
Heteromer Q695T7; Q9BYF1; | 99.8 | 58×NAG; 64×NAG; 2×LEU; 2×ZN; | |||
| S protein of SARS-CoV-2 in complex bound with P5A-2F11_2B |
Heteromer A0A5C2G1U0; P01834; P0DP01; V9HW68; | 99.8 | 21×NAG; 2×NAG; 28×NAG; | |||
| SARS-CoV-2 Omicron BA.2 Variant Spike Trimer with two human ACE2 Bound |
Heteromer Q9BYF1; | 97.08 | 39×NAG; 2×CL; 2×ZN; | |||
| S-ECD (Omicron BA.2.75) in complex with PD of ACE2 |
Heteromer Q9BYF1; | 96.9 | 37×NAG; 29×NAG; | |||
| Trypsin-digested S protein of SARS-CoV-2 bound with PD of ACE2 in the conformation 3 (3 up RBD and … |
Heteromer Q9BYF1; | 99.8 | 32×NAG; 29×NAG; | |||
| S-ECD (Omicron BA.5) in complex with PD of ACE2 |
Heteromer Q9BYF1; | 97.5 | 38×NAG; 28×NAG; | |||
| S-ECD (Omicron BA.2) in complex with PD of ACE2 |
Heteromer Q9BYF1; | 97.2 | 38×NAG; 28×NAG; | |||
| S-ECD (Omicron) in complex with PD of ACE2 |
Heteromer Q9BYF1; | 100.0 | 23×NAG; 45×NAG; | |||
| S protein of SARS-CoV-2 in complex bound with T-ACE2 |
Heteromer Q9BYF1; | 99.8 | 35×NAG; 34×NAG; | |||
| SARS-CoV-2 Omicron BA.1 Variant Spike Trimer with one mouse ACE2 Bound |
Heteromer Q8R0I0; | 97.62 | 37×NAG; 1×ZN; | |||
| S protein of SARS-CoV-2 bound with PD of ACE2 in the conformation 2 (1 up RBD and 1 PD bound) |
Heteromer Q9BYF1; | 99.8 | 26×NAG; 30×NAG; | |||
| S protein of SARS-CoV-2 in complex bound with P5A-2F11_3B |
Heteromer A0A5C2G1U0; P01834; P0DP01; V9HW68; | 99.8 | 22×NAG; 3×NAG; 27×NAG; | |||
| SARS-CoV-2 Omicron BA.2 Variant Spike Trimer with two mouse ACE2 Bound |
Heteromer Q8R0I0; | 97.08 | 37×NAG; 2×ZN; | |||
| State 2 of SARS-CoV-2 XBB Variant Spike protein trimer complexed with antibody PW5-5 |
Heteromer | 99.14 | ||||
| Cryo-EM structure of the SARS-CoV-2 S-6P in complex with BD-368-2 Fabs |
Heteromer | 99.4 | 5×NAG; 31×NAG; | |||
| Omicron BA.4/5 SARS-CoV-2 S in complex with TH027 Fab |
Heteromer | 96.97 | 37×NAG; | |||
| CryoEM structure of the SARS-CoV-2 S6P(B.1.617.2) in complex with SWC11 Fab |
Heteromer | 99.0 | ||||
| Structure of the SARS-CoV-2 S 6P trimer in complex with the mouse antibody Fab fragment, M8a-6 |
Heteromer | 100.0 | 48×NAG; | |||
| S protein of SARS-CoV-2 in complex bound with P5A-3C12_1B |
Heteromer | 99.8 | 21×NAG; 27×NAG; | |||
| Structure of XBB spike protein (S) dimer-trimer in complex with bispecific antibody G7-Fc at 3.75 A… |
Heteromer | 99.14 | ||||
| Structure of the SARS-CoV-2 S 6P trimer in complex with the human neutralizing antibody Fab fragmen… |
Heteromer | 99.4 | 33×NAG; | |||
| Cryo-EM structure of the SARS-CoV-2 spike glycoprotein bound to Fab 2-4 |
Heteromer A0A5C2GJG2; | 99.81 | 7×NAG; 3×NAG; 2×NAG; 36×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 S-D614G variant in complex with neutralizing antibodies, RBD-chAb15… |
Heteromer | 99.7 | 27×NAG; 21×NAG; | |||
| Omicron BA.4/5 SARS-CoV-2 S in complex with TH132 Fab |
Heteromer | 96.97 | 36×NAG; | |||
| Omicron BA.4/5 SARS-CoV-2 S in complex with TH281 Fab |
Heteromer | 96.97 | 36×NAG; | |||
| BA.4/5-5 FAB IN COMPLEX WITH SARS-COV-2 BA.4 SPIKE GLYCOPROTEIN |
Heteromer | 97.53 | 12×NAG; 27×NAG; | |||
| Cryo-EM structure of the SARS-CoV-2 S-6P in complex with Fab30 |
Heteromer | 99.38 | 13×NAG; 27×NAG; | |||
| S protein of SARS-CoV-2 in complex with GW01 |
Heteromer | 99.5 | 23×NAG; 25×NAG; | |||
| S protein of SARS-CoV-2 in complex bound with P36-5D2(state2) |
Heteromer | 99.5 | 17×NAG; 28×NAG; | |||
| SARS-CoV-2 Omicron BA.1 Spike in complex with IY-2A |
Heteromer | 97.62 | ||||
| Omicron BA.4/5 SARS-CoV-2 S in complex with TH236 Fab |
Heteromer | 96.97 | 37×NAG; | |||
| SARS-CoV-2 spike protein in complex with a trivalent nanobody |
Heteromer | 99.29 | ||||
| Omicron BA.4/5 SARS-CoV-2 S in complex with TH027/132 Fab |
Heteromer | 96.97 | 37×NAG; | |||
| S protein of SARS-CoV-2 in complex bound with P36-5D2 (state1) |
Heteromer | 99.5 | ||||
| SARS-CoV-2 Omicron BA.2 Variant Spike Trimer with three JMB2002 Fab Bound |
Heteromer | 97.08 | 2×NAG; 35×NAG; | |||
| Structure of the SARS-CoV-2 S 6P trimer in complex with neutralizing antibody C032 |
Heteromer | 100.0 | 4×NAG; 1×NAG; 22×NAG; | |||
| S-ECD (Omicron) in complex with STS165 |
Heteromer | 100.0 | 19×NAG; 33×NAG; | |||
| SARS-CoV-2 Omicron spike in complex with 5817 Fab |
Heteromer | 97.15 | 2×NAG; 36×NAG; | |||
| SARS-CoV 2 Spike Protein bound to LY-CoV555 |
Heteromer | 99.27 | 3×NAG; 16×NAG; | |||
| Structure of the SARS-CoV-2 S 6P trimer in complex with the human neutralizing antibody Fab fragmen… |
Heteromer | 99.38 | 11×NAG; 26×NAG; | |||
| SARS-CoV-2 Omicron Variant S Trimer complexed with two JMB2002 Fab |
Heteromer | 97.62 | 2×NAG; 36×NAG; | |||
| Cryo EM structure of SARS-CoV-2 spike in complex with TAU-2212 mAbs in conformation 4 |
Heteromer | 99.8 | 33×NAG; | |||
| SARS-CoV-2 spike in complex with the ZB8 neutralizing antibody Fab (2u1d) |
Heteromer | 99.8 | 17×NAG; 20×NAG; | |||
| Omicron BA.4/5 SARS-CoV-2 S in complex with TH272/281 Fab |
Heteromer | 96.97 | 37×NAG; | |||
| S protein of SARS-CoV-2 in complex bound with P5A-3A1 |
Heteromer | 99.8 | 22×NAG; 26×NAG; | |||
| BD23-Fab in complex with the S ectodomain trimer |
Heteromer | 99.79 | 5×NAG; 1×NAG; 32×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 spike in complex with a neutralizing antibody RBD-chAb-25 |
Heteromer | 99.8 | 27×NAG; 21×NAG; | |||
| overall structure of hu33 and spike |
Heteromer | 98.71 | 3×NAG; 10×NAG; 26×NAG; | |||
| CryoEM structure of the SARS-CoV-2 S6P(B.1.617.2) in complex with SWA9 Fab |
Heteromer | 98.99 | ||||
| SARS-CoV-2 Omicron Variant S Trimer complexed with three JMB2002 Fab |
Heteromer | 97.62 | 2×NAG; 35×NAG; | |||
| S protein of SARS-CoV-2 in complex bound with P5A-3C12_2B |
Heteromer | 99.8 | 22×NAG; 26×NAG; | |||
| Structure of SARS-CoV-2 XBB Variant Spike protein complexed with broadly neutralizing antibody PW5-… |
Heteromer | 99.14 | ||||
| Omicron BA.4/5 SARS-CoV-2 S in complex with TH003 Fab |
Heteromer | 96.97 | 37×NAG; | |||
| SARS-CoV-2 spike in complex with the ZB8 neutralizing antibody Fab (3U) |
Heteromer | 99.8 | 18×NAG; 18×NAG; | |||
| Structure of the SARS-CoV-2 S 6P trimer in complex with neutralizing antibody N-612-017 |
Heteromer | 100.0 | 6×NAG; 19×NAG; | |||
| Omicron BA.4/5 SARS-CoV-2 S in complex with TH272 Fab |
Heteromer | 96.97 | 36×NAG; | |||
| State 1 of SARS-CoV-2 XBB Variant Spike protein trimer complexed with antibody PW5-5 |
Heteromer | 99.14 | ||||
| Cryo-EM structure of SARS-CoV-2 spike in complex with a neutralizing antibody RBD-chAb-45 |
Heteromer | 99.8 | 24×NAG; 24×NAG; | |||
| SARS-CoV-2 Omicron Variant S Trimer complexed with one JMB2002 Fab |
Heteromer | 97.62 | 2×NAG; 33×NAG; | |||
| S protein of Delta variant in complex with ZWC6 |
Heteromer | 100.0 | 23×NAG; 25×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 Omicron spike glycoprotein in complex with three F61 Fab and three … |
Heteromer | 97.62 | 31×NAG; | |||
| The structure of HKU1-B S protein with bsAb1 |
Heteromer | 96.97 | ||||
| S protein of Delta variant in complex with ZWD12 |
Heteromer | 100.0 | 23×NAG; 25×NAG; | |||
| SARS-CoV-2 spike in complex with LCB3 (2RBDs open) |
Heteromer | 99.49 | 13×NAG; 33×NAG; | |||
| S protein of SARS-CoV-2 in complex bound with P5A-2G7 |
Heteromer A0A0C4DH41; A0A5C2G2G8; Q6IPQ0; V9HW68; | 99.8 | 21×NAG; 28×NAG; | |||
| S protein of SARS-CoV-2 in complex bound with P5A-1B8_3B |
Heteromer A0A5C2GCZ2; A0A5C2GG81; Q6GMX6; Q8TCD0; | 99.8 | 20×NAG; 31×NAG; | |||
| S protein of SARS-CoV-2 in complex bound with FabP5A-1B8 |
Heteromer A0A5C2GCZ2; A0A5C2GF00; Q6GMX6; Q8TCD0; | 99.8 | 21×NAG; 28×NAG; | |||
| S protein of SARS-CoV-2 in complex bound with P2B-1A1 |
Heteromer A0A5C2GM57; P01825; Q5EFE5; Q8N5F4; | 99.8 | 23×NAG; 28×NAG; | |||
| S protein of SARS-CoV-2 in complex bound with P5A-1B6_2B |
Heteromer P01594; P0DOX5; P0DP02; Q8TCD0; | 99.8 | 21×NAG; 28×NAG; | |||
| S protein of SARS-CoV-2 in complex bound with P2B-1A10 |
Heteromer A0A5C2GF00; P01594; P0DOX5; Q8TCD0; | 99.8 | 21×NAG; 28×NAG; | |||
| S protein of SARS-CoV-2 in complex bound with P5A-2G9 |
Heteromer A0A5C2GMM2; P01772; P0DOX5; Q8N5F4; | 99.8 | 21×NAG; 28×NAG; | |||
| S protein of SARS-CoV-2 in complex bound with P5A-1B8_2B |
Heteromer A0A5C2GCZ2; A0A5C2GG81; Q6GMX6; Q8TCD0; | 99.8 | 20×NAG; 30×NAG; | |||
| S protein of SARS-CoV-2 in complex bound with P5A-1B6_3B |
Heteromer P01594; P0DOX5; P0DP02; Q8TCD0; | 99.8 | 20×NAG; 31×NAG; | |||
| S protein of SARS-CoV-2 in complex bound with P5A-1B9 |
Heteromer A0A5C2G1U0; P01825; Q6GMX6; Q8TCD0; | 99.8 | 19×NAG; 33×NAG; | |||
| S protein of SARS-CoV-2 in complex bound with FabP5A-2G7 |
Heteromer A0A0C4DH41; A0A5C2G2G8; Q6IPQ0; V9HW68; | 99.8 | 20×NAG; 29×NAG; | |||
| SARS-CoV-2 Spike trimer in complex with XG014 Fab |
Heteromer | 99.8 | 24×NAG; | |||
| Structure of the SARS-CoV-2 S 6P trimer in complex with the neutralizing antibody Fab fragment, C17… |
Heteromer | 100.0 | 6×NAG; 1×NAG; 27×NAG; | |||
| SARS-CoV-2 S trimer in complex with 1F Fab |
Heteromer | 99.8 | 15×NAG; 26×NAG; | |||
| Structure of SARS-CoV-2 XBB.1 spike glycoprotein in complex with ACE2 (1-up state) |
Heteromer Q9BYF1; | 100 | 8×NAG; 1×NAG; 1×NAG; 36×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 Omicron EG.5.1 spike protein(6P) in complex with human ACE2 |
Heteromer Q9BYF1; | 100 | 36×NAG; 1×ZN; | |||
| Structure of the SARS-CoV-2 Spike trimer with all RBDs down in complex with the Fab fragment of hum… |
Heteromer | 99.8 | 21×NAG; 30×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 Omicron Spike protein in complex with BA7208 fab |
Heteromer | 97.62 | 11×NAG; 16×NAG; | |||
| SARS-CoV-2 Omicron BA.1 spike trimer (x2-4P) in complex with 3 D1F6 Fabs (0 RBD up) |
Heteromer | 97.56 | 12×NAG; 24×NAG; | |||
| Structure of the SARS-CoV-2 S 6P trimer in complex with the ACE2 protein decoy, CTC-445.2 (State 4) |
Heteromer | 99.4 | 2×NAG; 27×NAG; | |||
| SARS-CoV-2 S glycoprotein in complex with S2X259 Fab |
Heteromer | 99.35 | 12×NAG; 30×NAG; | |||
| SARS-CoV-2 spike in complex with the S2H13 neutralizing antibody (closed conformation) |
Heteromer | 99.8 | 12×NAG; 36×NAG; | |||
| SARS-CoV-2 spike in complex with neutralizing antibody NIV-11 |
Heteromer | 99.4 | 12×NAG; 36×NAG; | |||
| SARS-CoV-2 spike in complex with the S2A4 neutralizing antibody Fab fragment |
Heteromer | 99.8 | 12×NAG; 3×NAG; 33×NAG; | |||
| P5C3 is a potent fab neutralizer |
Heteromer | 99.4 | ||||
| Structure of the SARS-CoV-2 Spike trimer with two RBDs down in complex with the Fab fragment of hum… |
Heteromer | 99.8 | 21×NAG; 30×NAG; | |||
| Structure of the SARS-CoV-2 S 6P trimer in complex with the human neutralizing antibody Fab fragmen… |
Heteromer | 99.4 | 15×NAG; 33×NAG; | |||
| Structure of the SARS-CoV-2 Spike trimer with one RBD down in complex with the Fab fragment of huma… |
Heteromer | 99.8 | 23×NAG; 28×NAG; | |||
| SARS-CoV-2 spike in complex with AHB2-2GS-SB175 |
Heteromer | 99.39 | 12×NAG; 36×NAG; | |||
| SARS-CoV-2 spike in complex with the S2E12 neutralizing antibody Fab fragment |
Heteromer | 99.4 | 15×NAG; 33×NAG; | |||
| SARS-CoV-2 S (B.1.429 / epsilon variant) + S2M11 + S2L20 Global Refinement |
Heteromer | 99.3 | 3×NAG; 6×NAG; 39×NAG; | |||
| SARS-CoV-2 BA.2.75 S Trimer in complex with XG2v024 |
Heteromer | 100 | 15×NAG; 9×NAG; 24×NAG; | |||
| Structure of the SARS-CoV-2 S 6P trimer in complex with neutralizing antibody C118 (State 1) |
Heteromer | 100.0 | 39×NAG; | |||
| SARS-CoV-2 Omicron BQ.1.1 Variant Spike Protein Complexed with MO11 Fab |
Heteromer | 100 | 9×NAG; 3×NAG; 3×NAG; 21×NAG; | |||
| SARS-CoV-2 spike in complex with the S2H13 neutralizing antibody (one RBD open) |
Heteromer | 99.8 | 11×NAG; 36×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 Omicron BA.4/5 spike protein in complex with white-tailed deer ACE2 |
Heteromer A0A6J0Z472; | 100.0 | 14×NAG; 25×NAG; 2×ZN; | |||
| Cryo-EM structure of SARS-CoV-2 Omicron JN.1 spike protein in complex with human ACE2 |
Heteromer Q9BYF1; | 100 | 6×NAG; 13×NAG; 3×ZN; 37×NAG; | |||
| Structure of the SARS-CoV-2 EG.5.1 spike glycoprotein in complex with ACE2 (1-up state) |
Heteromer Q9BYF1; | 100 | 8×NAG; 1×NAG; 1×NAG; 33×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 Delta Spike protein in complex with BA7054 and BA7125 fab |
Heteromer | 98.81 | 12×NAG; 12×NAG; | |||
| Cryo-EM structure of the SARS-CoV-2 spike glycoprotein bound to Fab 2-43 |
Heteromer | 99.8 | 6×NAG; 3×NAG; 31×NAG; | |||
| Cryo-EM structure of the SARS-CoV-2 spike glycoprotein bound to Fab 2-15 |
Heteromer | 99.8 | 7×NAG; 1×NAG; 1×NAG; 31×NAG; | |||
| Cryo-EM structure of the SARS-CoV-2 spike glycoprotein bound to Fab 2-7 |
Heteromer | 99.74 | 6×NAG; 30×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 Delta Spike protein in complex with BA7208 and BA7125 fab |
Heteromer | 100.0 | 12×NAG; 12×NAG; | |||
| SARS-CoV-2 Delta Spike in complex with JL-8C |
Heteromer | 99.03 | ||||
| Spike Trimer of BA.2.86 in complex with two hACE2s |
Heteromer Q9BYF1; | 97.56 | 15×NAG; 41×NAG; 2×ZN; 2×CL; | |||
| Spike Trimer of BA.2.86 in complex with one hACE2 |
Heteromer Q9BYF1; | 97.56 | 17×NAG; 35×NAG; 1×ZN; 1×CL; | |||
| BA.2.86 Spike in complex with bovine ACE2 (bound 2 ACE2) |
Heteromer Q58DD0; | 98.04 | 12×NAG; 1×NAG; | |||
| SARS-CoV-2 spike in complex with the S2K146 neutralizing antibody Fab fragment (two receptor-bindin… |
Heteromer | 99.39 | 8×NAG; 37×NAG; | |||
| SARS-CoV-2 Delta Spike in complex with FP-12A |
Heteromer | 98.31 | 7×NAG; 21×NAG; | |||
| SARS-CoV-2 BA.4 variants S ectodomain trimer in complex with neutralizing antibody 10-5B and 6-2C |
Heteromer | 97.44 | 3×NAG; | |||
| SARS-CoV-2 spike in complex with neutralizing antibody NIV-8 (state 2) |
Heteromer | 99.36 | 8×NAG; 27×NAG; | |||
| Cryo-EM structure of SARS-CoV2 Omicron BA.5 spike in complex with 8-9D Fabs |
Heteromer | 97.56 | 27×NAG; | |||
| Structure of SARS-CoV-2 Omicron BA.1 spike in complex with antibody Fab 1C3 |
Heteromer | 97.67 | 3×NAG; 18×NAG; | |||
| SARS-CoV-2 Spike (BA.1) in complex with Fab of JH-8B |
Heteromer | 97.73 | 4×NAG; 1×NAG; 7×NAG; | |||
| Conformation 1 of SARS-CoV-2 Omicron BA.1 Variant Spike protein complexed with MO1 Fab |
Heteromer | 97.56 | 22×NAG; | |||
| Conformation 2 of SARS-CoV-2 Omicron BA.1 Variant Spike protein complexed with MO1 Fab |
Heteromer | 97.56 | 28×NAG; | |||
| Structure of the SARS-CoV-2 spike glycoprotein in complex with the S309 neutralizing antibody Fab f… |
Heteromer | 99.79 | 12×NAG; 3×NAG; 33×NAG; | |||
| Structure of the SARS-CoV-2 spike glycoprotein in complex with the S309 neutralizing antibody Fab f… |
Heteromer | 99.79 | 10×NAG; 1×NAG; 1×NAG; 35×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 Omicron BA.2.86 spike protein(6P) in complex with human ACE2 |
Heteromer Q9BYF1; | 97.37 | 1×NAG; 5×NAG; 1×ZN; 33×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 Omicron HV.1 spike protein(6P) in complex with human ACE2 |
Heteromer Q9BYF1; | 97.09 | 29×NAG; 1×ZN; | |||
| Structure of SARS-CoV-2 XBB.1.5 spike glycoprotein in complex with ACE2 (1-up state) |
Heteromer Q9BYF1; | 98.99 | 8×NAG; 1×NAG; 1×NAG; 35×NAG; | |||
| Structure of SARS-CoV-2 XBB.1.5 spike glycoprotein in complex with ACE2 (2-up state) |
Heteromer Q9BYF1; | 98.99 | 9×NAG; 2×NAG; 2×NAG; 42×NAG; | |||
| Minor cryo-EM structure of S protein trimer of SARS-CoV2 with K-874A VHH, composite map |
Heteromer | 100.0 | ||||
| Major cryo-EM structure of S protein trimer of SARS-CoV2 with K-874, composite map |
Heteromer | 100.0 | ||||
| Structure of SARS-CoV-2 BA.2.86 spike glycoprotein in complex with ACE2 (3-up state) |
Heteromer Q9BYF1; | 97.44 | 6×NAG; 3×NAG; 3×NAG; 45×NAG; | |||
| Structure of SARS-CoV-2 BA.2.86 spike glycoprotein in complex with ACE2 (2-up state) |
Heteromer Q9BYF1; | 97.44 | 10×NAG; 2×NAG; 2×NAG; 38×NAG; | |||
| Structure of SARS-CoV-2 BA.2.86 spike glycoprotein in complex with ACE2 (2-up and 1-down state) |
Heteromer Q9BYF1; | 97.56 | 7×NAG; 2×NAG; 1×NAG; 1×NAG; 32×NAG; | |||
| A neutralizing nanobody VHH60 against wt SARS-CoV-2 |
Heteromer | 99.4 | 6×NAG; 20×NAG; | |||
| VFLIP Spike Trimer with GAR03 |
Heteromer | 98.37 | ||||
| SARS-CoV-2 S Omicron Spike B.1.1.529 - RBD and NTD (Local) |
Heteromer | 98.0 | 1×NAG; 2×NAG; 2×NAG; | |||
| Protective effect of human non-neutralizing cross-reactive spike antibodies elicited by SARS-CoV-2 … |
Heteromer | 100 | 1×NAG; 2×NAG; | |||
| Structure of the SARS-CoV-2 S1 subunit in complex with antibody N-612-004 |
Heteromer | 100.0 | ||||
| Local refinement of SARS-CoV-2 spike/nanobody mixture complex around NTD |
Heteromer | 99.79 | 35×NAG; | |||
| CryoEM structure of SARS-CoV-2 spike monomer in complex with neutralising antibody P008_60 |
Heteromer | 100.0 | 8×NAG; 1×3Q9; | |||
| Omicron spike variant BA.1 with Bn03 |
Heteromer | 97.67 | ||||
| XBB spike protein (S) in complex with monoclonal antibody 6I18 |
Heteromer | 99.14 | ||||
| Monomer state of SARS-CoV-2 XBB Variant Spike protein trimer complexed with antibody PW5-5 |
Heteromer | 99.14 | ||||
| Omicron spike variant XBB with Bn03 |
Heteromer | 99.06 | ||||
| Omicron spike variant XBB with n3130v-Fc |
Heteromer | 99.06 | ||||
| Dissociated S1 domain of SARS-CoV-2 Spike bound to ACE2 (Unmasked Refinement) |
Heteromer Q9BYF1; | 100.0 | 1×NAG; 7×NAG; 1×ZN; | |||
| Dissociated S1 domain of Alpha Variant SARS-CoV-2 Spike bound to ACE2 |
Heteromer Q9BYF1; | 100 | 1×ZN; 7×NAG; | |||
| Structure of the SARS-CoV-2 S S1 doamin in complex with the mouse antibody Fab fragment, HSW-2 |
Heteromer | 100.0 | 4×NAG; | |||
| Omicron spike variant BQ.1.1 with n3130v-Fc |
Heteromer | 100 | ||||
| Complex of SARS-CoV-2 spike and CR3022 Fab (Homogeneous Refinement) |
Heteromer | 100.0 | 2×NAG; | |||
| SARS-CoV-2 wildtype S1 in complex with YB9-258 Fab and R1-32 Fab |
Heteromer | 100.0 | 1×NAG; | |||
| SARS-CoV-2 S1 in complex with H18 and R1-32 Fab |
Heteromer | 100.0 | 1×NAG; | |||
| Dimer of SARS-CoV-2 S1 in complex with H18 and R1-32 Fabs |
Heteromer | 100.0 | 2×NAG; | |||
| local refinement of SARS-CoV-2 spike/Nb4 complex with 2 RBDs up and 3 Nb4 bound |
Heteromer | 99.83 | 12×NAG; | |||
| SARS-CoV-2 spike/Nb3 complex with 2 RBDs up and 3 Nb3 (local refinement) |
Heteromer | 100.0 | 2×NAG; | |||
| SARS-CoV-2 spike/Nb3 complex with 1 RBD up and 2 Nb3 (local refinement) |
Heteromer | 100.0 | 7×NAG; | |||
| SARS-CoV-2 Omicron BA.1 spike trimer (6P) complex with YB9-258 Fab, focused refinement of RBD-dimer… |
Heteromer | 98.18 | 7×NAG; | |||
| SARS-CoV-2 Omicron BA.1 spike trimer (6P) in complex with YB9-258 Fab, focused refinement of Fab re… |
Heteromer | 94.01 | 7×NAG; | |||
| SARS-CoV-2 spike trimer RBD in complex with Fab NA8 |
Heteromer | 100.0 | 4×NAG; | |||
| SARS-CoV-2 spike trimer RBD in complex with Fab NE12 |
Heteromer | 100.0 | 3×NAG; | |||
| SARS-CoV-2 S protein bound to neutralising antibody UZGENT_A3 |
Heteromer | 100.0 | 2×NAG; 3×NAG; 1×NAG; | |||
| SARS-CoV-2 S protein bound to human neutralising antibody UZGENT_G5 |
Heteromer | 100.0 | 3×NAG; 3×NAG; | |||
| Complex of SARS-CoV-2 spike and CR3022 Fab (Non-Uniform Refinement) |
Heteromer | 100.0 | 2×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 spike (Omicron BA.1 variant) in complex with nanobody W25 (map 5, f… |
Heteromer | 98.18 | 1×NAG; 1×NAG; 5×NAG; | |||
| SARS-CoV-2 Spike (2P) in complex with G32R7 Fab (RBD and NTD local reconstruction) |
Heteromer | 100 | 1×NAG; 1×NAG; 2×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 spike (HexaPro variant) in complex with nanobody W25 (map 3, focus … |
Heteromer | 100 | 3×NAG; 1×NAG; 1×NAG; | |||
| SARS-CoV-2 NTD in complex with N9 Fab |
Heteromer | 100.0 | ||||
| local refinement of XBB.1.5 spike/Nanosota-3C complex |
Heteromer | 100 | ||||
| Cryo-EM structure of the SARS-CoV-2 S-6P in complex with 35B5 Fab (state1, local refinement of the … |
Heteromer | 100.0 | 2×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 spike protein in complex with nanobody C5G2 (localized refinement) |
Heteromer | 100.0 | 4×NAG; | |||
| Local CryoEM structure of the SARS-CoV-2 S6PV2 in complex with BD-804 Fab |
Heteromer | 98.36 | 1×NAG; | |||
| Local CryoEM structure of the SARS-CoV-2 S6PV2 in complex with BD-813 Fab and BD-744 Fab |
Heteromer | 98.36 | ||||
| Local CryoEM of the SARS-CoV-2 S6PV2 in complex with BD-667 |
Heteromer | 98.36 | 1×NAG; | |||
| Crystal structure of a chimeric protein mimic of SARS-CoV-2 Spike HR1 in complex with HR2 |
Heteromer | 84.21 | ||||
| SARS-CoV-2 Spike S2 bound to Fab 54043-5 |
Heteromer | 97.98 | 3×NAG; 15×NAG; | |||
| Structure of a SARS-CoV-2 spike S2 subunit in a pre-fusion, open conformation |
Heteromer | 97.97 | 3×NAG; 15×NAG; | |||
| Structure of the SARS-CoV-2 NTD in complex with C1520, local refinement |
Heteromer | 100.0 | 3×NAG; 4×NAG; | |||
| Structure of viral peptides IPB19/N52 |
Heteromer | 100 | ||||
| Crystal structure of the N-terminal domain of SARS-CoV-2 beta variant spike glycoprotein in complex… |
Heteromer | 98.64 | 2×NAG; 1×NAG; 2×NAG; 6×CL; 1×PEG; 3×GOL; 1×PO4; 7×NAG; 1×PG4; | |||
| Cryo-EM structure of SARS-CoV-2 Gamma (P.1) spike protein in complex with Fab 4-8 (focused refineme… |
Heteromer | 98.17 | 6×NAG; | |||
| SARS-CoV-2 S NTD B.1.617.2 delta variant + S2L20 Local Refinement |
Heteromer | 97.66 | 1×NAG; 4×NAG; | |||
| SARS-CoV-2 S NTD B.1.1.529 Omicron variant + S309 Local Refinement |
Heteromer | 98.11 | 6×NAG; | |||
| SARS-CoV-2 S NTD B.1.617.1 kappa variant S2L20 Local Refinement |
Heteromer | 98.78 | 1×NAG; 5×NAG; | |||
| SARS-CoV-2 S + S2L20 (local refinement of NTD and S2L20 Fab variable region) |
Heteromer | 100.0 | 1×NAG; 1×NAG; 4×NAG; | |||
| Crystal structure of SARS-CoV-2 S NTD bound to S2M28 Fab |
Heteromer | 99.64 | 2×NAG; 2×NAG; 1×NAG; 2×NAG; 1×UNX; 1×XYL; 1×SO4; | |||
| SARS-CoV-2 S NTD (C.37 Lambda variant) plus S2L20 and S2X303 Fabs, local refinement |
Heteromer | 100.0 | 1×NAG; 2×NAG; 5×NAG; | |||
| SARS-CoV-2 S NTD B.1.617.1 kappa variant S2X303 Local Refinement |
Heteromer | 98.84 | 1×NAG; 6×NAG; | |||
| SARS-CoV-2 Spike NTD in complex with neutralizing Fab SARS2-57 (local refinement) |
Heteromer | 100.0 | 2×NAG; 4×NAG; | |||
| Crystallographic structure of neutralizing antibody 2-51 in complex with SARS-CoV-2 spike N-termina… |
Heteromer | 100.0 | 1×NAG; 6×NAG; 23×CA; 3×ACT; 1×PGE; | |||
| an engineered 5-helix bundle derived from SARS-CoV-2 S2 in complex with HR2P |
Heteromer | 81.25 | ||||
| Structure of the SARS-CoV-2 Omicron spike post-fusion bundle |
Heteromer | 95.78 | ||||
| Cryo-EM structure of the SARS-CoV-2 Omicron HR1-42G complex |
Heteromer | 95.78 | ||||
| Cryo-EM structure of the SARS-CoV-2 HR1HR2 fusion core complex with D936Y mutation |
Heteromer | 98.59 | ||||
| Cryo-EM structure of the SARS-CoV-2 HR1HR2 fusion core complex with L938F mutation |
Heteromer | 98.59 | ||||
| Cryo-EM structure of the SARS-CoV-2 HR1HR2 fusion core complex |
Heteromer | 100 | ||||
| Cryo-EM structure of the SARS-CoV-2 HR1HR2 fusion core complex with A942S mutation |
Heteromer | 98.59 | ||||
| Cryo-EM structure of the SARS-CoV-2 HR1HR2 fusion core complex with extended HR2 |
Heteromer | 100 | ||||
| Cryo-EM structure of the SARS-CoV-2 HR1HR2 fusion core complex with S940F mutation |
Heteromer | 98.59 | ||||
| Cryo-EM structure of the SARS-CoV-2 HR1HR2 fusion core complex with V1176F mutation |
Heteromer | 100 | ||||
| Cryo-EM structure of the N-terminal domain of Omicron BA.1 in complex with nanobody N235 and S2L20 … |
Heteromer | 97.83 | 5×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 Gamma (P.1) spike protein in complex with Fab 4A8 (focused refineme… |
Heteromer | 98.04 | 1×NAG; 5×NAG; | |||
| SARS-CoV-2 S (B.1.429 / epsilon variant) + S2M11 + S2L20 (Local Refinement of the NTD/S2L20) |
Heteromer | 100.0 | 5×NAG; | |||
| XBB-4 Fab in complex with SARS-CoV-2 BA.2.12.1 Spike Glycoprotein |
Heteromer | 93.93 | ||||
| Cryo-EM structure of SARS-CoV-2 Omicron BA.2 spike protein in complex with Fab 4A8 (focused refinem… |
Heteromer | 90.0 | 1×NAG; 4×NAG; | |||
| SARS-CoV-2 Spike Protein N terminal domain in Complex with N11 Fab |
Heteromer | 100.0 | ||||
| SARS-CoV-2 Spike in complex with PVI.V6-14 Fab |
Heteromer A0A5C2FYK4; | 100 | 2×NAG; 3×NAG; | |||
| Local CryoEM structure of del68-76/del679-688 prefusion-stabilized spike in complex with the Fab of… |
Heteromer | 100 | ||||
| SARS-CoV-2 spike in complex with the ZB8 neutralizing antibody Fab (focused refinement on Fab-RBD) |
Heteromer | 100 | ||||
| SARS-CoV-2 Spike (2P) in complex with C12C9 Fab (NTD local reconstruction) |
Heteromer | 100 | 5×NAG; | |||
| A proof of concept for neutralizing antibody-guided vaccine design against SARS-CoV-2 |
Heteromer | 100.0 | ||||
| SARS-CoV-2 Beta spike SD1 in complex with S3H3 Fab |
Heteromer | 100 | ||||
| The local refined map of SARS-CoV-2 XBB Variant Spike protein complexed with antibody PW5-535 |
Heteromer | 92.03 | ||||
| SARS-CoV-2 Omicron spike protein SD1 in complex with S3H3 Fab |
Heteromer | 100 | ||||
| sd1.040 Fab in complex with SARS-CoV-2 Spike 2P glycoprotein |
Heteromer | 100 | 1×NAG; | |||
| SARS-CoV-2 spike/Nb2 complex with 1 RBD up (local refinement at 5.6 A) |
Heteromer | 100.0 | ||||
| Dissociated S1 domain of SARS-CoV-2 Spike bound to ACE2 (Non-Uniform Refinement) |
Heteromer Q9BYF1; | 100.0 | 1×NAG; 7×NAG; 1×ZN; | |||
| Dissociated S1 domain of Mink Variant SARS-CoV-2 Spike bound to ACE2 (Non-Uniform Refinement) |
Heteromer Q9BYF1; | 99.6 | 1×ZN; 6×NAG; | |||
| Dissociated S1 domain of Alpha Variant SARS-CoV-2 Spike bound to ACE2 (Non-Uniform Refinement) |
Heteromer Q9BYF1; | 99.6 | 1×ZN; 8×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 Omicron RBD in complex with S309 fab (local refinement) |
Heteromer | 94.05 | 1×NAG; | |||
| Dissociated S1 domain of Beta Variant SARS-CoV-2 Spike bound to ACE2 (Non-Uniform Refinement) |
Heteromer Q9BYF1; | 98.8 | 7×NAG; 1×ZN; | |||
| SARS-CoV-2 RBD in complex with Omicron-neutralizing antibody 2A10 |
Heteromer | 100.0 | 1×NAG; | |||
| Cryo-EM structure of spike binding to Fab of neutralizing antibody (locally refined) |
Heteromer | 100.0 | 1×NAG; | |||
| Antibody A7V3 bound to N-terminal domain of the spike |
Heteromer | 100.0 | 5×NAG; | |||
| SARS-CoV-2 S-NTD + Fab CM25 |
Heteromer | 100.0 | ||||
| Local refinement of SARS-CoV-2 (HP-GSAS-Mut7) spike NTD in complex with TXG-0078 Fab |
Heteromer | 100.0 | 1×NAG; 2×NAG; | |||
| SARS-CoV-2 S/S2M11/S2M28 Local Refinement |
Heteromer | 100.0 | 1×NAG; 2×NAG; | |||
| SARS-CoV-2 S/S2M11/S2L28 Local Refinement |
Heteromer | 100.0 | 1×NAG; 1×NAG; | |||
| OMI-38 FAB IN COMPLEX WITH SARS-COV-2 BETA SPIKE RBD (local refinement) |
Heteromer | 98.78 | 1×NAG; | |||
| SARS-CoV-2 S/S2M11/S2X333 Local Refinement |
Heteromer | 100.0 | 1×NAG; 1×NAG; | |||
| Structure of human SARS-CoV-2 neutralizing antibody C1C-A3 Fab |
Heteromer | 100 | 1×NAG; 1×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 WT RBD in complex with W328-6H2 (local refinement) |
Heteromer | 100.0 | 2×NAG; | |||
| Crystallographic structure of two neutralizing nanobodies in complex with SARS-CoV-2 spike receptor… |
Heteromer | 99.5 | 1×NAG; 1×NAG; 3×PEG; 2×GOL; | |||
| Structures of Omicron Spike complexes illuminate broad-spectrum neutralizing antibody development |
Heteromer | 93.12 | ||||
| Structure of SARS-CoV-2 spike protein receptor binding domain in complex with a neutralizing antibo… |
Heteromer | 100 | 1×NAG; | |||
| SARS-CoV-2 spike in complex with the 17T2 neutralizing antibody Fab fragment (local refinement of R… |
Heteromer | 92.86 | 2×NAG; | |||
| SARS-CoV-2 Spike:5A6 Fab complex I focused refinement |
Heteromer | 100 | 4×NAG; | |||
| SARS-CoV-2 Spike:Fab 3D11 complex focused refinement |
Heteromer | 100 | 2×NAG; | |||
| The SARS-CoV-2 receptor binding domain bound with the Fab fragment of a human neutralizing antibody… |
Heteromer | 100 | 1×NAG; | |||
| Structure of SARS-CoV-2 spike protein receptor binding domain in complex with a potent neutralizing… |
Heteromer | 100 | 1×NAG; | |||
| CC6.33 IgG in complex with SARS-CoV-2-6P-Mut7 S protein (RBD/Fv local refinement) |
Heteromer | 100.0 | 1×NAG; 1×NAG; | |||
| Structures of Omicron Spike complexes illuminate broad-spectrum neutralizing antibody development |
Heteromer | 100 | 1×NAG; | |||
| SARS Cov2 Spike RBD in complex with Fab47 |
Heteromer | 99.51 | ||||
| immune complex of SARS-CoV-2 RBD and cross-neutralizing antibody 7D6 |
Heteromer | 100 | 1×NAG; 1×NAG; | |||
| Crystal structure of the SARS-CoV-2 RBD in complex with a human single domain antibody n3113 |
Heteromer | 100 | 1×NAG; | |||
| Local refinement of BA.5 spike/Nanosota-9 complex |
Heteromer | 91.67 | ||||
| Local refinement of JN.1 spike/Nanosota-9 complex |
Heteromer | 86.36 | ||||
| Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immuni… |
Heteromer Q9BYF1; | 99.51 | 1×NAG; 8×CL; 1×SO4; 4×NA; 1×PG5; 1×ZN; 4×NAG; 1×PGE; | |||
| Structure of RBD directed antibody DH1047 in complex with SARS-CoV-2 spike: Local refinement of RBD… |
Heteromer | 100 | 2×NAG; | |||
| Structure of sybody SR31 in complex with the SARS-CoV-2 S Receptor Binding domain (RBD) |
Heteromer | 100 | 1×NAG; 13×FMT; 5×GOL; 2×ACT; | |||
| SARS-CoV-2 Wuhan-hu-1-Spike-RBD bound to computationally engineered ACE2 mimetic CVD293 |
Heteromer Q9BYF1; | 100 | 7×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 Alpha (B.1.1.7) spike protein in complex with human ACE2 (focused r… |
Heteromer Q9BYF1; | 99.5 | 7×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 Gamma (P.1) spike protein in complex with human ACE2 (focused refin… |
Heteromer Q9BYF1; | 98.51 | 7×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 Kappa (B.1.617.1) spike protein in complex with human ACE2 (focused… |
Heteromer Q9BYF1; | 99.0 | 7×NAG; | |||
| Neutral Omicron Spike Trimer in complex with ACE2. |
Heteromer Q9BYF1; | 92.54 | 5×NAG; | |||
| Cryo-EM structure of the SARS-CoV-2 N501Y mutant spike protein ectodomain bound to human ACE2 ectod… |
Heteromer Q9BYF1; | 99.5 | 5×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 Beta (B.1.351) spike protein in complex with human ACE2 (focused re… |
Heteromer Q9BYF1; | 98.51 | 7×NAG; | |||
| Local refinement of SARS-CoV-2 S-Beta variant (B.1.351) RBD and Angiotensin-converting enzyme 2 (AC… |
Heteromer Q9BYF1; | 98.51 | 3×NAG; 5×NAG; | |||
| Cryo-EM structure of the SARS-CoV-2 D614G,N501Y,E484K,K417N mutant spike protein ectodomain bound t… |
Heteromer Q9BYF1; | 98.51 | 7×NAG; | |||
| Local refinement of SARS-CoV-2 S-Gamma variant (P.1) RBD and Angiotensin-converting enzyme 2 (ACE2)… |
Heteromer Q9BYF1; | 98.51 | 5×NAG; 3×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 Omicron BA.1 spike protein in complex with mouse ACE2 (focused refi… |
Heteromer Q8R0I0; | 92.54 | 3×NAG; | |||
| Cryo-EM structure of the SARS-CoV-2 D614G,N501Y mutant spike protein ectodomain bound to human ACE2… |
Heteromer Q9BYF1; | 99.5 | 7×NAG; | |||
| Structures of Omicron Spike complexes illuminate broad-spectrum neutralizing antibody development |
Heteromer Q9BYF1; | 92.54 | 7×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 Omicron BA.2 spike protein in complex with human ACE2 (focused refi… |
Heteromer Q9BYF1; | 92.04 | 7×NAG; | |||
| Cryo-EM structure of the SARS-CoV-2 D614G mutant spike protein ectodomain bound to human ACE2 ectod… |
Heteromer Q9BYF1; | 100 | 7×NAG; | |||
| Cryo-EM structure of the SARS-CoV-2 D614G,N501Y,E484K,K417T mutant spike protein ectodomain bound t… |
Heteromer Q9BYF1; | 98.51 | 7×NAG; | |||
| Cryo-EM structure of the SARS-CoV-2 D614G,N501Y,E484K mutant spike protein ectodomain bound to huma… |
Heteromer Q9BYF1; | 99.0 | 7×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 Omicron spike protein in complex with human ACE2 (focused refinemen… |
Heteromer Q9BYF1; | 92.54 | 7×NAG; | |||
| Local refinement of SARS-CoV-2 S-Delta variant (B.1.617.2) RBD and Angiotensin-converting enzyme 2 … |
Heteromer Q9BYF1; | 99.0 | 1×NAG; 4×NAG; 3×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 Omicron BA.2 spike protein in complex with mouse ACE2 (focused refi… |
Heteromer Q8R0I0; | 92.04 | 3×NAG; | |||
| Local refinement of SARS-CoV-2 S-Kappa variant (B.1.617.1) RBD and Angiotensin-converting enzyme 2 … |
Heteromer Q9BYF1; | 99.0 | 2×NAG; 1×NAG; 4×NAG; | |||
| Cryo-EM structure of the SARS-CoV-2 D614G,L452R mutant spike protein ectodomain bound to human ACE2… |
Heteromer Q9BYF1; | 99.5 | 7×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 Epsilon (B.1.429) spike protein in complex with human ACE2 (focused… |
Heteromer Q9BYF1; | 99.5 | 7×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 Delta (B.1.617.2) spike protein in complex with human ACE2 (focused… |
Heteromer Q9BYF1; | 99.0 | 7×NAG; | |||
| SARS-CoV-2 Wuhan-hu-1-Spike-RBD bound to linker variant of affinity matured ACE2 mimetic CVD432 |
Heteromer Q9BYF1; | 100 | 7×NAG; | |||
| SARS-CoV-2 Omicron variant spike RBD in complex with Fab XGv051 |
Heteromer | 92.54 | ||||
| SARS-CoV-2 Spike RBD in complex with the single chain fragment scFv76 (Focused Refinement) |
Heteromer | 100 | 1×NAG; | |||
| SARS-CoV-2 Omicron variant spike RBD in complex with Fab XGv289 |
Heteromer | 94.03 | ||||
| The SARS-CoV-2 receptor binding domain bound with the Fab fragment of a human neutralizing antibody… |
Heteromer | 100 | 1×NAG; 1×NAG; 1×NAG; | |||
| SARS-CoV-2 Omicron variant spike RBD in complex with Fab XGv282 |
Heteromer | 92.54 | ||||
| The interface structure of Omicron RBD binding to 5817 Fab |
Heteromer | 92.54 | 1×NAG; | |||
| SARS-CoV-2 Omicron variant spike RBD in complex with Fab XGv347 |
Heteromer | 94.03 | ||||
| SARS-CoV-2 S-RBD + Fab 54042-4 |
Heteromer | 100 | ||||
| Cryo-EM structure of SARS-CoV-2 spike in complex with a neutralizing antibody chAb-45 (Focused refi… |
Heteromer | 100.0 | ||||
| SARS-CoV-2 Omicron variant spike RBD in complex with Fab XGv265 |
Heteromer | 92.54 | ||||
| Structure of the SARS-CoV-2 BA.1 RBD with UT28-RD |
Heteromer | 92.54 | ||||
| SARS-CoV-2 Omicron variant spike RBD in complex with Fab 9A8 |
Heteromer | 92.54 | ||||
| Cryo-EM structure of SARS-CoV-2 spike in complex with a neutralizing antibody chAb-25 (Focused refi… |
Heteromer | 100.0 | ||||
| Crystal structure of the SARS-CoV-2 receptor binding domain in complex with CR3022 Fab |
Heteromer | 100 | 8×DMS; 5×MLI; 2×NAG; 1×1PE; | |||
| SARS-CoV-2 Beta RBD in complex with human ACE2 and S304 Fab and S309 Fab |
Heteromer Q9BYF1; | 98.5 | 2×NAG; 30×EDO; 22×CL; 2×ZN; 13×NAG; | |||
| SARS-CoV-2 RBD in complex with Fab 15033-7 |
Heteromer | 100 | 1×NAG; | |||
| SARS-CoV-2 RBD in complex with Fab 15033 |
Heteromer | 100 | 1×NAG; | |||
| A human neutralizing antibody targeting SARS-CoV-2 RBD |
Heteromer | 100 | 1×NAG; | |||
| A neutralizing MAb targeting receptor-binding-domain of SARS-CoV-2 |
Heteromer | 100 | 1×NAG; | |||
| Structures of Omicron Spike complexes illuminate broad-spectrum neutralizing antibody development |
Heteromer | 100 | ||||
| SARS-CoV-2 S RBD B.1.617.1 kappa variant S309 Local Refinement |
Heteromer | 98.5 | 1×NAG; 1×NAG; | |||
| Cryo-EM structure of S309-RBD-RBD-S309 in the S309-bound Omicron spike protein (local refinement) |
Heteromer | 92.5 | 2×NAG; | |||
| Local refinement of the SARS-CoV-2 Spike trimer in complex with RmAb 9H1 Fab |
Heteromer | 100 | 1×NAG; 1×NAG; | |||
| The SARS-CoV-2 receptor binding domain bound with an Fv-clasp form of a human neutralizing antibody… |
Heteromer | 100 | 1×NAG; | |||
| Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody CC12.3 |
Heteromer | 100 | 1×NAG; | |||
| SARS-CoV-2 spike RBD with A8 and H3 nanobodies bound |
Heteromer | 100 | 1×NAG; | |||
| Crystal structure of the receptor binding domain of SARS-CoV-2 Omicron BQ.1.1 variant spike protein… |
Heteromer Q9BYF1; | 89.95 | 3×NAG; 1×NAG; 1×NAG; 1×ZN; 1×NAG; | |||
| SARS-CoV-2 spike receptor-binding domain (RBD) in complex with S2E12 Fab, S309 Fab, and S304 Fab |
Heteromer | 100 | 1×NAG; 2×CL; | |||
| Structure of the SARS-CoV-2 RBD in complex with the mouse antibody Fab fragment, HSW-2 |
Heteromer | 100 | 1×NAG; | |||
| Structure of SARS-CoV-2 spike RBD in complex with cyclic peptide |
Heteromer | 100 | 1×NAG; | |||
| Structure of SARS-CoV-2 XBB.1.5 spike RBD in complex with ACE2 |
Heteromer Q9BYF1; | 88.94 | 1×NAG; 1×NAG; 1×NAG; 4×NAG; | |||
| Local refinement of SARS-CoV-2 spike/nanobody mixture complex around RBD |
Heteromer | 100 | ||||
| The interface of JMB2002 Fab binds to SARS-CoV-2 Omicron Variant S |
Heteromer | 92.46 | ||||
| Structure of SARS-CoV-2 BA.2.86 spike RBD in complex with ACE2 (down state) |
Heteromer Q9BYF1; | 86.84 | 1×NAG; 1×NAG; 1×NAG; 5×NAG; | |||
| The local refined map of XBB spike protein (S) in complex with bispecific antibody G7-Fc |
Heteromer | 88.94 | ||||
| H6 and F2 nanobodies bound to SARS-CoV-2 spike RBD |
Heteromer | 98.48 | 1×NAG; 3×GOL; | |||
| B5-5 nanobody bound to SARS-CoV-2 spike RBD (Wuhan) |
Heteromer | 100 | 1×NAG; 4×EDO; 2×GOL; 1×NO3; | |||
| Structure of sybody MR17-SR31 fusion in complex with the SARS-CoV-2 S Receptor Binding domain (RBD) |
Heteromer | 100.0 | 1×NAG; 5×GOL; 14×ACT; 2×1PE; 5×BU2; 17×CD; | |||
| Nanobody F2 bound to RBD |
Heteromer | 100 | 1×NAG; | |||
| SARS-CoV-2 spike receptor-binding domain with a G485R mutation in complex with human ACE2 |
Heteromer Q9BYF1; | 99.5 | 1×NAG; 4×NAG; 3×EDO; 1×ZN; | |||
| Crystal structure of SARS-CoV-2 Spike RBD in complex with FP-12A Fab |
Heteromer | 100 | 1×NAG; | |||
| Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by st… |
Heteromer | 100 | 1×NAG; | |||
| Crystal structure of S43 bound to SARS-CoV-2 RBD |
Heteromer | 100 | 1×NAG; 1×NAG; | |||
| Crystal structure of a neutralizing monoclonal antibody (Ab08) in complex with SARS-CoV-2 receptor-… |
Heteromer | 100 | 1×NAG; 3×MPD; 1×CA; 1×CL; | |||
| SARS-CoV-2 Omicron RBD in complex with human ACE2 and S304 Fab and S309 Fab |
Heteromer Q9BYF1; | 92.42 | 4×EDO; 11×CL; 1×ZN; 6×NAG; | |||
| Crystal structure of SARS-CoV-2 B.1.351 variant receptor binding domain in complex with neutralizin… |
Heteromer | 98.48 | 1×NAG; 5×EDO; 11×SO4; | |||
| Structure of the SARS-CoV-2 RBD in complex with neutralizing antibody N-612-056 |
Heteromer | 100 | 1×NAG; | |||
| Crystal structure of SARS-CoV-2 omicron variant spike receptor-binding domain (RBD) in complex with… |
Heteromer | 92.35 | 7×SO4; | |||
| SARS-CoV-2 Omicron BA.2 Variant RBD complexed with human ACE2 |
Heteromer Q9BYF1; | 91.92 | 1×CL; 1×ZN; 3×NAG; | |||
| SARS-CoV-2 Omicron Variant RBD complexed with ACE2 |
Heteromer Q9BYF1; | 92.42 | 3×NAG; 1×CL; 1×ZN; | |||
| SIT1-ACE2-BA.2 RBD |
Heteromer Q9BYF1; Q9NP91; | 91.92 | 16×NAG; 6×NAG; 6×3PH; 2×ZN; | |||
| SIT1-ACE2-BA.5 RBD |
Heteromer Q9BYF1; Q9NP91; | 91.41 | 16×NAG; 6×NAG; 6×3PH; 2×ZN; | |||
| Local refinement of RBD-ACE2 |
Heteromer Q9BYF1; | 92.42 | 1×NAG; 6×NAG; 1×ZN; | |||
| The second RBD of SARS-CoV-2 Omicron Variant in complexed with RBD-ACE2 |
Heteromer Q9BYF1; | 92.39 | 2×NAG; 1×CL; 1×ZN; 3×NAG; | |||
| The SARS-CoV-2 receptor binding domain bound with the Fab fragment of a human neutralizing antibody… |
Heteromer | 100 | 1×NAG; 1×NAG; | |||
| Omicron RBDs bound with P3E6 Fab (one up and one down) |
Heteromer | 92.42 | ||||
| The local refined map of Omicron spike with bispecific antibody FD01 |
Heteromer | 92.42 | ||||
| The SARS-CoV-2 receptor binding domain bound with the Fab fragment of a human neutralizing antibody… |
Heteromer | 100 | 1×NAG; | |||
| Local refinement of SARS-CoV-2 vaccine induced antibody DH1338 bound to SARS-CoV-2 HexaPro RBD Spik… |
Heteromer | 100.0 | 1×NAG; | |||
| The SARS-CoV-2 receptor binding domain bound with the Fab fragment of a human neutralizing antibody… |
Heteromer | 100 | 1×NAG; | |||
| The SARS-CoV-2 receptor binding domain bound with the Fab fragment of a human neutralizing antibody… |
Heteromer | 100 | 1×NAG; | |||
| Local refinement of SARS-CoV-2 Omicron S trimer complexed with XG005 |
Heteromer | 92.42 | ||||
| Three RBD-down state of SARS-CoV-2 D614G spike in complex with the SP1-77 neutralizing antibody Fab… |
Heteromer | 100 | 1×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 XBB.1.5 spike protein in complex with human ACE2 (focused refinemen… |
Heteromer Q9BYF1; | 88.89 | 2×NAG; 5×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 XBB.1.5 spike protein in complex with mouse ACE2 (focused refinemen… |
Heteromer Q8R0I0; | 88.89 | 1×NAG; 1×NAG; 1×NAG; | |||
| Nanobody H3 AND C1 bound to RBD with Kent mutation |
Heteromer | 99.49 | 1×NAG; 1×CIT; 1×CL; | |||
| Crystal structure of synthetic nanobody (Sb14+Sb68) complexes with SARS-CoV-2 receptor binding doma… |
Heteromer | 100 | 3×EDO; 1×GOL; | |||
| Nanobody H3 AND C1 bound to RBD |
Heteromer | 100 | 1×NAG; 1×CIT; 1×CL; | |||
| Crystal structure of SARS-CoV-2 spike receptor-binding domain (RBD) in complex with NCV2SG48 Fab |
Heteromer | 100 | 1×NAG; 1×SO4; | |||
| Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing human antibody… |
Heteromer | 100 | 1×NAG; | |||
| SARS-CoV-2 receptor binding domain in complex with WNb-2 |
Heteromer | 100.0 | 1×NAG; 1×PG4; | |||
| Crystal structure of SARS-CoV-2 Spike RBD in complex with MW01 Fab |
Heteromer | 100 | 1×CIT; 1×NAG; | |||
| Crystal structure of SARS-CoV-2 RBD in complex with a neutralizing antibody scFv |
Heteromer | 100 | 1×CA; 1×NAG; | |||
| Crystal structure of SARS-CoV-2 spike protein receptor-binding domain in complex with a cross-neutr… |
Heteromer | 100 | 1×NAG; | |||
| Antibodies to the SARS-CoV-2 receptor-binding domain that maximize breadth and resistance to viral … |
Heteromer | 100 | 1×NAG; | |||
| H11-D4, SARS-CoV-2 RBD, CR3022 ternary complex |
Heteromer | 100 | 1×NAG; | |||
| Crystal structure of BD55-1403 and SARS-CoV-2 Omicron RBD |
Heteromer | 92.39 | 1×NAG; | |||
| Crystal structure of human ACE2 bound to the spike receptor-binding domain from a cave bat sarbecov… |
Heteromer Q9BYF1; | 96.95 | 1×NAG; 6×NAG; 4×SO4; 1×TRS; 5×PEG; 1×ZN; 2×CL; 1×GOL; | |||
| Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing human antibody… |
Heteromer | 100 | ||||
| Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing human antibody… |
Heteromer | 100 | 1×NAG; | |||
| Crystal structure of receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with EY6A … |
Heteromer | 100 | 1×NAG; 1×PO4; | |||
| Crystal structure of the SARS-CoV-2 receptor binding domain in complex with CR3022 Fab (crystal for… |
Heteromer | 100 | ||||
| SARS-CoV-2 Omicron S monomer complexed with 553-49 |
Heteromer | 92.39 | ||||
| Cryo-EM structure of SARS-CoV-2 BA.2 RBD in complex with BA7535 fab (local refinement) |
Heteromer | 91.88 | ||||
| SARS-CoV-2 BA.1 spike ectodomain trimer in complex with the S2X324 neutralizing antibody Fab fragme… |
Heteromer | 92.39 | 1×NAG; | |||
| The SARS-CoV-2 receptor binding domain bound with the Fab fragment of a human neutralizing antibody… |
Heteromer | 100 | 1×NAG; | |||
| SARS-CoV-2 Omicron variant spike RBD in complex with Fab XGv264 |
Heteromer | 92.39 | ||||
| SARS-CoV-2 Omicron variant spike RBD in complex with Fab XGv286 |
Heteromer | 92.39 | ||||
| RBD-1 of SARS-CoV-2 Beta spike in complex with S5D2 Fab |
Heteromer | 98.48 | ||||
| Cryo-EM structure of SARS-CoV-2 Omicron BA.2 RBD in complex with golden hamster ACE2 (local refinem… |
Heteromer A0A1U7QTA1; | 91.88 | 1×ZN; 6×NAG; | |||
| Cryo-EM structure of the SARS-CoV-2 N501Y mutant spike protein ectodomain bound to Fab ab1 (focused… |
Heteromer | 99.49 | 1×NAG; | |||
| Nanobody C5 bound to RBD |
Heteromer | 100 | 1×NAG; 1×ACT; | |||
| SARS-CoV-2 BQ.1.1 RBD bound to the S2V29 and the S2H97 Fab fragments |
Heteromer | 89.8 | 9×EDO; 1×NAG; 1×NI; 1×TRS; | |||
| The crystal structure of RBD-Nanobody complex, DL4 (SA4) |
Heteromer | 100 | 1×NAG; 8×GOL; 8×ACT; | |||
| Crystal structure of SARS-CoV-2 RBD in complex with aRBD5 |
Heteromer | 100 | 1×NAG; | |||
| Crystal structure of nanobody 1-2C7 with SARS-CoV-2 RBD |
Heteromer | 98.47 | 1×NAG; | |||
| Crystallographic structure of neutralizing antibody P14-44 in complex with SARS-CoV-2 spike recepto… |
Heteromer | 100 | 1×NAG; 3×GOL; | |||
| Nanobody H11-B5 and H11-F2 bound to RBD |
Heteromer | 100 | 1×NAG; 5×PEG; | |||
| Crystal structure of the SARS-CoV-2 receptor binding domain in complex with VNAR 3B4 |
Heteromer | 100 | 1×NAG; 3×EDO; | |||
| Crystal structure of SARS-CoV-2 spike protein receptor-binding domain in complex with two cross-neu… |
Heteromer | 100 | 1×NAG; 16×EDO; | |||
| Crystal structure of JM-1A in complex with SARS-CoV-2 RBD |
Heteromer | 100.0 | 1×NAG; 1×CL; 1×PO4; | |||
| Crystal structure of SARS-CoV-2 Receptor Binding Domain bound to A6 repebody |
Heteromer | 100 | 1×NAG; | |||
| Crystal Structure of SARS-CoV-2 S delta variant receptor-binding domain (RBD) in complex CoV11 Fab … |
Heteromer | 98.98 | 1×NAG; 1×CIT; | |||
| The crystal structure of the SARS-CoV-2 receptor binding domain in complex with the neutralizing na… |
Heteromer | 100 | 1×NAG; 2×SO4; | |||
| Structure of the SARS-CoV-2 RBD in complex with the mouse antibody Fab fragment, M8a-34 |
Heteromer | 100 | 1×NAG; | |||
| Crystal structure of synthetic nanobody (Sb45) complexes with SARS-CoV-2 receptor binding domain |
Heteromer | 100 | ||||
| Nanobody H11-A10 and F2 bound to RBD |
Heteromer | 100 | 1×NAG; | |||
| RBD domain of SARS-CoV2 in complex with neutralizing nanobody NM1226 |
Heteromer | 100 | 1×NAG; 1×PO4; 3×PEG; | |||
| Crystal structure of SARS-CoV-2 spike receptor-binding domain (RBD) in complex with NCV2SG53 Fab |
Heteromer | 100 | 3×SO4; 1×NAG; | |||
| Fab arm of antibodies 4G1-C2 and 10G4 bound to CoV-2 receptor binding domain (RBD) |
Heteromer Q6GMX0; | 100 | 6×GOL; 2×NAG; | |||
| SARS-CoV-2 receptor binding domain bound to Fab WCSL 129 and Fab PDI 93 |
Heteromer | 100 | 1×NAG; 1×GOL; | |||
| Crystal structure of nanobody 3-2A2-4 with SARS-CoV-2 RBD |
Heteromer | 100 | 1×NAG; | |||
| Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibodies CV0… |
Heteromer | 100 | 8×EDO; 1×NAG; 10×SO4; | |||
| Crystal structure of SARS-CoV-2 spike receptor-binding domain in complex with broadly neutralizing … |
Heteromer | 100 | 1×NAG; | |||
| Crystal structure of SARS-CoV-2 spike RBD in complex with human monoclonal antibody AZD8895 |
Heteromer | 100 | 6×GOL; 1×NAG; | |||
| Nanobody H11 and F2 bound to RBD |
Heteromer | 100 | 1×NAG; | |||
| Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in a ternary comp… |
Heteromer | 99.49 | 1×NAG; 3×IMD; 5×CL; 1×GLU; 3×GLY; 1×PGE; 1×GOL; 1×PG4; | |||
| Crystal structure of SARS-CoV-2 RBD in complex with the neutralizing IGHV3-53-encoded antibody EH3 … |
Heteromer | 100 | 1×NAG; | |||
| SARS-CoV-2-Beta-RBD and CB6-092-Fab complex |
Heteromer | 98.47 | ||||
| Crystal Structure of COVID-19 virus spike receptor-binding domain complexed with a neutralizing ant… |
Heteromer | 100 | 1×NAG; 2×NI; 2×EDO; | |||
| Fab arms of antibodies GAR03 and 10G4 bound to the receptor binding domain of SARS-CoV-2 in a 1:1:1… |
Heteromer | 100.0 | 1×NAG; 2×CL; | |||
| SARS-CoV-2-prototyped-RBD and CB6-092-Fab complex |
Heteromer | 100 | ||||
| Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing nanobody 17F6 |
Heteromer | 100 | 1×NAG; | |||
| SARS-CoV2 RBD bound to Fab06 |
Heteromer | 100 | 1×NAG; | |||
| Crystal structure of the SARS-CoV-2 RBD in complex with the ultrapotent antibody CV2.1169 and CR3022 |
Heteromer | 99.49 | 1×NAG; 1×SO4; | |||
| SARS-CoV-2-Beta-RBD and B38-GWP/P-VK antibody complex |
Heteromer | 98.45 | 1×NAG; | |||
| The crystal structure of RBD-Nanobody complex, DL28 (SC4) |
Heteromer | 100 | 1×NAG; 2×GOL; | |||
| Soaking competent crystal form of the SARS-CoV-2 Receptor Binding Domain (RBD):CR3022 complex. |
Heteromer | 100 | 1×NAG; | |||
| Structure of the SARS-CoV-2 RBD in complex with neutralizing antibodies BG4-25 and CR3022 |
Heteromer | 100 | 1×NAG; | |||
| Structure of the SARS-CoV-2 receptor binding domain in complex with the human neutralizing antibody… |
Heteromer | 100 | 1×NAG; | |||
| Structure of SARS-CoV-2 spike receptor-binding domain complexed with high affinity ACE2 mutant 3N39 |
Heteromer Q9BYF1; | 100 | 2×NAG; 2×NAG; 1×NAG; 1×NAG; 1×ZN; 1×SO4; | |||
| Crystal structure of SARS-CoV-2 Spike RBD in complex with MW06 Fab |
Heteromer | 100 | 1×NAG; | |||
| Crystal structure of SARS-CoV-2 receptor binding domain in complex with SARS-CoV-2 reactive human a… |
Heteromer | 100 | 1×NAG; | |||
| Locally refined SARS-CoV-2 BA-2.86 Spike receptor binding domain (RBD) complexed with angiotensin c… |
Heteromer Q9BYF1; | 86.75 | 6×NAG; | |||
| XBB.1.5 RBD in complex with ACE2 |
Heteromer Q9BYF1; | 88.78 | 5×NAG; | |||
| cryo-EM structure of omicron spike in complex with de novo designed binder, local |
Heteromer Q9VKJ9; | 92.35 | 1×NAG; | |||
| Local CryoEM structure of the SARS-CoV-2 S6P in complex with 7B3 Fab |
Heteromer | 100 | 1×NAG; | |||
| SARS-CoV-2 BA.2.75 S Trimer in complex with S309 (interface) |
Heteromer | 91.33 | 1×NAG; | |||
| SARS-CoV-2 Omicron BA.4 spike trimer (6P) in complex with D1F6 Fab, focused refinement of RBD region |
Heteromer | 91.33 | 2×NAG; | |||
| CryoEM structure of SARS CoV-2 RBD and Aptamer complex |
Heteromer | 100 | 1×NAG; | |||
| The local refined map of SARS-CoV-2 Omicron BA.1 Spike complexed with antibody PW5-570 |
Heteromer | 92.35 | ||||
| Cryo-EM structure of SARS-CoV-2 spike in complex with neutralizing antibody A23-58.1 that targets t… |
Heteromer | 100 | 1×NAG; 1×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 Delta RBD in complex with BA7054 and BA7125 fab (local refinement) |
Heteromer | 98.98 | ||||
| SARS-CoV-2 Spike RBD (dimer) in complex with two Fu2 nanobodies |
Heteromer | 100 | 2×NAG; | |||
| The complex structure of Omicron BA.4 RBD with BD604, S309, and S304 |
Heteromer | 91.33 | 1×NAG; | |||
| SARS-CoV-2 S B.1.1.529 Omicron variant (RBD + S309 Local Refinement) |
Heteromer | 93.37 | 1×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 spike in complex with neutralizing antibody B1-182.1 that targets t… |
Heteromer | 100 | 1×NAG; | |||
| MaP OF P5C3RBD Interface |
Heteromer | 100 | ||||
| Local refinement of SARS-CoV-2 BA.2.86 Spike and XBB-7 Fab |
Heteromer | 86.75 | ||||
| SARS-CoV-2 Spike RBD (dimer) in complex with two 2S-1244 nanobodies |
Heteromer | 91.53 | ||||
| CryoEM structure of SARS CoV-2 RBD and Aptamer complex |
Heteromer | 100 | 1×NAG; | |||
| The SARS-CoV-2 spike protein receptor binding domain bound to neutralizing nanobodies WNb 2 and WNb… |
Heteromer | 100 | ||||
| SARS-CoV-2 (wuhan variant) Spike protein in complex with the single chain fragment scFv76-77 (focus… |
Heteromer | 100.0 | 1×NAG; | |||
| XBB.1.5 RBD in complex with BD55-1205 |
Heteromer | 88.78 | ||||
| Locally refined region of SARS-CoV-2 spike in complex with antibodies B1-182.1 and A19-61.1 |
Heteromer | 100 | 1×NAG; | |||
| XBB.1.5.10 RBD in complex with ACE2 |
Heteromer Q9BYF1; | 88.27 | 4×NAG; | |||
| Local CryoEM structure of the SARS-CoV-2 S6P in complex with 14B1 Fab |
Heteromer | 100 | 1×NAG; | |||
| Local refine of Omicron spike bitrimer with 6m6 antibody |
Heteromer | 92.35 | 2×NAG; | |||
| SARS-CoV-2 XBB.1.5.70 in complex with ACE2 |
Heteromer Q9BYF1; | 87.75 | 4×NAG; | |||
| Local refinement of cryo-EM structure of the interface of the Omicron RBD in complex with antibodie… |
Heteromer | 92.35 | 1×NAG; | |||
| SARS-CoV-2 spike trimer (6P) in complex with R1-26 Fab, focused refinement of RBD-Fab region |
Heteromer | 100 | 1×NAG; | |||
| 17B10 fab in complex with up-RBD of SARS-CoV-2 Spike G614 trimer |
Heteromer | 100 | 1×NAG; | |||
| VIR-7229 Fab fragment bound the SARS-CoV-2 BA.2.86 spike trimer (local refinement of the BA 2.86 RB… |
Heteromer A0A7S5BYU0; | 87.67 | 2×NAG; | |||
| RBD of SARS-CoV2 spike protein with ACE2 decoy |
Heteromer Q9BYF1; | 100 | 2×NAG; 2×NAG; 1×NAG; 1×NAG; 1×ZN; 1×SO4; | |||
| Crystal structure of neutralizing VHH P17 in complex with SARS-CoV-2 Alpha variant spike receptor-b… |
Heteromer | 99.49 | 1×NAG; 12×EDO; | |||
| Crystal structure of SARS-CoV-2 spike protein receptor-binding domain in complex with a cross-neutr… |
Heteromer | 100 | 1×NAG; | |||
| Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody 21B6 |
Heteromer | 100 | 1×NAG; 8×SO4; | |||
| Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with C… |
Heteromer | 99.49 | 1×NAG; 19×EDO; 3×NO3; 1×PEG; 1×SO4; 1×CL; | |||
| Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody CC25.4 |
Heteromer | 100 | 1×NAG; 5×MPD; | |||
| H11-D4 complex with SARS-CoV-2 RBD |
Heteromer | 100 | 1×NAG; 12×EDO; 4×ACT; | |||
| THSC20.HVTR26 Fab bound to SARS-CoV-2 Receptor Binding Domain |
Heteromer | 100 | 1×NAG; 1×EPE; | |||
| SARS-CoV-2 spike receptor-binding domain (RBD) in complex with S2X35 Fab and S309 Fab |
Heteromer | 100 | 1×NAG; 23×SO4; 3×GOL; 3×CL; 2×POL; | |||
| Structure of COVID-19 virus spike receptor-binding domain complexed with a neutralizing antibody |
Heteromer | 100.0 | 1×NAG; | |||
| H11-H4 complex with SARS-CoV-2 |
Heteromer | 100 | 1×NAG; 1×SO4; | |||
| Crystal structure of SARS-CoV-2 receptor binding domain complexed with nanobodies VHH E and U |
Heteromer | 100 | 1×NAG; 5×EDO; | |||
| Fab arm of antibody 10G4 bound to CoV-2 receptor binding domain (RBD) |
Heteromer | 100 | 1×NAG; 1×NAG; 2×MG; 3×CL; | |||
| SARS-CoV-2 Omicron BA.4/5 RBD in complex with Beta-27 Fab and C1 nanobody |
Heteromer | 90.77 | 10×GOL; 6×IPA; 1×NAG; 1×PG4; | |||
| The crystal structure of the SARS-CoV-2 receptor binding domain in complex with the neutralizing na… |
Heteromer | 100 | 1×NAG; 1×MPO; | |||
| immune complex of SARS-CoV-2 RBD and cross-neutralizing antibody 6D6 |
Heteromer | 100 | 1×NAG; | |||
| Crystal structure of SARS-CoV-2 RBD in complex with the neutralizing nanobodies VHH-F04 and VHH-G09 |
Heteromer | 99.48 | 1×NAG; 5×CL; | |||
| Crystal structure of the SARS-CoV-2 receptor binding domain in complex with VNAR 2C02 |
Heteromer | 100 | 2×EDO; 1×NAG; 1×CL; | |||
| Crystal structure of the SARS-CoV-2 neutralizing VHH 7A9 bound to the spike receptor binding domain |
Heteromer | 100 | 1×NAG; | |||
| Crystal structure of the SARS-CoV-2 receptor binding domain in complex with the human neutralizing … |
Heteromer | 100.0 | 1×NAG; | |||
| Crystal structure of monoclonal antibody complexed with SARS-CoV-2 RBD |
Heteromer | 100 | ||||
| Crystal structure of SARS-CoV-2 antibody P2C-1F11 with mutated RBD |
Heteromer | 98.44 | 1×NAG; | |||
| Crystal structure of SARS-CoV-2 spike receptor-binding domain bound with 6-2C Fab |
Heteromer | 100.0 | 1×NAG; | |||
| SARS-CoV-2 receptor binding domain bound to Fab WCSL 119 |
Heteromer | 100 | 1×NAG; | |||
| Structural basis for a germline-biased antibody response to SARS-CoV-2 (RBD:C1A-B12 Fab) |
Heteromer | 100 | 1×NAG; | |||
| Structural basis for a germline-biased antibody response to SARS-CoV-2 (RBD:C1A-F10 Fab) |
Heteromer | 100 | 1×NAG; | |||
| Structural basis for a germline-biased antibody response to SARS-CoV-2 (RBD:C1A-C2 Fab) |
Heteromer | 100 | 1×NAG; | |||
| Fab arm of antibody GAR12 bound to the receptor binding domain of SARS-CoV-2. |
Heteromer | 100 | 1×NAG; | |||
| Complex between the Fab arm of AB-3467 and the SARS-CoV-2 receptor binding domain (RBD) |
Heteromer | 100 | 1×NAG; 2×CL; 3×SCN; | |||
| Crystal structure of antibody Ab246 in complex with SARS-CoV-2 receptor binding domain |
Heteromer | 100 | 1×CL; 6×GOL; 1×NAG; | |||
| Crystal structure of SARS-CoV-2 BA.2 receptor binding domain in complex with neutralizing antibody … |
Heteromer | 91.8 | 1×NAG; 3×EDO; 1×GOL; 1×GLY; 1×PEG; | |||
| Crystal structure of SARS-CoV-2 RBD binding to pangolin ACE2 |
Heteromer | 100 | 2×NAG; 1×ZN; | |||
| Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with C… |
Heteromer | 99.49 | 2×NAG; 2×GOL; 2×TRS; | |||
| Crystal structure of the SARS-CoV-2 RBD in complex with the human antibody CV2.2325 |
Heteromer | 99.49 | 1×NAG; 1×NA; 3×CL; | |||
| Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with C… |
Heteromer | 99.49 | 1×NAG; 2×GOL; 4×CL; 1×PG4; | |||
| The receptor binding domain of SARS-CoV-2 Omicron variant spike glycoprotein in complex with Beta-5… |
Heteromer | 91.49 | 1×NAG; 9×GOL; 2×ACT; 1×CL; | |||
| Structure of SARS-CoV-2 spike receptor-binding domain Y453F mutation complexed with human ACE2 |
Heteromer Q9BYF1; | 99.49 | 4×NAG; 1×ZN; | |||
| Crystal structure of SARS-CoV-2 spike receptor-binding domain in complex with neutralizing nanobody… |
Heteromer | 100 | 1×NAG; | |||
| Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with C… |
Heteromer | 99.49 | 1×NAG; 2×GOL; 6×FMT; | |||
| SARS-CoV-2 S protein RBD in complex with A5-10 Fab |
Heteromer | 100 | 1×NAG; | |||
| Structure of novel coronavirus spike receptor-binding domain complexed with its receptor ACE2 |
Heteromer Q9BYF1; | 100 | 4×NAG; 1×ZN; | |||
| Crystal structure of SARS CoV-2 Spike Receptor Binding Domain in complex with shark neutralizing VN… |
Heteromer | 100 | 1×NAG; 1×GOL; | |||
| Crystal structure of synthetic nanobody (Sb16) complexes with SARS-CoV-2 receptor binding domain |
Heteromer | 100 | ||||
| Crystal structure of the T478K mutant receptor binding domain of SARS-CoV-2 Spike glycoprotein in c… |
Heteromer | 98.97 | 1×NAG; 1×NAG; 3×GOL; 5×CL; | |||
| Structure of the SARS-CoV-2 RBD in complex with neutralizing antibody C099 and CR3022 |
Heteromer | 100.0 | 1×NAG; | |||
| Structure of SARS-CoV-2 Beta variant spike receptor-binding domain complexed with human ACE2 |
Heteromer Q9BYF1; | 98.46 | 1×NAG; 5×NAG; 1×ZN; | |||
| Crystal structure of SARS-CoV-2 receptor binding domain in complex with antibodies CC12.1 and CR3022 |
Heteromer | 100.0 | 1×NAG; | |||
| Crystal structure of Omicron BA.3 RBD complexed with hACE2 |
Heteromer Q9BYF1; | 92.31 | 1×NAG; 1×NAG; 1×NAG; 1×ZN; 3×NAG; | |||
| Structure of SARS-CoV-2 spike receptor-binding domain F486L mutation complexed with human ACE2 |
Heteromer Q9BYF1; | 99.49 | 4×NAG; 1×ZN; | |||
| Crystal structure of SARS-CoV-2 spike protein receptor-binding domain complexed with a pre-pandemic… |
Heteromer | 100.0 | 1×NAG; | |||
| Structure of sybody MR17 in complex with the SARS-CoV-2 S receptor-binding domain (RBD) |
Heteromer | 100 | 1×NAG; 1×GOL; | |||
| Structural basis for a germline-biased antibody response to SARS-CoV-2 (RBD:C1A-B3 Fab) |
Heteromer | 100 | 1×NAG; | |||
| Structure of SARS-CoV-2 Gamma variant spike receptor-binding domain complexed with human ACE2 |
Heteromer Q9BYF1; | 98.46 | 1×NAG; 5×NAG; 1×ZN; | |||
| Crystal structure of Nanobody nb112 and SARS-CoV-2 RBD |
Heteromer | 100 | 1×NAG; | |||
| Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody CC25.… |
Heteromer | 100 | 1×NAG; | |||
| Structure of SARS-CoV-2 Alpha variant spike receptor-binding domain complexed with human ACE2 |
Heteromer Q9BYF1; | 99.49 | 1×NAG; 4×NAG; 1×ZN; | |||
| The crystal structure of SARS-CoV-2 Omicron BA.1 variant RBD in complex with equine ACE2 |
Heteromer F6V9L3; | 92.31 | 1×ZN; 6×BR; 1×NAG; | |||
| Crystal structure of SARS-CoV-2 receptor binding domain in complex with antibodies eCR3022.20 and C… |
Heteromer | 100.0 | 1×NAG; | |||
| Crystal structure of the receptor binding domain of SARS-CoV-2 Delta variant in complex with IMCAS7… |
Heteromer | 98.97 | 1×NAG; | |||
| Molecular basis for a potent human neutralizing antibody targeting SARS-CoV-2 RBD |
Heteromer | 100 | 1×NAG; | |||
| Crystal structure of SARS-CoV-2 receptor binding domain in complex with antibodies CC12.3 and CR3022 |
Heteromer | 100.0 | 1×NAG; | |||
| SARS-CoV-2-Omicron-RBD and B38-GWP/P-VK antibody complex |
Heteromer | 92.31 | ||||
| Crystal structure of SARS-CoV-2 spike protein receptor-binding domain in complex with cross-neutral… |
Heteromer | 100 | 1×NAG; | |||
| Crystal structure of SARS-CoV-2 RBD and horse ACE2 |
Heteromer F6V9L3; | 100 | 5×NAG; | |||
| Crystal structure of Omicron BA.2 RBD complexed with hACE2 |
Heteromer Q9BYF1; | 91.8 | 1×NAG; 2×NAG; 1×ZN; 3×NAG; | |||
| Structure of SARS-CoV-2 Omicron BA.2.75 RBD in complex with human ACE2 |
Heteromer Q9BYF1; | 91.28 | 1×NAG; 1×NAG; 1×ZN; 3×NAG; | |||
| Crystal structure of T6 Fab bound to theSARS-CoV-2 RBD of B.1.351 |
Heteromer | 98.44 | 2×NAG; | |||
| Crystal structure of SARS-CoV-2 spike receptor-binding domain in complex with broadly neutralizing … |
Heteromer | 100 | 1×NAG; | |||
| Structure of sybody MR17-K99Y in complex with the SARS-CoV-2 S Receptor-binding domain (RBD) |
Heteromer | 100 | 1×NAG; 1×GOL; | |||
| Crystal structure of SARS-CoV-2 receptor binding domain in complex with the Fab fragments of neutra… |
Heteromer | 100 | 1×NAG; | |||
| THSC20.HVTR04 Fab bound to SARS-CoV-2 Receptor Binding Domain |
Heteromer | 100 | 1×NAG; 2×SO4; | |||
| Fab HbnC3t1p1_C6 bound to SARS-CoV-2 RBD |
Heteromer Q6PIL8; | 100 | 1×NAG; | |||
| Crystal structure of SARS-CoV-2 RBD binding to dog ACE2 |
Heteromer | 100 | 1×ZN; 1×NAG; | |||
| Crystal structure of the receptor binding domain of SARS-CoV-2 Omicron variant spike glycoprotein i… |
Heteromer Q9BYF1; | 92.31 | 1×NAG; 5×NAG; 1×ZN; | |||
| Crystal structure of SARS-CoV-2 spike RBD in complex with human monoclonal antibodies AZD8895 and A… |
Heteromer | 100 | 2×PO4; 1×NAG; | |||
| Crystal structure of monoclonal antibody complexed with SARS-CoV-2 RBD |
Heteromer | 100 | 1×NAG; | |||
| Crystal structure of Omicron BA.1.1 RBD complexed with hACE2 |
Heteromer Q9BYF1; | 91.8 | 6×NAG; 1×ZN; | |||
| Crystal structure of SARS-CoV-2 spike receptor-binding domain in complex with broadly neutralizing … |
Heteromer | 100 | 1×NAG; | |||
| Crystal structure of SARS-CoV-2 receptor binding domain in complex with human antibody CR3022 |
Heteromer | 100 | 1×GOL; 2×SO4; 1×NAG; | |||
| Crystal structure of the complex of Wuhan SARS-CoV-2 RBD (319-541) with P2C5 nanobody |
Heteromer | 100 | 1×NAG; | |||
| Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody CC12.1 |
Heteromer | 100.0 | 1×NAG; | |||
| Crystal structure of neutralizing antibody 80 in complex with SARS-CoV-2 receptor binding domain |
Heteromer | 100 | 2×NAG; | |||
| Crystal structure of the receptor binding domain of SARS-CoV-2 P.1 variant Spike glycoprotein in co… |
Heteromer Q9BYF1; | 97.95 | 5×NAG; | |||
| Structural basis for cross-species recognition of COVID-19 virus spike receptor binding domain to b… |
Heteromer E2DHI3; | 100 | 1×ZN; | |||
| Crystal structure of SARS-CoV-2 Spike RBD in complex with MW05 Fab |
Heteromer | 100 | 1×NAG; | |||
| Crystal structure of SARS-CoV-2 Receptor Binding Domain in complex with the monoclonal antibody m31… |
Heteromer | 100 | 1×NAG; 1×NAG; | |||
| Crystal structure of SARS-CoV-2 spike receptor binding domain bound with P5S-3B11 Fab |
Heteromer | 99.47 | ||||
| Crystal structure of SARS-CoV-2 Omicron spike receptor-binding domain in complex with civet ACE2 |
Heteromer Q56NL1; | 92.31 | 1×NAG; 4×NAG; 1×ZN; | |||
| Crystal structure of SARS-CoV-2 spike receptor-binding domain in complex with broadly neutralizing … |
Heteromer | 100 | 1×NAG; | |||
| H11-D4, SARS-CoV-2 RBD, CR3022 ternary complex |
Heteromer | 100 | 1×NAG; | |||
| Crystal structure of SARS-CoV-2 receptor-binding domain in complex with intermediate horseshoe bat … |
Heteromer A0A7D7FA76; | 100 | 1×ZN; 1×NAG; | |||
| Ternary complex CR3022 H11-H4 and RBD (SARS-CoV-2) |
Heteromer | 100 | ||||
| Crystal structure of the receptor binding domain of SARS-CoV-2 Delta variant spike glycoprotein in … |
Heteromer Q9BYF1; | 98.97 | 1×NAG; 1×NAG; 4×NAG; 1×ZN; | |||
| Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody 25F9 |
Heteromer | 100 | 1×NAG; 1×SO4; 1×BCN; | |||
| Crystal structure of the receptor binding domain of SARS-CoV-2 Omicron BA.4/5 variant spike protein… |
Heteromer Q9BYF1; | 91.28 | 2×NAG; 2×NAG; 1×ZN; 1×NAG; | |||
| Crystal structure of BF.7 RBD complexed with human ACE2 |
Heteromer Q9BYF1; | 90.77 | 1×NAG; 1×ZN; 3×NAG; | |||
| Crystal structure of SARS-CoV-2 receptor binding domain in complex with antibodies CV503 and COVA1-… |
Heteromer | 100 | 3×NAG; | |||
| A neutralizing nanobody VHH60 against wt SARS-CoV-2 |
Heteromer | 100.0 | ||||
| Crystal structure of JE-5C in complex with SARS-CoV-2 RBD |
Heteromer | 100.0 | 1×NAG; 2×SO4; | |||
| Crystal structure of BQ.1.1 RBD complexed with human ACE2 |
Heteromer Q9BYF1; | 89.74 | 1×NAG; 1×ZN; 4×NAG; | |||
| Crystal structure of antibody WRAIR-2123 in complex with SARS-CoV-2 receptor binding domain |
Heteromer | 100 | 1×NAG; | |||
| Crystal structure of antibody WRAIR-2123 in complex with SARS-CoV-2 receptor binding domain |
Heteromer | 100 | 1×NAG; | |||
| Crystal structure of SARS-CoV-2 receptor binding domain in complex with human antibody COVA309-22 |
Heteromer | 100 | 1×NAG; | |||
| SARS-CoV-2 receptor binding domain bound to Fab PDI 210 |
Heteromer | 100.0 | 1×NAG; | |||
| Crystal structure of neutralizing antibody D29 Fab in complex with SARS-CoV-2 spike receptor bindin… |
Heteromer | 100.0 | ||||
| Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody WRAIR… |
Heteromer | 100 | 1×NAG; 2×GOL; | |||
| Structure of SARS-CoV-2 spike receptor-binding domain F486L mutation complexed with American mink A… |
Heteromer A0A8C7BTF2; | 99.49 | 1×ZN; | |||
| Cryo-EM structure of hACE2-bound SARS-CoV-2 Omicron spike protein with L371S, P373S and F375S mutat… |
Heteromer Q9BYF1; | 93.85 | 1×NAG; 5×NAG; 1×ZN; | |||
| Structure of SARS-CoV-2 XBB.1 spike RBD in complex with ACE2 |
Heteromer Q9BYF1; | 88.72 | 2×NAG; 1×NAG; 1×NAG; 3×NAG; | |||
| SARS-CoV-2 Omicron BQ.1 RBD complexed with human ACE2 |
Heteromer Q9BYF1; | 90.26 | 1×NAG; 1×NAG; 5×NAG; 1×ZN; | |||
| Cryo-EM structure of SARS-CoV-2 spike receptor-binding domain in complex with sea lion ACE2 |
Heteromer A0A6J2EID0; | 100 | 1×ZN; 1×NAG; | |||
| SARS-CoV-2 Omicron HV.1 RBD in complex with human ACE2 (local refinement from the spike protein) |
Heteromer Q9BYF1; | 87.69 | 6×NAG; 1×ZN; | |||
| SARS-CoV-2 Omicron XBB RBD complexed with human ACE2 |
Heteromer Q9BYF1; | 88.72 | 1×NAG; 6×NAG; 1×ZN; | |||
| Cryo-EM structure of SARS-CoV-2 Omicron BA.2 RBD in complex with mouse ACE2 (local refinement) |
Heteromer Q8R0I0; | 91.8 | 3×NAG; 1×ZN; | |||
| SARS-CoV-2 BA.2.75 S Trimer in complex with ACE2(interface) |
Heteromer Q9BYF1; | 91.28 | ||||
| BA.2.86 RBD in complex with hACE2 (local refinement) |
Heteromer Q9BYF1; | 87.33 | 1×ZN; 1×CL; 6×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 Omicron spike receptor-binding domain in complex with mouse ACE2 |
Heteromer Q8R0I0; | 92.31 | 1×ZN; 1×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 spike receptor-binding domain complexed with its receptor minke wha… |
Heteromer A0A452CBT6; | 100 | 1×ZN; | |||
| SARS-CoV-2 Omicron EG.5.1 RBD in complex with human ACE2 (local refined from the spike protein) |
Heteromer Q9BYF1; | 88.2 | 1×NAG; 5×NAG; 1×ZN; | |||
| The structure of fox ACE2 and PT RBD complex |
Heteromer A0A3Q7RAT9; | 100 | 1×ZN; | |||
| The structure of fox ACE2 and Omicron BF.7 RBD complex |
Heteromer A0A3Q7RAT9; | 90.77 | 1×ZN; | |||
| Cryo-EM structure of SARS-CoV-2 Omicron BA.2 RBD in complex with human ACE2 (local refinement) |
Heteromer Q9BYF1; | 91.8 | 1×ZN; 7×NAG; | |||
| SARS-CoV-2 Omicron BQ.1.1 RBD complexed with human ACE2 |
Heteromer Q9BYF1; | 89.74 | 1×NAG; 1×NAG; 5×NAG; 1×ZN; | |||
| Cryo-EM structure of human ACE2 complexed with SARS-CoV-2 Omicron RBD |
Heteromer Q9BYF1; | 92.31 | 4×NAG; 1×ZN; | |||
| Cryo-EM structure of SARS-CoV-2 Omicron BA.4/5 RBD in complex with human ACE2 (local refinement) |
Heteromer Q9BYF1; | 91.28 | 1×NAG; 1×NAG; 5×NAG; 1×ZN; | |||
| SARS-CoV-2 Omicron BF.7 RBD complexed with human ACE2 |
Heteromer Q9BYF1; | 90.77 | 1×NAG; 1×NAG; 5×NAG; 1×ZN; | |||
| Cryo-EM structure of SARS-CoV-2 Omicron RBD in complex with human ACE2 ectodomain (local refinement) |
Heteromer Q9BYF1; | 92.31 | 1×NAG; 1×ZN; 6×NAG; | |||
| Cryo-EM structure of cat ACE2 and SARS-CoV-2 RBD |
Heteromer Q56H28; | 100 | 1×ZN; | |||
| Cryo-EM structure of the SARS-CoV-2 S-6P in complex with Fab30 (local refinement of the RBD and Fab… |
Heteromer | 100 | 1×NAG; | |||
| Nanobody E bound to Spike-RBD in a localized reconstruction |
Heteromer | 100 | 1×NAG; | |||
| Potent neutralizing nanobodies resist convergent circulating variants of SARS-CoV-2 by targeting no… |
Heteromer | 100 | ||||
| Cryo-EM structure of SARS-CoV-2 Delta RBD in complex with BA7208 and BA7125 fab (local refinement) |
Heteromer | 98.97 | ||||
| SARS-CoV-2 Spike RBD in complex with neutralizing Fab 2B04 (local refinement) |
Heteromer | 100 | 1×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 Omicron Prototype RBD in complex with fab L4.65 and L5.34 |
Heteromer | 100 | 1×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 D614G spike protein in complex with VH ab6 (focused refinement of N… |
Heteromer | 100 | 1×NAG; | |||
| Cryo-EM structure of the SARS-CoV-2 N501Y mutant spike protein ectodomain bound to VH ab8 (focused … |
Heteromer | 99.49 | 1×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 prototype spike protein receptor-binding domain in complex with hip… |
Heteromer | 100 | 1×ZN; 1×NAG; | |||
| Structure of the SARS-CoV-2 spike S1 protein in complex with CR3022 Fab |
Heteromer | 100 | ||||
| Cryo-EM structure of Omicron RBD complexed with ACE2 and 304 Fab |
Heteromer Q9BYF1; | 92.31 | 1×NAG; 5×NAG; 1×ZN; | |||
| Cryo-EM structure of the SARS-CoV-2 S-6P in complex with 35B5 Fab(state2, local refinement of the R… |
Heteromer | 100 | 1×NAG; | |||
| SARS-CoV-2 (wuhan variant) Spike protein in complex with the single chain fragment scFv41N (focused… |
Heteromer | 100.0 | 1×NAG; | |||
| Cryo-EM structure of RBD/E77-Fab complex |
Heteromer | 99.49 | 1×NAG; | |||
| SARS-CoV-2 Omicron XBB.1.5 RBD complexed with human ACE2 and S304 |
Heteromer Q9BYF1; | 88.72 | 1×NAG; 1×NAG; 5×NAG; 1×ZN; | |||
| Locally refined region of SARS-CoV-2 spike in complex with antibody A19-46.1 |
Heteromer | 92.31 | 1×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 Epsilon (B.1.429) spike protein in complex with VH ab6 (focused ref… |
Heteromer | 99.49 | 1×NAG; | |||
| SARS-CoV-2 spike in complex with AHB2-2GS-SB175 (local refinement of the RBD and AHB2) |
Heteromer | 100 | 1×NAG; | |||
| SARS-CoV-2 Spike RBD in complex with Mab-23 (Fab) |
Heteromer | 100 | ||||
| RBD in complex with Fab14 |
Heteromer P0DOX5; | 100 | 1×NAG; | |||
| SARS-CoV-2 Omicron BA.2 RBD complexed with BD-604 and S304 Fab |
Heteromer | 91.53 | ||||
| SARS-CoV-2 RBD + IMCAS-123 + IMCAS-72 Fab |
Heteromer | 100 | 1×NAG; | |||
| Cryo-EM structure of the 123-316 scDb/PT-RBD complex |
Heteromer | 100 | 1×NAG; | |||
| Complex of SARS-CoV-2 receptor binding domain with the Fab fragments of neutralizing antibodies REG… |
Heteromer | 100 | 1×NAG; | |||
| SARS-CoV-spike RBD bound to two neutralising nanobodies. |
Heteromer | 100 | 1×NAG; | |||
| The complex structure of Omicron BA.1 RBD with BD604, S309,and S304 |
Heteromer | 92.31 | 1×NAG; | |||
| G32Q4 Fab in complex with SARS-CoV-2 Spike 6P (RBD local reconstruction) |
Heteromer | 100 | ||||
| SARS-CoV-2 RBD + IMCAS-364 + hACE2 |
Heteromer Q9BYF1; | 100 | 4×NAG; 1×ZN; | |||
| Structure of RBD directed antibody DH1042 in complex with SARS-CoV-2 spike: Local refinement of RBD… |
Heteromer | 100 | 1×NAG; | |||
| SARS-CoV-2 Spike RBD in complex with neutralizing Fab 2H04 (local refinement) |
Heteromer | 100.0 | 1×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 receptor binding domain in complex with K202.B bispecific antibody |
Heteromer | 100 | 1×NAG; | |||
| Structure of SARS-CoV-2 BA.2.86 spike RBD in complex with ACE2 (up state) |
Heteromer Q9BYF1; | 86.75 | 2×NAG; 1×NAG; 1×NAG; 4×NAG; | |||
| Structure of SARS-CoV-2 JN.1 spike RBD in complex with ACE2 (up state) |
Heteromer Q9BYF1; | 86.09 | 2×NAG; 1×NAG; 1×NAG; 2×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 Beta (B.1.351) spike protein in complex with VH domain F6 (focused … |
Heteromer | 98.46 | 1×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 Omicron BA.2.12.1 RBD in complex with human ACE2 (local refinement) |
Heteromer Q9BYF1; | 91.28 | 1×NAG; 1×NAG; 5×NAG; 1×ZN; | |||
| Cryo-EM structure of SARS-CoV-2 XBB.1.5 receptor-binding domain (RBD) complexed with CB6 mutant,S30… |
Heteromer | 88.72 | 1×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 prototype spike protein receptor-binding domain in complex with whi… |
Heteromer A0A6J0Z472; | 100 | 3×NAG; 1×ZN; | |||
| Cryo-EM structure of SARS-CoV-2 receptor-binding domain (RBD) complexed with CB6 mutant,S309, and S… |
Heteromer | 100 | 1×NAG; | |||
| SARS-CoV-2 spike in complex with the S2A4 neutralizing antibody Fab fragment (local refinement of t… |
Heteromer | 100.0 | 1×NAG; | |||
| SARS-CoV-2 RBD + IMCAS-364 (Local Refinement) |
Heteromer | 100 | 1×NAG; | |||
| C98C7 Fab in complex with SARS-CoV-2 Spike 6P (RBD local reconstruction) |
Heteromer | 100 | ||||
| Cryo-EM structure of SARS-CoV-2 Omicron BA.2 RBD in complex with rat ACE2 (local refinement) |
Heteromer Q5EGZ1; | 91.8 | 1×ZN; 1×NAG; | |||
| SARS-CoV-2 Omicron BA.4 RBD + IMCAS-316 + ACE2 |
Heteromer Q9BYF1; | 91.28 | 1×NAG; 6×NAG; 1×ZN; | |||
| BA.2.86 Spike in complex with bovine ACE2 (Local refinement) |
Heteromer Q2HJI5; | 87.33 | 7×NAG; 1×ZN; 1×CL; | |||
| Cocktail GC2050-GC2225 |
Heteromer | 88.72 | ||||
| Nanobody H11-H6 bound to RBD |
Heteromer | 100 | 1×NAG; 1×GOL; | |||
| Nanobody H11-H4 Q98R H100E bound to RBD |
Heteromer | 100 | 1×NAG; 3×GOL; 2×NO3; | |||
| Crystal structure of the SARS-CoV-2 S RBD in complex with pT1611 scFV |
Heteromer | 100 | 1×NAG; | |||
| Nanobody C5 bound to Kent variant RBD (N501Y) |
Heteromer | 99.48 | 1×NAG; 1×GOL; | |||
| Crystal structure of the SARS-CoV-2 S RBD in complex with pT1375 scFV |
Heteromer | 100 | 1×NAG; | |||
| LY-CoV488 neutralizing antibody against SARS-CoV-2 |
Heteromer | 100 | 1×NAG; 1×GOL; 1×PRO; | |||
| LY-CoV481 neutralizing antibody against SARS-CoV-2 |
Heteromer | 100 | 2×GOL; 1×NAG; | |||
| Crystal structure of the receptor binding domain of SARS-CoV-2 beta variant spike glycoprotein in c… |
Heteromer | 98.45 | 1×NAG; 13×GOL; 14×CL; 14×K; 3×TAR; | |||
| SARS-CoV-2 receptor binding domain bound to Fab WCSL 129 |
Heteromer | 100 | 1×NAG; 14×GOL; 1×PG4; | |||
| Crystal structure of the SARS-CoV-2 RBD with the antibody Cv2.3194 |
Heteromer Q6PJF2; | 99.48 | 1×NAG; 1×PRO; 2×GOL; | |||
| Crystal structure of SARS-CoV-2 receptor binding domain N501Y mutant in complex with neutralizing n… |
Heteromer | 99.48 | 1×NAG; | |||
| Crystal structure of the receptor binding domain of SARS-CoV-2 beta variant spike glycoprotein in c… |
Heteromer | 98.45 | 1×NAG; 1×CL; | |||
| Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody K398.… |
Heteromer | 100 | 1×NAG; 1×EDO; | |||
| Crystal structure of the K417T mutant receptor binding domain of SARS-CoV-2 Spike glycoprotein in c… |
Heteromer | 98.97 | 1×NAG; 3×GOL; 4×PEG; 12×SO4; 1×CIT; 7×CL; | |||
| Crystal structure of SARS-CoV-2 spike receptor-binding domain in complex with neutralizing nanobody… |
Heteromer | 100 | ||||
| SARS-CoV-2 receptor binding domain bound to Fab PDI 42 |
Heteromer | 100.0 | 1×NAG; 6×GOL; | |||
| Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with C… |
Heteromer | 99.48 | 1×NAG; 3×PEG; 3×GOL; 2×SO4; 6×CL; 1×TRS; | |||
| Crystal structure of the SARS-CoV-2 S RBD in complex with pT1631 scFV |
Heteromer | 100 | 1×NAG; | |||
| Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody 47D1 |
Heteromer | 100 | 1×NAG; 1×NAG; | |||
| Crystal structure of SARS-CoV-2 RBD in complex with a neutralizing antibody scFv |
Heteromer | 100 | 1×NAG; | |||
| Crystal structure of SARS-CoV-2 receptor binding domain in complex with human antibody BIOLS56 |
Heteromer | 100 | 1×NAG; | |||
| Crystal structure of SARS-CoV-2 RBD in complex with a neutralizing antibody Fab |
Heteromer | 100 | 1×NAG; | |||
| Crystal structure of SARS-CoV-2 Spike RBD in complex with IS-9A Fab |
Heteromer | 100 | ||||
| Structure of sybody SR4 in complex with the SARS-CoV-2 S Receptor Binding domain (RBD) |
Heteromer | 100 | 8×GOL; 1×NAG; | |||
| Crystal structure of SARS-CoV-2 spike receptor binding domain bound with P2S-2E9 Fab |
Heteromer | 98.93 | ||||
| Crystal structure of SARS-CoV-2 spike protein receptor-binding domain in complex with antibody CC12… |
Heteromer | 100 | 1×NAG; | |||
| SARS-CoV-2-Beta-RBD and BD-236-GWP/P-VK antibody complex |
Heteromer | 98.45 | ||||
| Crystal structure of SARS-CoV-2 receptor binding domain in complex with antibodies CV05-163 and CR3… |
Heteromer | 100 | 1×NAG; | |||
| SARS-CoV-2 receptor binding domain bound to Fab WCSL 129 and Fab PDI 96 |
Heteromer | 100 | 1×NAG; 1×MPD; 2×GOL; | |||
| Crystal structure of SARS-CoV-2 spike protein receptor-binding domain complexed with a pre-pandemic… |
Heteromer | 100 | 1×NAG; 4×EDO; 2×SO4; 2×PGE; | |||
| Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing human antibody… |
Heteromer | 100 | 1×NAG; 2×GOL; | |||
| Crystal structure of SARS-CoV-2 RBD in complex with the neutralizing nanobody VHH-12 |
Heteromer | 99.48 | 1×NAG; 3×CL; 3×GOL; 1×SO4; | |||
| Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with C… |
Heteromer | 99.48 | 1×NAG; 3×NO3; 5×CL; | |||
| Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody K288.2 |
Heteromer | 100 | 3×CAC; | |||
| SARS-CoV-2 Delta-RBD complexed with Omi-42 and Beta-49 Fabs |
Heteromer | 98.97 | 1×NAG; 3×GOL; 1×SO4; 1×CL; | |||
| Crystal Structure of the SARS-CoV-2 Receptor Binding Domain in Complex with Antibody ION-300 |
Heteromer | 100 | 1×NAG; | |||
| Crystal structure of SARS-CoV-2 delta variant spike receptor-binding domain (RBD) in complex with N… |
Heteromer | 98.97 | 1×NAG; | |||
| Crystal structure of the SARS-CoV-2 RBD in complex with BD-236 Fab |
Heteromer | 100.0 | 1×NAG; | |||
| Crystal structure of the N501Y mutant receptor binding domain of SARS-CoV-2 Spike glycoprotein in c… |
Heteromer | 98.97 | 10×SO4; 3×GOL; 1×NAG; 1×PEG; 1×CL; | |||
| SARS-CoV-2-Omicron-RBD and BD-236-GWP/P-VK antibody complex |
Heteromer | 92.27 | ||||
| Crystal structure of SARS-CoV-2 antibody P22A-1D1 with RBD |
Heteromer | 100.0 | 1×NAG; | |||
| Crystal structure of the SARS-CoV-2 S RBD in complex with BD-623 Fab |
Heteromer | 100.0 | ||||
| Crystal structure of the SARS-Cov-2 RBD in complex with Fab 2303 |
Heteromer | 100 | 1×NAG; | |||
| LY-CoV1404 neutralizing antibody against SARS-CoV-2 |
Heteromer | 100 | 1×NAG; | |||
| The crystal structure of nanobody Nb4 in complex with receptor binding domain (RBD) of BA.1 Spike p… |
Heteromer | 92.27 | ||||
| Crystal structure of SARS-CoV-2 spike receptor-binding domain bound with ACE2 |
Heteromer Q9BYF1; | 100 | 1×ZN; 1×CL; 5×NAG; | |||
| Crystal structure of SARS-CoV-2 RBD in complex with the ridge-binding nAb EH8 isolated from a nonva… |
Heteromer | 100 | 1×NAG; 1×NAG; 1×NA; | |||
| SARS-CoV-2 receptor binding domain bound to Fab PDI 37 |
Heteromer | 100 | 1×NAG; 1×SO4; 1×CL; 1×GOL; | |||
| Structure of SARS-CoV-2 spike receptor-binding domain in complex with high affinity ACE2 mutant (T2… |
Heteromer Q9BYF1; | 100 | 5×NAG; | |||
| Crystal structure of R14 bound to SARS-CoV-2 RBD |
Heteromer | 100 | 1×NAG; | |||
| Crystal structure of the SARS-CoV-2 receptor binding domain in complex with neutralizing antibody W… |
Heteromer | 100 | 5×GOL; 1×NAG; | |||
| Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in a ternary comp… |
Heteromer | 99.48 | 1×NAG; 1×ACT; 1×GOL; 1×NAG; | |||
| Crystal structure of SARS-CoV-2 antibody P5A-1D2 with RBD |
Heteromer | 100 | 1×NAG; | |||
| Crystal structure of SARS-CoV-2 spike protein receptor-binding domain in complex with a cross-neutr… |
Heteromer | 100 | 1×NAG; | |||
| SARS-CoV-2 Receptor-Binding Domain SPEEDesign Immunogen 3 Bound to P2B-2F6 Fab |
Heteromer | 95.88 | 1×NAG; | |||
| Crystal structure of synthetic nanobody (Sb45+Sb68) complexes with SARS-CoV-2 receptor binding doma… |
Heteromer | 100 | ||||
| Crystal structure of SARS-CoV-2 omicron RBD and human ACE2 |
Heteromer Q9BYF1; | 92.27 | 1×NAG; 1×ZN; 1×CL; 4×NAG; | |||
| Crystal structure of receptor binding domain of SARS-CoV-2 Spike glycoprotein in ternary complex wi… |
Heteromer | 100 | 1×NAG; 5×CL; 1×MG; | |||
| SARS-CoV-2 RBD and Nb22 |
Heteromer | 100 | 1×PG4; | |||
| Crystal structure of the SARS-CoV-2 RBD in complex with BD-604 Fab and BD-368-2 Fab |
Heteromer | 100.0 | ||||
| Structure of SARS-CoV-2 spike receptor-binding domain in complex with high affinity ACE2 mutant (S1… |
Heteromer Q9BYF1; | 100 | 5×NAG; | |||
| Structure of SARS-CoV-2 Gamma variant receptor-binding domain complexed with high affinity human AC… |
Heteromer Q9BYF1; | 98.45 | 1×ZN; 1×NAG; | |||
| Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody CV07-… |
Heteromer | 100 | 1×NAG; 5×SO4; | |||
| Crystal structure of SARS-CoV-2 receptor binding domain complexed with nanobody VHH W and antibody … |
Heteromer | 100.0 | 1×NAG; | |||
| Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody ADG20 |
Heteromer | 100 | 1×NAG; 5×SO4; 1×CIT; | |||
| Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing human antibodi… |
Heteromer | 100 | 3×GOL; 1×NAG; | |||
| Crystal structure of the SARS-CoV-2 RBD in complex with the human antibody CV2.6264 |
Heteromer | 99.48 | 1×NAG; 1×NAG; | |||
| Crystal structure of SARS-CoV-2 spike receptor binding domain bound with P5S-1H1 Fab |
Heteromer | 100.0 | 1×NAG; | |||
| Crystal structure of SARS-CoV-2 spike protein receptor-binding domain in complex with antibody CC12… |
Heteromer | 100 | 1×NAG; | |||
| Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody ADI-5… |
Heteromer | 100 | 1×NAG; 9×SO4; | |||
| Crystal structure of SARS-CoV-2 Spike RBD in complex with IY-2A Fab |
Heteromer | 100 | 1×NAG; | |||
| crystal structure of SARS-CoV-2 antibody with RBD |
Heteromer | 100 | 1×NAG; | |||
| Crystal structure of SARS-CoV-2 B.1.351 variant receptor binding domain in complex with neutralizin… |
Heteromer | 98.45 | 1×NAG; 13×SO4; 2×EDO; | |||
| Crystal structure of the SARS-CoV-2 S RBD in complex with pT1511 scFV |
Heteromer | 100 | 1×NAG; | |||
| SARS-CoV-2 RBD bound to neutralizing antibody Fab ICO-hu23 |
Heteromer | 100 | 1×GOL; 1×ZN; 1×NAG; | |||
| Crystal structure of the receptor binding domain of SARS-CoV-2 beta variant spike glycoprotein in c… |
Heteromer | 98.45 | 1×NAG; 3×SO4; | |||
| SARS-CoV-2 Delta RBD and Nb22 |
Heteromer | 98.97 | ||||
| SARS-CoV-2 Omicron BA.2 RBD in complex with COVOX-150 Fab |
Heteromer | 91.75 | ||||
| Crystal structure of SARS-CoV-2 antibody P2C-1F11 with RBD |
Heteromer | 100.0 | 1×NAG; | |||
| Complex Structure of antibody BD-503 and RBD-501Y.V2 of COVID-19 |
Heteromer | 98.45 | 1×NAG; | |||
| Complex Structure of antibody BD-503 and RBD-E484K of COVID-19 |
Heteromer | 99.48 | 1×NAG; | |||
| Complex Structure of antibody BD-503 and RBD of COVID-19 |
Heteromer | 100 | 1×NAG; | |||
| Crystal structure of SARS-CoV-2 spike receptor-binding domain in complex with nanobody N19 |
Heteromer | 100 | ||||
| Crystal structure of spike protein receptor binding domain of escape mutant SARS-CoV-2 from immunoc… |
Heteromer Q9BYF1; | 96.91 | 1×NAG; 2×NAG; 1×NAG; 1×NAG; 1×NAG; 1×ZN; 1×CL; 1×NAG; | |||
| SARS-CoV-2 Omicron RBD in complex with nanobody C1, Omi-18 and Omi-31 Fabs |
Heteromer | 92.27 | 1×NAG; | |||
| SARS-CoV-2 receptor binding domain bound to Fab PDI 231 |
Heteromer | 100 | 1×NAG; 1×SO4; | |||
| Crystal structure of the SARS-CoV-2 S RBD in complex with BD-515 Fab |
Heteromer | 100.0 | ||||
| SARS-CoV-2 Omicron RBD in complex with Omi-3 and EY6A Fabs |
Heteromer | 92.27 | 4×GOL; 2×IPA; | |||
| SARS-CoV-2 Delta-RBD complexed with BA.4/5-2 and Beta-49 Fabs |
Heteromer | 98.94 | 1×NAG; | |||
| Crystal structure of antibody WRAIR-2134 in complex with SARS-CoV-2 receptor binding domain |
Heteromer | 100 | 1×NAG; | |||
| Crystal structure of antibody WRAIR-2134 in complex with SARS-CoV-2 receptor binding domain |
Heteromer | 100 | 1×NAG; | |||
| Epitope-based selection of SARS-CoV-2 neutralizing antibodies from convalescent patients |
Heteromer | 100.0 | 1×NAG; | |||
| Crystal structure of SARS-CoV-2 RBD complexed with Nanosota-1 |
Heteromer | 100 | 1×NAG; | |||
| Crystal structure of the receptor binding domain of SARS-CoV-2 beta variant spike glycoprotein in c… |
Heteromer | 98.45 | 1×NAG; 1×NAG; 15×SO4; | |||
| SARS-CoV-2 Omicron BA.2 RBD in complex with COVOX-150 Fab (P21) |
Heteromer | 91.75 | 1×NAG; | |||
| Crystal structure of the SARS-CoV-2 spike receptor-binding domain (RBD) with nanobody Nb20 |
Heteromer | 100 | 2×CAC; | |||
| BA.2/AZD1061/AZD3152 structure analysis |
Heteromer | 91.75 | ||||
| Crystal structure of SARS-CoV-2 antibody P2C-1A3 with RBD |
Heteromer | 100 | 1×NAG; | |||
| Bovine Fab SKD in complex with Sars COV-2 receptor binding domain |
Heteromer P0DOX5; P0DOY2; | 100 | 1×NAG; | |||
| Crystal structure of the SARS-CoV-2 RBD in complex with BD-236 Fab and BD-368-2 Fab |
Heteromer | 100.0 | ||||
| SARS-CoV-2 Omicron BA.2 RBD in complex with ACE2 |
Heteromer Q9BYF1; | 91.75 | 6×NAG; 1×ZN; | |||
| SARS-CoV-2 Receptor Binding Domain in Complex with Ab17 |
Heteromer | 100.0 | ||||
| SARS-CoV-2 Delta-RBD complexed with BA.2-10 and EY6A Fabs |
Heteromer | 98.45 | ||||
| Molecular basis for neutralizing antibody 2B11 targeting SARS-CoV-2 RBD |
Heteromer | 100.0 | ||||
| Complex Structure of antibody BD-503 and RBD-S477N of COVID-19 |
Heteromer | 99.48 | 1×NAG; | |||
| Crystal structure of the receptor binding domain of SARS-CoV-2 beta variant spike glycoprotein in c… |
Heteromer | 98.45 | 1×NAG; | |||
| SARS-CoV-2 delta RBD complexed with XBB-6 and beta-49 Fabs |
Heteromer | 98.97 | 1×NAG; | |||
| Crystal structure of the Wuhan SARS-CoV-2 RBD (333-541) complexed with P2C5 nanobody |
Heteromer | 100 | 1×NAG; | |||
| SARS-CoV-2 delta RBD complexed with BA.4/5-9 Fab |
Heteromer | 98.97 | 1×NAG; 1×SO4; | |||
| Crystal structure of SARS-CoV-2 RBD with P2C-1F11 and P2B-1G5 |
Heteromer | 100 | 2×NAG; | |||
| SARS-CoV-2 Omicron RBD in complex with Omi-9 Fab and nanobody F2 |
Heteromer | 93.19 | ||||
| SARS-CoV-2 Omicron RBD in complex with Omi-6 and COVOX-150 Fabs |
Heteromer | 92.27 | ||||
| SARS-CoV-2 Omicron RBD in complex with Omi-12 and Beta-54 Fabs |
Heteromer | 93.01 | ||||
| SARS-CoV-2 Omicron BA.1 spike protein receptor-binding domain in complex with white-tailed deer ACE2 |
Heteromer A0A6J0Z472; | 92.27 | 1×NAG; 1×NAG; 4×NAG; 1×ZN; | |||
| Cryo-EM structure of SARS-CoV-2 BA.3 RBD in complex with golden hamster ACE2 (local refinement) |
Heteromer A0A1U7QTA1; | 92.27 | 1×NAG; 1×ZN; 2×NAG; | |||
| SARS-CoV-2 Delta S-RBD-ACE2 complex |
Heteromer Q9BYF1; | 98.97 | ||||
| Cryo-EM structure of SARS-CoV-2 Delta RBD in complex with golden hamster ACE2 (local refinement) |
Heteromer A0A1U7QTA1; | 98.97 | 2×NAG; 1×ZN; 2×NAG; | |||
| SARS-CoV-2 Delta S-RBD-ACE2 |
Heteromer Q9BYF1; | 98.97 | ||||
| Cryo-EM structure of SARS-CoV2 RBD-ACE2 complex |
Heteromer Q9BYF1; | 99.48 | 1×ZN; 1×CL; 5×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 Omicron spike protein with human ACE2 (focus refinement on RBD-1/AC… |
Heteromer Q9BYF1; | 92.27 | ||||
| SARS-COV-2 Spike RBDMACSp25 binding to hACE2 |
Heteromer Q9BYF1; | 98.97 | 5×NAG; | |||
| ACE2-RBD in SARS-CoV-2 Kappa variant S-ACE2 complex |
Heteromer Q9BYF1; | 98.97 | 1×ZN; 5×NAG; | |||
| SARS-CoV-2 Delta S-RBD-ACE2 |
Heteromer Q9BYF1; | 98.97 | ||||
| SARS-COV-2 Spike RBDMACSp36 binding to hACE2 |
Heteromer Q9BYF1; | 98.45 | 5×NAG; | |||
| SARS-COV-2 Spike RBDMACSp36 binding to mACE2 |
Heteromer Q8R0I0; | 98.45 | 3×NAG; | |||
| Cryo-EM structure of the RBD-ACE2 interface of the SARS-CoV-2 trimeric spike protein bound to ACE2 … |
Heteromer A0A7T0Q2W2; | 99.48 | ||||
| SARS-CoV-2 Omicron BA.2 Variant RBD complexed with mouse ACE2 |
Heteromer Q8R0I0; | 91.75 | 1×NAG; 1×ZN; 2×NAG; | |||
| Cryo-EM structure of the RBD-ACE2 interface of the SARS-CoV-2 trimeric spike protein bound to ACE2 … |
Heteromer A0A7T0Q2W2; | 99.46 | 1×NAG; 1×NAG; 2×NAG; | |||
| SARS-CoV-2 Omicron BA.1 Variant RBD with mouse ACE2 Bound |
Heteromer Q8R0I0; | 92.27 | 1×NAG; 1×ZN; 2×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 prototype RBD in complex with rabbit ACE2 (local refinement) |
Heteromer G1TEF4; | 100 | 1×NAG; 1×ZN; | |||
| SARS-CoV-2 receptor binding domain bound to Fab PDI 222 |
Heteromer | 100 | 1×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 Delta variant spike protein in complex with three nAbs X01, X10 and… |
Heteromer | 98.97 | 1×NAG; | |||
| Local refinement of SARS-CoV-2 Omicron BA.1 Spike glycoprotein in complex with rabbit monoclonal an… |
Heteromer | 92.27 | ||||
| Locally refined region of SARS-CoV-2 Spike in complex with IgG 553-15 |
Heteromer | 100 | 1×NAG; | |||
| SARS-CoV-2 Spike RBD in complex with DMAbs 2130 and 2196 |
Heteromer | 100 | 1×NAG; | |||
| SARS-CoV-2 spike in complex with the S2E12 neutralizing antibody Fab fragment (local refinement of … |
Heteromer | 100 | 1×NAG; | |||
| SARS-CoV-2 Spike RBD in complex with DMAb 2196 |
Heteromer | 100 | 1×NAG; | |||
| SARS-CoV-2 Omicron variant spike in complex with three human neutralizing antibodies |
Heteromer A0A5C2G4I7; A0A5C2GTV1; A0A5C2GVU3; | 92.27 | 1×NAG; | |||
| Locally refined region of SARS-CoV-2 Spike in complex with IgG 553-60 |
Heteromer | 100 | 1×NAG; | |||
| The SARS-CoV-2 receptor binding domain bound with the Fab fragment of a human neutralizing antibody… |
Heteromer | 100 | 1×NAG; | |||
| Structure of SARS-CoV-2 spike RBD in complex with neutralizing antibody NIV-11 |
Heteromer | 100 | 1×NAG; | |||
| Association of two complexes of largely structurally disordered Spike ectodomain with bound EY6A Fab |
Heteromer | 100 | 1×NAG; | |||
| Structure of the SARS-CoV-2 spike glycoprotein in complex with the 10D12 heavy-chain-only antibody … |
Heteromer | 100 | ||||
| CryoEM structure of SARS-CoV-2 RBD in complex with nanobodies Nb21 and Nb105 |
Heteromer | 100 | 1×NAG; | |||
| CryoEM structure of SARS-CoV-2 RBD in complex with nanobodies Nb17 and Nb105 |
Heteromer | 100 | ||||
| SARS-CoV-2 receptor binding domain in complex with AZ090 Fab |
Heteromer | 100 | 2×NAG; | |||
| SARS-CoV-2 Delta-RBD complexed with Fabs BA.2-36, BA.2-23, EY6A and COVOX-45 |
Heteromer | 98.97 | ||||
| G32A4 Fab in complex with SARS-CoV-2 Spike 6P (RBD local reconstruction) |
Heteromer | 100 | ||||
| SARS-CoV-2 spike in complex with the CA521 neutralizing antibody Fab (focused refinement on Fab-RBD) |
Heteromer | 100 | 1×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 Omicron BA.4 RBD in complex with fab L4.65 and L5.34 |
Heteromer | 91.24 | 1×NAG; | |||
| Structure of SARS-CoV-2 spike RBD in complex with neutralizing antibody NIV-8 |
Heteromer | 100 | 1×NAG; | |||
| SARS-CoV-2 spike protein in complex with three human neutralizing antibodies |
Heteromer A0A5C2G4I7; A0A5C2GTV1; A0A5C2GVU3; | 100 | 1×NAG; | |||
| Local refinement of the SARS-CoV-2 BA.1 Spike trimer in complex with 55A8 Fab |
Heteromer | 92.23 | ||||
| Association of three complexes of largely structurally disordered Spike ectodomain with bound EY6A … |
Heteromer | 100 | 3×NAG; | |||
| SARS-CoV-2 spike protein RBD and P17 fab complex |
Heteromer | 100 | ||||
| Cryo-EM structure of SARS-CoV-2 BA.4/5 spike protein in complex with 1G11 (local refinement) |
Heteromer | 91.24 | ||||
| SARS-CoV-2 Delta S-RBD-8D3 |
Heteromer | 98.97 | ||||
| Cryo-EM structure of SARS-CoV-2 spike protein in complex with double nAbs 3E2 and 1C4 (local refine… |
Heteromer | 100.0 | 1×NAG; | |||
| The structure of FC08 Fab-hA.CE2-RBD complex |
Heteromer Q9BYF1; | 100 | 5×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 spike protein in complex with double nAbs 8H12 and 3E2 (local refin… |
Heteromer | 100 | 1×NAG; | |||
| SARS-CoV-2 spike in complex with LCB3 (local refinement of the RBD and LCB3) |
Heteromer | 100 | 1×NAG; | |||
| Local refined cryo-EM structure of Omicron BA.5 RBD in complex with 8-9D Fab |
Heteromer | 90.96 | ||||
| RBD/XG005 local refinement |
Heteromer | 100 | 1×NAG; | |||
| The SARS-CoV-2 receptor binding domain bound with the Fab fragment of a human neutralizing antibody… |
Heteromer | 100 | 1×NAG; | |||
| RBD of SARS-CoV-2 Spike protein in complex with pan-sarbecovirus nanobodies 2-10, 2-67, 2-62 and 1-… |
Heteromer | 100 | ||||
| SARS-CoV-2 spike in complex with the Ab1 neutralizing antibody (focused refinement on Fab-RBD) |
Heteromer | 100 | 1×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 spike protein in complex with three nAbs X01, X10 and X17 |
Heteromer | 100.0 | 1×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 spike protein in complex with double nAbs 8H12 and 1C4 (local refin… |
Heteromer | 100 | 1×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 spike protein in complex with double nAbs XMA01 and 3E2 (local refi… |
Heteromer | 100 | 1×NAG; | |||
| Local refinement of the SARS-CoV-2 BA.1 Spike trimer in complex with 55A8 Fab and 58G6 Fab |
Heteromer | 92.23 | ||||
| The interface of H014 Fab binds to SARS-CoV-2 S |
Heteromer | 100.0 | ||||
| CryoEM structure of SARS-CoV-2 RBD in complex with nanobodies Nb21 and Nb36 |
Heteromer | 100 | ||||
| SARS-CoV-2 S bound to S2X259 Fab (local refinement of the RBD/S2X259 variable domains) |
Heteromer | 100.0 | 1×NAG; | |||
| SARS-CoV-2 RBD in complex with A5-10 Fab and A34-2 Fab |
Heteromer | 100 | 1×NAG; 1×MES; | |||
| SARS-COV-2 Spike RBDMACSp6 binding to hACE2 |
Heteromer Q9BYF1; | 99.48 | 5×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 Omicron BA.4/5 spike protein receptor-binding domain in complex wit… |
Heteromer A0A6J0Z472; | 91.24 | 5×NAG; 1×ZN; | |||
| Binding interface of SARS-CoV-2 RBD and its neutralizing antibody HB27 |
Heteromer | 100 | ||||
| SARS-CoV-2 spike in complex with the Ab4 neutralizing antibody (State 3) |
Heteromer | 100 | 1×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 alpha variant spike protein in complex with raccoon dog ACE2 (local… |
Heteromer B4XEP4; | 99.48 | 4×NAG; 1×ZN; 1×NAG; | |||
| The SARS-CoV-2 receptor binding domain bound with the Fab fragment of a human neutralizing antibody… |
Heteromer | 100 | 1×NAG; | |||
| The SARS-CoV-2 receptor binding domain bound with the Fab fragment of a human neutralizing antibody… |
Heteromer | 100 | 1×NAG; | |||
| SARS-CoV-2 S RBD (C.37 Lambda variant) plus S309 Fab, local refinement |
Heteromer | 98.37 | 1×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 prototype RBD in complex with raccoon dog ACE2 (local refinement) |
Heteromer B4XEP4; | 100 | 4×NAG; 1×ZN; 1×NAG; | |||
| SARS-Cov-2 spike in complex with the Ab5 neutralizing antibody (focused refinement on Fab-RBD) |
Heteromer | 100 | 1×NAG; | |||
| cryoEM structure of a broadly neutralizing anti-SARS-CoV-2 antibody STI-9167 |
Heteromer | 100 | 1×NAG; | |||
| SARS-CoV-2 BQ.1.1 spike RBD bound to the human ACE2 ectodomain and the S309 neutralizing antibody F… |
Heteromer Q9BYF1; | 89.84 | 1×NAG; 5×NAG; 1×ZN; | |||
| Interface of SARS-CoV-2 WT Spike in complex with R15 Fab and P14 Nanobody |
Heteromer | 100 | ||||
| Complex of SARS-CoV-2 receptor binding domain with the Fab fragments of two neutralizing antibodies |
Heteromer | 100 | 1×NAG; | |||
| Cryo-EM structure of the Omicron RBD in complex with 35B5 Fab( local refinement of the RBD and 35B5… |
Heteromer | 92.27 | 1×NAG; | |||
| ACE2-RBD in SARS-CoV-2 Beta variant S-ACE2 complex |
Heteromer Q9BYF1; | 98.45 | 1×ZN; 5×NAG; | |||
| Crystallographic structure of neutralizing antibody 10-40 in complex with SARS-CoV-2 spike receptor… |
Heteromer | 100 | 1×NAG; | |||
| Crystal structure of SARS-CoV-2 S RBD in complex with a stapled peptide |
Heteromer | 100 | 1×29N; | |||
| CRYSTAL STRUCTURE OF SARS-COV-2 RECEPTOR BINDING DOMAIN (RBD) in complex with 1D1 Fab |
Heteromer | 100.0 | 1×NAG; 5×GOL; 1×TRS; | |||
| SARS-CoV-2 Receptor-Binding Domain SPEEDesign Immunogen 1 Bound to C144 scFv |
Heteromer | 95.86 | ||||
| Crystal structure of SARS-CoV-2 spike receptor-binding domain in complex with neutralizing nanobody… |
Heteromer | 100.0 | 1×NAG; | |||
| Crystal Structure of SARS-CoV-2 S receptor-binding domain (RBD) in complex CoV11 Fab |
Heteromer | 100 | 1×NAG; 5×SO4; 4×ACT; | |||
| Crystal structure of the SARS-CoV-2 S RBD in complex with pT1580 scFV |
Heteromer | 100 | 1×NAG; | |||
| LY-CoV555 neutralizing antibody against SARS-CoV-2 |
Heteromer | 100 | 1×GOL; | |||
| Crystal structure of SARS-CoV-2 RBD in complex with a neutralizing antibody scFv |
Heteromer | 100 | 1×NAG; | |||
| Crystal structure of SARS-CoV-2 RBD and NIV-10 complex |
Heteromer | 100.0 | 1×NAG; | |||
| Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with C… |
Heteromer | 100 | 7×CL; 10×SO4; 3×GOL; 1×NAG; | |||
| Crystal structure of the K417N mutant receptor binding domain of SARS-CoV-2 Spike glycoprotein in c… |
Heteromer | 99.48 | 3×GOL; 1×NAG; 13×SO4; 1×CL; 1×CIT; | |||
| Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody COVA2… |
Heteromer | 100 | 1×NAG; | |||
| SARS-CoV-2 BA.2.12.1 RBD in complex with Beta-27 Fab and C1 nanobody |
Heteromer | 90.91 | 1×NAG; 12×GOL; 1×PO4; | |||
| Crystal structure of chimeric omicron RBD (strain BA.2) complexed with human ACE2 |
Heteromer Q9BYF1; | 84.57 | 2×NAG; 1×ZN; 1×CL; 5×NAG; 1×NA; | |||
| Crystal structure of nanobody Nb70 with antibody 1F11 fab and SARS-CoV-2 RBD |
Heteromer | 100 | 1×NAG; | |||
| Crystal structure of the receptor binding domain of SARS-CoV-2 beta variant spike glycoprotein in c… |
Heteromer | 98.45 | 1×NAG; 4×GOL; 4×CL; 4×IOD; 2×PEG; | |||
| The co-crystal structure of BA.1-RBD with Fab-5549 |
Heteromer | 91.19 | 1×NAG; | |||
| Crystal structure of the receptor binding domain of SARS-CoV-2 B.1.351 variant Spike glycoprotein i… |
Heteromer | 98.45 | 19×SO4; 2×GOL; 1×NAG; 2×PEG; | |||
| Crystal structure of chimeric SARS-CoV-2 RBD complexed with chimeric raccoon dog ACE2 |
Heteromer B4XEP4; Q9BYF1; | 88.08 | 1×NAG; 1×NAG; 1×NAG; 1×NAG; 1×ZN; 1×CL; 1×NAG; | |||
| Crystal structure of the receptor binding domain of SARS-CoV-2 P.1 variant Spike glycoprotein in co… |
Heteromer | 98.45 | 15×SO4; 2×GOL; 1×NAG; 1×PEG; | |||
| Complex Structure of antibody BD-503 and RBD-N501Y of COVID-19 |
Heteromer | 99.48 | ||||
| Crystal structure of Omicron BA.4/5 in complex with a neutralizing antibody scFv D1 |
Heteromer | 91.67 | ||||
| SARS-CoV-2 Delta-RBD complexed with BA.2-13 Fab and C1 nanobody |
Heteromer | 98.96 | 1×NAG; 5×GOL; 1×PG0; | |||
| Crystal structure of chimeric omicron RBD (strain BA.2) complexed with chimeric mouse ACE2 |
Heteromer Q9BYF1; | 84.57 | 1×NAG; 1×ZN; 1×CL; 3×NAG; 5×EDO; | |||
| SARS-CoV-2 Omicron BA.2.75 RBD in complex with ACE2 |
Heteromer Q9BYF1; | 91.19 | 12×GOL; 6×NAG; 1×CL; 1×PGE; | |||
| Crystal structure of SARS-CoV-2 spike receptor binding domain bound with P5S-2B10 |
Heteromer | 100 | ||||
| Crystal structure of the SARS-CoV-2 S RBD in complex with BD-508 Fab |
Heteromer | 100.0 | ||||
| Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with F… |
Heteromer | 100 | 1×NAG; 3×SO4; 2×NO3; 2×CL; | |||
| Crystal structure of the receptor binding domain of SARS-CoV-2 beta variant spike glycoprotein in c… |
Heteromer | 98.45 | 1×NAG; 2×GOL; 14×SO4; 1×PEG; | |||
| Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with F… |
Heteromer | 100.0 | 1×NAG; | |||
| Crystal structure of SARS-CoV-2 Y453F-RBD bound to mink ACE2 |
Heteromer A0A8C7BTF2; | 99.46 | 1×NAG; 1×NAG; 2×NAG; | |||
| Crystal structure of the SARS-COV-2 RBD with neutralizing-VHHs Re30H02 and Re21D01 |
Heteromer | 99.48 | ||||
| Crystal structure of the receptor binding domain of SARS-CoV-2 beta variant spike glycoprotein in c… |
Heteromer | 98.45 | 1×NAG; | |||
| Crystal structure of the SARS-CoV-2 S RBD in complex with pT1616 Fab |
Heteromer | 100 | ||||
| Crystal structure of FD20, a neutralizing single-chain variable fragment (scFv) in complex with SAR… |
Heteromer | 100 | 1×NAG; | |||
| Crystal structure of the receptor binding domain of SARS-CoV-2 beta variant spike glycoprotein in c… |
Heteromer | 98.45 | 1×NAG; 1×NAG; | |||
| Crystal structure of the SARS-CoV-2 S RBD in complex with BD-604 Fab |
Heteromer | 100.0 | ||||
| Crystal structure of neutralizing antibody 10-28 in complex with SARS-CoV-2 spike receptor binding … |
Heteromer | 100.0 | 1×NAG; | |||
| Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with F… |
Heteromer | 100.0 | 1×NAG; 2×PO4; | |||
| Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody COVA2… |
Heteromer | 100 | 1×NAG; | |||
| SARS-CoV-2 Delta-RBD complexed with BA.4/5-1 and EY6A Fabs |
Heteromer | 98.96 | 1×NAG; | |||
| Crystal structure of affinity-enhancing and catalytically inactive ACE2 in complex with SARS-CoV-2 … |
Heteromer Q9BYF1; | 100.0 | 6×NAG; 1×ZN; | |||
| Crystal structure of the receptor binding domain of SARS-CoV-2 beta variant spike glycoprotein in c… |
Heteromer | 98.45 | ||||
| Beta SARS-CoV-2 Spike bound to mouse ACE2 (local) |
Heteromer Q8R0I0; | 98.45 | 1×NAG; 1×NAG; | |||
| BA.2.12.1 SARS-CoV-2 Spike bound to mouse ACE2 (local) |
Heteromer Q8R0I0; | 91.19 | 1×NAG; 1×NAG; | |||
| BA.1 SARS-CoV-2 Spike bound to mouse ACE2 (local) |
Heteromer Q8R0I0; | 92.23 | 1×NAG; 1×NAG; | |||
| BA.4/5 SARS-CoV-2 Spike bound to human ACE2 (local) |
Heteromer Q9BYF1; | 91.19 | 6×NAG; 1×ZN; | |||
| BA.4/5 SARS-CoV-2 Spike bound to mouse ACE2 (local) |
Heteromer Q8R0I0; | 91.19 | 1×NAG; 1×NAG; | |||
| Structure of the SARS-CoV-2 EG.5.1 spike RBD in complex with ACE2 |
Heteromer Q9BYF1; | 88.08 | 2×NAG; 1×NAG; 1×NAG; 3×NAG; | |||
| Structure of SARS-CoV-2 spike receptor-binding domain Y453F mutation complexed with American mink A… |
Heteromer A0A8C7BTF2; | 99.48 | 1×NAG; 1×ZN; | |||
| SARS-CoV-2 Spike (6P) in complex with 3 R1-32 Fabs and 3 ACE2, focused refinement of RBD region |
Heteromer Q9BYF1; | 100 | 1×ZN; 4×NAG; | |||
| Local CryoEM structure of the SARS-CoV-2 S6P(B.1.617.2) in complex with SWA9 Fab |
Heteromer | 98.94 | ||||
| Local CryoEM structure of the SARS-CoV-2 S6P(B.1.617.2) in complex with SWC11 Fab |
Heteromer | 98.94 | ||||
| SARS-CoV-2 BN.1 spike RBD bound to the human ACE2 ectodomain and the S309 neutralizing antibody Fab… |
Heteromer Q9BYF1; | 89.73 | 1×NAG; 5×NAG; | |||
| Omicron BA.4/5 SARS-CoV-2 S RBD in complex with TH027 Fab |
Heteromer | 91.19 | ||||
| Structure of SARS-CoV-2 spike with antibody Fabs 2A10 and 1H2 (Local refinement of the RBD and Fabs… |
Heteromer | 100 | 1×NAG; | |||
| Local structure of BD55-3500 and omicron RBD complex |
Heteromer | 91.98 | 1×NAG; | |||
| Omicron BA.4/5 SARS-CoV-2 S RBD in complex with TH272 Fab |
Heteromer | 91.19 | ||||
| Local structure of BD55-1239 Fab and SARS-COV2 Omicron RBD complex |
Heteromer | 91.98 | ||||
| Model and map from local refinement of a CAB-A17 - Omicron Ba.1 spike complex |
Heteromer | 92.63 | ||||
| Local CryoEM structure of the SARS-CoV-2 S6P(B.1.1.529) in complex with BD55-3152 Fab |
Heteromer | 91.98 | 1×NAG; | |||
| Local structure of BD55-3546 Fab and SARS-COV2 Delta RBD complex |
Heteromer | 98.94 | 1×NAG; | |||
| Omicron BA.4/5 SARS-CoV-2 S RBD in complex with TH132 Fab |
Heteromer | 91.19 | ||||
| Omicron BA.4/5 SARS-CoV-2 S RBD in complex with TH236 Fab |
Heteromer | 91.19 | ||||
| Omicron BA.4/5 SARS-CoV-2 S RBD in complex with TH272 Fab |
Heteromer | 91.19 | ||||
| SARS-CoV-2 spike in complex with LCB1 (local refinement of the RBD and LCB1) |
Heteromer | 100 | 1×NAG; | |||
| SARS-CoV2 Omicron BA.1 RBD in complex with CAB-A17 antibody |
Heteromer | 92.63 | ||||
| the complex structure of the H4B6 Fab with the RBD of Omicron BA.5 S protein |
Heteromer | 91.19 | ||||
| SARS-CoV-2 spike in complex with the S2D106 neutralizing antibody Fab fragment (local refinement of… |
Heteromer | 100.0 | 1×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 Omicron BA.2 RBD in complex with fab L4.65 and L5.34 |
Heteromer | 91.71 | 1×NAG; | |||
| Neutralization antibody ZCP3B4 bound with SARS-CoV-2 Omicron BA.5 RBD |
Heteromer | 80.85 | ||||
| Neutralization antibody ZCP4C9 bound with SARS-CoV-2 Omicron BA.5 RBD |
Heteromer | 80.85 | ||||
| Local CryoEM structure of the SARS-CoV-2 S6P(B.1.1.529) in complex with BD55-4637 Fab |
Heteromer | 91.98 | 1×NAG; | |||
| SARS-CoV-2 receptor binding domain bound to Fab PDI 215 |
Heteromer | 100 | 1×NAG; 2×IPA; | |||
| Crystal structure of SARS-CoV-2 spike protein receptor-binding domain in complex with a highly pote… |
Heteromer | 100.0 | 1×NAG; 2×GOL; | |||
| Crystal structure of SARS-CoV-2 receptor binding domain complexed with nanobody VHH V and antibody … |
Heteromer | 100.0 | 1×NAG; | |||
| Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody CC25.… |
Heteromer | 100.0 | 1×NAG; | |||
| Crystal structure of SARS-CoV-2 spike protein receptor-binding domain in complex with antibody CC12… |
Heteromer | 100 | 1×NAG; | |||
| Crystal structure of SARS-CoV-2 RBD in complex with antibody NT-193 |
Heteromer | 100.0 | 1×NAG; | |||
| Potent SARS-CoV-2 binding and neutralization through maturation of iconic SARS-CoV-1antibodies |
Heteromer | 100 | 1×NAG; 1×CL; | |||
| ACE2-RBD Focused Refinement Using Symmetry Expansion of Applied C3 for Triple ACE2-bound SARS-CoV-2… |
Heteromer Q9BYF1; | 100 | 2×NAG; 5×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 RBD in complex with anti-SARS-CoV-2 DARPin,SR22, and two antibody F… |
Heteromer | 100 | 1×NAG; | |||
| SARS-CoV-2 spike omicron (BA.1) ectodomain trimer in complex with SC27 Fab, local refinement |
Heteromer | 91.94 | 1×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 RBD in complex with anti-SARS-CoV-2 DARPin,SR16m, and two antibody … |
Heteromer | 100 | 1×NAG; | |||
| Local structure of BD55-5514 and BD55-5840 Fab and Omicron BA.1 RBD complex |
Heteromer | 92.19 | 1×NAG; | |||
| Local resolution of BD55-5840 Fab and SARS-COV2 Omicron RBD |
Heteromer | 91.89 | 1×NAG; | |||
| SARS-CoV-2 spike in complex with the S2K146 neutralizing antibody Fab fragment (local refinement of… |
Heteromer | 100.0 | 1×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 spike in complex with FSR22, an anti-SARS-CoV-2 DARPin (Local refin… |
Heteromer | 100 | ||||
| SARS-CoV-2 spike omicron (BA.1) RBD ectodomain dimer-of-trimers in complex with SC27 Fabs |
Heteromer | 91.94 | 2×NAG; | |||
| Crystal structure of the SARS-CoV-2 S RBD in complex with pT1610 scFV |
Heteromer | 100 | 1×NAG; | |||
| CRYSTAL STRUCTURE OF SARS-COV-2 RECEPTOR BINDING DOMAIN (RBD-beta variant) in complex with 3D2 Fab |
Heteromer | 98.84 | 1×NAG; 4×GOL; | |||
| Crystal Structure of SARS-CoV-2 S delta variant receptor-binding domain (RBD) in complex CoV11 Fab … |
Heteromer | 98.94 | 1×NAG; 2×PO4; 2×MPD; | |||
| Crystal structure of Omicron BA.4/5 RBD in complex with a neutralizing antibody scFv |
Heteromer | 91.1 | ||||
| Crystal structure of SARS-CoV-2 Spike RBD in complex with MW07 Fab |
Heteromer | 100 | 1×NAG; | |||
| Crystal structure of SARS-CoV-2 delta variant spike receptor-binding domain (RBD) in complex with N… |
Heteromer | 98.95 | ||||
| SARS-CoV-2 Beta RBD in complex with nanobody C1, Omi-18 and Omi-31 Fabs |
Heteromer | 98.43 | 1×NAG; | |||
| SARS-CoV-2 Omicron RBD in complex with Omi-25 Fab |
Heteromer | 92.43 | ||||
| SARS-CoV-2 (B.1.1.529/Omicron variant) Spike protein in complex with the single chain fragment scFv… |
Heteromer | 92.15 | 1×NAG; | |||
| Crystal structure of SARS-CoV-2 antibody P5A-3C8 with RBD |
Heteromer | 100.0 | 1×NAG; | |||
| S-RBD (Omicron BF.7) in complex with PD of ACE2 |
Heteromer Q9BYF1; | 90.06 | 6×NAG; 1×NAG; | |||
| S-RBD (Omicron XBB.1) in complex with PD of ACE2 |
Heteromer Q9BYF1; | 87.98 | 6×NAG; 1×NAG; | |||
| XBB 1.0 RBD bound to P4J15 (Local) |
Heteromer | 88.42 | 1×NAG; | |||
| Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody nCoV6… |
Heteromer | 100 | ||||
| SARS-CoV-2 S protein in complex with pT1696 Fab |
Heteromer | 100 | 1×NAG; | |||
| Structure of SARS-CoV-2 spike receptor-binding domain complexed with its receptor equine ACE2 |
Heteromer F6V9L3; | 100 | 1×ZN; 1×NAG; | |||
| Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody 20A7 |
Heteromer | 100.0 | 1×NAG; | |||
| Crystal structure of the SARS-CoV-2 RBD (Wuhan) with neutralizing VHHs Ma6F06 and Re21H01 |
Heteromer | 99.47 | 1×P4G; 2×EDO; | |||
| SARS-CoV-2 Spike RBD in complex with neutralizing Fab SARS2-38 (local refinement) |
Heteromer | 100 | 1×NAG; | |||
| Crystal structure of SARS-CoV-2 Beta RBD complexed with P36-5D2 Fab |
Heteromer | 98.28 | 1×NAG; | |||
| Crystal structure of SARS-CoV-2 Spike RBD in complex with the D27 neutralizing antibody Fab fragment |
Heteromer | 100 | ||||
| SARS-CoV-2 delta RBD complexed with XBB-2 Fab and NbC1 |
Heteromer | 98.92 | 1×NAG; 6×GOL; | |||
| Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with C… |
Heteromer | 100 | 1×NAG; 2×GOL; 2×CL; 2×PO4; 4×PRO; | |||
| SARS-CoV-2 Delta RBD in complex with XBB-9 Fab and an anti-Fab nanobody |
Heteromer | 98.92 | ||||
| SARS-CoV-2 Omicron BA.1 spike trimer (6P) in complex with YB13-292 Fab, focused refinement of Fab r… |
Heteromer | 91.94 | 1×NAG; | |||
| Ternary Crystal Complex Structure of RBD with NB1B5 and NB1C6 |
Heteromer | 100 | ||||
| Crystallographic structure of two neutralizing antibodies in complex with SARS-CoV-2 spike receptor… |
Heteromer | 100 | 1×TRS; 1×NAG; 2×GOL; | |||
| The receptor binding domain of SARS-CoV-2 spike glycoprotein in complex with Beta-55 and EY6A Fabs |
Heteromer | 100 | 1×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 Omicron BA.2.86 RBD in complex with human ACE2 |
Heteromer Q9BYF1; | 87.08 | 2×NAG; 1×NAG; 1×ZN; 5×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 Omicron JN.1 RBD in complex with human ACE2 (local refinement from … |
Heteromer Q9BYF1; | 86.39 | 2×NAG; 3×NAG; 1×ZN; 3×NAG; | |||
| Delta-RBD complex with BA.2-07 fab, SARS1-34 fab and C1 nanobody |
Heteromer | 98.92 | 1×NAG; | |||
| Crystal structure of the SARS-CoV-2 BA.1 RBD with neutralizing-VHHs Ma16B06 and Ma3F05 |
Heteromer | 90.76 | ||||
| Crystal structure of the L452R mutant receptor binding domain of SARS-CoV-2 Spike glycoprotein in c… |
Heteromer | 99.46 | 1×NAG; 1×NAG; 9×GOL; 1×PEG; 1×CL; 1×TRS; 1×PO4; | |||
| Structure of the SARS-CoV-2 receptor binding domain in complex with the human neutralizing antibody… |
Heteromer | 100 | 1×NAG; | |||
| SARS-CoV-2 Delta-RBD complexed with BA.4/5-35 Fab |
Heteromer | 98.91 | 1×NAG; | |||
| SARS-CoV-2 spike RBD in complex with neutralizing antibody UT28K |
Heteromer | 100.0 | ||||
| Cryo-EM structure of SARS-CoV-2 Omicron BA.4/5 RBD in complex with rabbit ACE2 (local refinement) |
Heteromer G1TEF4; | 90.76 | 1×ZN; 1×NAG; | |||
| Cryo-EM map of SARS-CoV-2 Omicron BA.2 spike in complex with 2130-1-0114-112 |
Heteromer | 90.81 | 1×NAG; | |||
| Structure Determination of the RBD-NB1A7 |
Heteromer | 100 | 1×NAG; | |||
| Crystal structure of the SARS-CoV-2 RBD in complex with STE90-C11 Fab |
Heteromer | 100 | 1×NAG; | |||
| Crystal structure of the N501Y mutant receptor binding domain of SARS-CoV-2 Spike glycoprotein in c… |
Heteromer | 99.45 | 1×NAG; 5×GOL; 3×SO4; | |||
| A SARS-CoV-2 neutralizing antibody |
Heteromer | 100 | 1×NAG; | |||
| Crystal structure of the SARS-CoV-2 S RBD in complex with BD-629 Fab |
Heteromer | 100 | ||||
| Crystal structure of the SARS-CoV-2 S RBD in complex with BD-629 Fab and BD-368-2 Fab |
Heteromer | 100 | ||||
| A SARS-CoV-2 neutralizing antibody |
Heteromer | 100 | ||||
| The receptor binding domain of SARS-CoV-2 spike glycoprotein in complex with COVOX-58 and COVOX-158… |
Heteromer | 100 | 2×GOL; 1×NAG; 1×NA; | |||
| Crystal structure of Omicron BA.1 in complex with a neutralizing antibody scFv T11 |
Heteromer | 91.8 | ||||
| Crystallographic structure of neutralizing antibody 2-15 in complex with SARS-CoV-2 spike receptor-… |
Heteromer | 100.0 | ||||
| Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in a ternary comp… |
Heteromer | 100 | 1×NAG; 1×NAG; 1×GOL; 4×ACT; | |||
| The 2019-nCoV RBD/ACE2-B0AT1 complex |
Heteromer Q695T7; Q9BYF1; | 100 | 14×NAG; 2×NAG; 10×NAG; 2×LEU; 2×ZN; | |||
| Cryo-EM structure of human ACE2 receptor bound to protein encoded by vaccine candidate BNT162b1 |
Heteromer Q9BYF1; | 100 | ||||
| Local map of Omicron Subvariant JN.1 RBD with ACE2 |
Heteromer Q9BYF1; | 86.39 | ||||
| local structure of hu33 and spike |
Heteromer | 98.36 | 1×NAG; | |||
| Local structure of BD55-3372 and delta spike |
Heteromer | 98.91 | ||||
| Cryo-EM structure of SARS-CoV-2 S2P trimer in complex with neutralizing antibody VacW-209 (local re… |
Heteromer A0A5C2GQT9; | 100 | 1×NAG; | |||
| CC6.30 fragment antigen binding in complex with SARS-CoV-2-6P-Mut7 S protein (RBD/Fv local refineme… |
Heteromer | 100.0 | 1×NAG; 1×NAG; | |||
| local CryoEM structure of the SARS-CoV-2 S6PV2 in complex with BD-812 Fab and BD-836 Fab |
Heteromer | 98.36 | ||||
| Local CryoEM structure of the SARS-CoV-2 S6PV2 in complex with BD-771 Fab and BD-821 Fab |
Heteromer | 98.36 | ||||
| Cryo-EM structure of SARS-CoV-2 recombinant spike protein STFK in complex with three neutralizing a… |
Heteromer | 100 | 1×NAG; 1×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 recombinant spike protein STFK1628x in complex with three neutraliz… |
Heteromer | 97.27 | 1×NAG; 1×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 Mu S6P trimer in complex with neutralizing antibody VacW-209 (local… |
Heteromer A0A5C2GQT9; | 98.36 | 1×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 Delta S6P trimer in complex with neutralizing antibody VacW-209 (lo… |
Heteromer A0A5C2GQT9; | 99.39 | 1×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 Omicron BA.2.86 RBD in complex with human ACE2 and S309 Fab |
Heteromer Q9BYF1; | 87.25 | 1×NAG; 2×NAG; 1×NAG; 3×NAG; 1×ZN; | |||
| Cryo-EM structure of SARS-CoV-2 Omicron S6P trimer in complex with neutralizing antibody VacW-209 (… |
Heteromer A0A5C2GQT9; | 91.8 | 1×NAG; | |||
| Crystal structure of the receptor binding domain of SARS-CoV-2 beta variant spike glycoprotein in c… |
Heteromer | 98.35 | 1×NAG; 1×PG0; 2×GOL; 2×PEG; 1×CL; | |||
| Crystal structure of The SARS-COV-2 BA.2.75 RBD with neutralizing-VHHs Re32D03 and Ma3B12 |
Heteromer | 91.38 | ||||
| A SARS-CoV-2 neutralizing antibody |
Heteromer | 97.04 | 1×NAG; | |||
| SARS-CoV-2 S protein RBD in complex with A8-1 Fab |
Heteromer | 100 | ||||
| SARS-CoV-2 Omicron RBD in complex with Omi-32 Fab and nanobody C1 |
Heteromer | 91.28 | ||||
| Cryo-EM structure of SARS-CoV-2 C.1.2 S6P trimer in complex with neutralizing antibody VacW-209 (lo… |
Heteromer A0A5C2GQT9; | 98.35 | 1×NAG; | |||
| SARS-CoV-2 S protein in complex with pT1644 Fab |
Heteromer | 100 | 1×NAG; | |||
| Crystal structure of the SARS-CoV-2 RBD with neutralizing-VHHs Re5D06 and Re9F06 |
Heteromer | 100.0 | 1×DMX; 1×SO4; | |||
| SARS-CoV-2 RBD in complex with a Fab fragment of a neutralising antibody mRBD2 |
Heteromer | 100.0 | 6×SO4; | |||
| Structure Determination of the NB1B11-RBD Complex |
Heteromer | 100.0 | 3×ZN; | |||
| Crystal Structure of SARS-CoV Spike Receptor-Binding Domain Complexed with Neutralizing Antibody |
Heteromer | 100.0 | ||||
| Crystal structure of neutralizing antibody P1D9 Fab in complex with SARS-CoV-2 spike receptor bindi… |
Heteromer | 100.0 | 1×NAG; | |||
| Crystal structure of SARS-CoV-2 RBD Q498Y complexed with human ACE2 |
Heteromer Q9BYF1; | 99.43 | 3×NAG; 1×ZN; 1×EDO; 1×CL; | |||
| Crystal structure of SARS-CoV-2 Alpha RBD in complex with the D27LEY neutralizing antibody Fab frag… |
Heteromer | 99.45 | ||||
| SARS-CoV-2 XBB.1 spike RBD bound to the human ACE2 ectodomain and the S309 neutralizing antibody Fa… |
Heteromer Q9BYF1; | 88.27 | 1×NAG; 5×NAG; | |||
| Antibody N3-1 bound to RBD in the up conformation |
Heteromer | 100.0 | ||||
| Antibody N3-1 bound to RBDs in the up and down conformations |
Heteromer | 100.0 | ||||
| SARS-CoV-2 BA.2 spike RBD in complex bound with VacBB-551 |
Heteromer | 91.16 | ||||
| SARS-CoV-2 spike glycoprotein trimer complexed with Fab fragment of anti-RBD antibody E7 (focused r… |
Heteromer | 100.0 | ||||
| CryoEM structure of RBD domain of COVID-19 in complex with Legobody |
Heteromer P06654; P99134; | 100.0 | 1×GLC; | |||
| Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in a ternary comp… |
Heteromer | 100.0 | 1×NAG; 2×IMD; 4×GOL; 6×BR; 1×PG6; | |||
| Crystal Structure of the SARS-CoV-2 Receptor Binding Domain in Complex with Antibody ION-360 |
Heteromer | 100.0 | 1×NAG; | |||
| Fab M2-7 complexed with SARS-Cov2 RBD and human ACE2 |
Heteromer Q9BYF1; | 100.0 | 1×ZN; 3×NAG; | |||
| SARS-COV-2 BA.1 Spike incomplex with VacBB-665 |
Heteromer | 92.49 | ||||
| SARS-CoV-2 BA.1 spike RBD in complex bound with VacBB-639 |
Heteromer | 91.67 | ||||
| Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody COVA2… |
Heteromer | 100.0 | 1×NAG; | |||
| S-RBD(Omicron BA.3) in complex with PD of ACE2 |
Heteromer Q9BYF1; | 91.02 | 6×NAG; 1×NAG; | |||
| S-RBD (Omicron BA.2.75) in complex with PD of ACE2 |
Heteromer Q9BYF1; | 89.82 | 6×NAG; 1×NAG; | |||
| SARS-CoV-2 RBD in complex with 1F Fab |
Heteromer | 100 | ||||
| Cryo-EM structure of Human ACE2 bound to a high-affinity SARS CoV-2 mutant |
Heteromer Q9BYF1; | 98.8 | 3×NAG; | |||
| SARS-CoV-2 (B.1.1.529/Omicron variant) Spike protein in complex with the single chain fragment scFv… |
Heteromer | 90.45 | 1×NAG; | |||
| Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody CV07-… |
Heteromer | 100.0 | 2×NAG; | |||
| Structure of P4A2 Fab in complex with Spike-RBD from SARS-CoV-2 |
Heteromer | 100 | ||||
| The structure of ZCB11 Fab against SARS-CoV-2 Omicron Spike |
Heteromer | 91.53 | ||||
| SARS-CoV-2 Omicron BA.2 spike trimer (6P) in complex with D1F6 Fab, focused refinement of RBD region |
Heteromer | 90.8 | ||||
| SARS-CoV-2 RBD-62 in complex with ACE2 peptidase domain |
Heteromer Q9BYF1; | 94.44 | 1×ZN; 3×NAG; | |||
| Structure of SARS-CoV-2 chimeric receptor-binding domain complexed with its receptor human ACE2 |
Heteromer P59594; Q9BYF1; | 100 | 3×NAG; 2×NAG; 1×ZN; 1×CL; 1×EDO; 1×NAG; | |||
| SARS-CoV-2 spike in complex with the S2H13 neutralizing antibody Fab fragment (local refinement of … |
Heteromer | 100.0 | ||||
| Cryo-EM structure of the SARS-CoV-2 HR1HR2 fusion core complex with N969K mutation |
Heteromer A0A8B6RKS7; | 100 | ||||
| SARS-CoV2 spike glycoprotein N-terminal heptad repeat domain + SARS-CoV2(QEYKKEKE) |
Heteromer A0A6C0RQ44; | 76.47 | ||||
| Crystal structure of SARS-CoV-2 spike stem helix peptide in complex with neutralizing antibody CC40… |
Heteromer | 100 | 1×ACT; 5×SO4; 1×GOL; | |||
| Crystal structure of human neutralizing mAb CV3-25 binding to SARS-CoV-2 S MPER peptide 1140-1165 |
Heteromer | 100 | 10×NA; | |||
| fp.006 Fab in complex with SARS-CoV-2 Fusion Peptide |
Heteromer | 100 | 1×PEG; 1×EDO; | |||
| Crystal structure of SARS-CoV-2 spike stem helix peptide in complex with neutralizing antibody COV3… |
Heteromer | 100 | ||||
| Crystal structure of SARS-CoV-2 spike stem helix peptide in complex with neutralizing antibody COV8… |
Heteromer | 100 | ||||
| Crystal structure of CV3-25 Fab bound to SARS-CoV-2 spike stem helix peptide |
Heteromer | 100 | 7×GOL; 2×SO4; | |||
| Antibody DH1058 Fab fragment bound to SARS-CoV-2 fusion peptide |
Heteromer | 100 | 2×CA; 1×PO4; | |||
| Human Leukocyte Antigen class II allotype DR1 presenting SARS-CoV-2 Spike peptide S761-775 |
Heteromer D7RIG0; P01903; | 100 | 5×EDO; | |||
| Human Leukocyte Antigen class II allotype DR1 presenting SARS-CoV-2 Omicron (BA.1) Spike peptide S7… |
Heteromer D7RIG0; P01903; | 93.33 | 7×EDO; 3×SO4; | |||
| Human Leukocyte Antigen class II allotype DR1 presenting SARS-CoV-2 Spike peptide S511-530 |
Heteromer D7RIG0; P01903; | 100 | 15×EDO; 2×SO4; 1×MES; | |||
| Crystal structure of SARS-CoV-2 fusion peptide in complex with neutralizing antibody COV44-62 |
Heteromer | 100 | ||||
| Human Leukocyte Antigen class II allotype DR1 presenting SARS-CoV-2 Omicron (BA.1) Spike peptide S4… |
Heteromer D7RIG0; P01903; | 78.57 | 30×EDO; 1×SO4; 1×DHL; | |||
| Human Leukocyte Antigen class II allotype DR1 presenting SARS-CoV-2 Spike peptide S486-505 |
Heteromer D7RIG0; P01903; | 100 | 10×EDO; 1×DHL; | |||
| Crystal structure of SARS-CoV-2 spike stem helix peptide in complex with Fab of broadly neutralizin… |
Heteromer | 100 | 2×GOL; | |||
| Crystal Structure of VP12E7 Fab in complex with SARS-CoV-2 S fusion peptide |
Heteromer | 100 | ||||
| S2P6 Fab fragment bound to the SARS-CoV/SARS-CoV-2 spike stem helix peptide |
Heteromer | 100 | 4×SO4; | |||
| Crystal structure of SARS-CoV-2 spike stem helix peptide in complex with neutralizing antibody COV9… |
Heteromer | 100 | ||||
| Crystal structure of the 76E1 Fab in complex with a SARS-CoV-2 spike peptide |
Heteromer | 100 | ||||
| The structure of HLA-A/Pep14 |
Heteromer A0A0G2JPD3; P61769; | 100 | ||||
| Crystal Structure of VN01H1 Fab in complex with SARS-CoV-2 S fusion peptide |
Heteromer | 100 | ||||
| The structure of HLA-A/14-3-D |
Heteromer A0A0G2JL56; P61769; | 91.67 | ||||
| Crystal structure of SARS-CoV-2 spike stem fusion peptide in complex with neutralizing antibody COV… |
Heteromer P01834; P0DOX5; | 100 | ||||
| Crystal structure of SARS-CoV-2 spike stem helix peptide in complex with neutralizing antibody CHM-… |
Heteromer | 100 | 1×FLC; | |||
| Crystal structure of SARS-CoV-2 spike stem fusion peptide in complex with neutralizing antibody COV… |
Heteromer | 100 | ||||
| B6 Fab fragment bound to the SARS-CoV/SARS-CoV-2 spike stem helix peptide |
Heteromer | 100 | 3×GOL; | |||
| Crystal structure of HLA B*13:01 in complex with SVLNDIFSRL, an 10-mer epitope from SARS-CoV-2 Spik… |
Heteromer C5IYE8; P61769; | 90.0 | 3×EDO; 2×NA; | |||
| Crystal structure of HLA B*13:01 in complex with SVLNDILARL, an 10-mer epitope from SARS-CoV-2 Spik… |
Heteromer C5IYE8; P61769; | 90.0 | 3×PEG; 4×EDO; 2×NA; | |||
| SARS-CoV-2 S stem helix peptide bound to Fab22 |
Heteromer | 100 | ||||
| Crystal structure of HLA-A*11:01 in complex with SVLNDIFSRL, an 10-mer epitope from SARS-CoV-2 Spik… |
Heteromer P61769; Q5S3G3; | 90.0 | 17×EDO; 3×NA; 1×PEG; 3×CL; 1×MG; | |||
| Crystal structure of SARS-CoV-2 neutralizing antibody WS6 in complex with spike S2 peptide |
Heteromer | 100 | 11×SO4; 2×PEG; | |||
| SARS-CoV-2 Spike-derived peptide S1215-1224 (YIWLGFIAGL) presented by HLA-A*02:01 |
Heteromer P61769; Q53Z42; | 100 | ||||
| Crystal Structure of HLA-A*02:01 in complex with KLNDLCFTNV, an 10-mer epitope from SARS-CoV-2 Spik… |
Heteromer A0A140T913; P61769; | 100 | 1×GOL; | |||
| Crystal structure of HLA-A*11:01 in complex with SVLNDILARL, an 10-mer epitope from SARS-CoV-2 Spik… |
Heteromer P61769; Q5S3G3; | 90.0 | 1×PEG; 8×EDO; 2×CL; 2×SO4; 2×NA; | |||
| Crystal structure of HLA-A*11:01 in complex with SVLNDILSRL, an 10-mer epitope from SARS-CoV-2 Spik… |
Heteromer P61769; Q5S3G3; | 100 | 1×PEG; 1×EDO; | |||
| Crystal Structure of HLA-B*35:01 in complex with IPFAMQMAY, an 9-mer epitope from SARS-CoV-2 spike … |
Heteromer P61769; Q546I9; | 100 | 2×PO4; 3×NA; | |||
| Crystal Structure of HLA-A*11:01 in complex with NSASFSTFK, an 9-mer epitope from SARS-CoV-2 spike … |
Heteromer P61769; U5YJK1; | 100 | 1×GOL; 2×SO4; 2×NA; 2×CL; 1×CA; | |||
| MHC I A02 Allele presenting YLQPRTFLL |
Heteromer A0A140T913; P61769; | 100 | 6×EDO; 1×ACT; 1×CA; | |||
| SARS-CoV-2 Spike-derived peptide S1185-1193 K1191N mutant (RLNEVANNL) presented by HLA-A*02:01 |
Heteromer P61769; Q53Z42; | 88.89 | 1×CD; 1×ZN; 1×NA; 1×ACT; 1×CL; | |||
| SARS-CoV-2 Spike-derived peptide S976-984 S982A mutant (VLNDILARL) presented by HLA-A*02:01 |
Heteromer P61769; Q53Z42; | 88.89 | 2×ACT; 2×EDO; 2×CD; 1×PEG; | |||
| SARS-CoV-2 spike-derived peptide S1060-1068 (VVFLHVTYV) presented by HLA-A*02:01 |
Heteromer A0A140T913; P61769; | 100 | 2×CD; 1×NA; | |||
| Crystal Structure of HLA-B*15:01 in complex with spike derived peptide NQKLIANQF from SARS-CoV-2 vi… |
Heteromer P61769; | 100 | 1×ACT; 1×PEG; | |||
| Complex Structure of HLA-A*2402 with the Peptide from HCoV(CoV-2) spike protein |
Heteromer A0A5H2UYS3; P61769; | 100 | ||||
| SARS-CoV-2 Spike-derived peptide S976-984 (VLNDILSRL) presented by HLA-A*02:01 |
Heteromer P61769; Q861F7; | 100 | 1×ACT; 1×CD; 1×ZN; | |||
| Human leukocyte antigen A*0201 in complex with SARS-CoV-2 epitope YLQPRTFLL |
Heteromer A0A140T913; P61769; | 100 | 4×GOL; | |||
| MHC I A02 Allele presenting YLQLRTFLL |
Heteromer A0A140T913; P61769; | 88.89 | 12×IOD; 1×PEG; | |||
| SARS-CoV-2 Spike-derived peptide S269-277 (YLQPRTFLL) presented by HLA-A*02:01 |
Heteromer P61769; Q53Z42; | 100 | ||||
| SARS-CoV-2 YLQ peptide binds to HLA-A2 |
Heteromer A0A140T913; P61769; | 100 | 1×PG4; | |||
| CRYSTAL STRUCTURE OF A MUTANT MYLU-B-67 FOR 2.2 ANGSTROM, 52M 53Q 54Q 55P 56W DELETED |
Heteromer G1PNR4; L5K3Y9; | 100 | ||||
| The structure of HLA-A/Pep16 |
Heteromer A0A0G2JPD3; P61769; | 100 | ||||
| CRYSTAL STRUCTURE OF BAT MHC CLASS I MYLU-B-67 |
Heteromer G1PNR4; L5K3Y9; | 100 | ||||
| SARS-CoV-2 Spike-derived peptide S489-497 (YFPLQSYGF) presented by HLA-A*29:02 |
Heteromer B0UXQ0; P61769; | 100 | 3×SO4; 2×MG; 1×NA; | |||
| HLA peptide complex |
Heteromer A0A140T913; P61769; | 100 | 4×EDO; | |||
| SARS-CoV-2 RLQ peptide-specific TCR pRLQ3 binds to RLQ-HLA-A2 |
Heteromer A0A140T913; P61769; | 100 | ||||
| SARS-CoV-2 YLQ peptide-specific TCR pYLQ7 binds to YLQ-HLA-A2 |
Heteromer A0A140T913; P61769; | 100 | ||||
| Complex structure of HLA2402 with recognizing SARS-CoV-2 Y453F epitope NYNYLFRLF |
Heteromer A0A7T3RIT5; P61769; | 88.89 | 2×EDO; | |||
| YLQ-SG3 TCR in complex with SARS-CoV-2 Spike-derived peptide S269-277 (YLQPRTFLL) presented by HLA-… |
Heteromer P61769; Q53Z42; | 100 | 4×NA; | |||
| SARS-CoV-2 specific private TCR RLQ7 in complex with RLQ-T1006I-HLA-A2 |
Heteromer A0A140T913; P61769; | 88.89 | 1×PG4; | |||
| The structure of FLA-K*00701/KP-CoV-9 |
Heteromer C6ZK69; Q5MGS7; | 100 | ||||
| SARS-CoV-2 specific private TCR RLQ7 in complex with RLQ-HLA-A2 |
Heteromer A0A140T913; P61769; | 100 | 1×PG4; | |||
| Complex structure of HLA0201 with recognizing SARS-CoV-2 epitope S1 |
Heteromer A0A5H2UU57; P61769; | 100 | ||||
| SARS-CoV-2 RLQ peptide binds to HLA-A2 |
Heteromer A0A140T913; P61769; | 100 | ||||
| Complex structure of HLA2402 with recognizing SARS-CoV-2 epitope QYIKWPWYI |
Heteromer F6IR24; P61769; | 100 | ||||
| Complex structure of HLA2402 with recognizing SARS-CoV-2 epitope pep4 |
Heteromer D9UAY1; P61769; | 100 | ||||
| Emergence of immune escape at dominant SARS-CoV-2 killer T-cell epitope |
Heteromer A0A140T913; P61769; | 100 | 1×PEG; 3×SO4; | |||
| The complex of TCR NYN-I and HLA-A24 bound to SARS-CoV-2 Spike448-456 peptide NYNYLYRLF |
Heteromer P61769; Q6IVJ7; | 100 | ||||
| TCR peptide HLA-A2 complex |
Heteromer A0A140T913; P61769; | 100 | ||||
| SARS-CoV-2 Spike-derived peptide S417-425 K417T mutant (TIADYNYKL) presented by HLA-A*02:01 |
Heteromer P61769; Q53Z42; | 100 | 1×ZN; 1×CD; 1×NA; | |||
| CRYSTAL STRUCTURE OF BAT MHC CLASS I MYLU-B-67 FOR 2.1 ANGSTROM |
Heteromer G1PNR4; L5K3Y9; | 100 | ||||
| CRYSTAL STRUCTURE OF BAT MHC CLASS I MYLU-B-67 FOR 2.2 ANGSTROM |
Heteromer G1PNR4; L5K3Y9; | 100 | ||||
| Epitope-directed anti-SARS CoV 2 scFv engineered against the key spike protein region. |
Heteromer | 100 | ||||
| CRYSTAL STRUCTURE OF A MUTANT MYLU-B-67 FOR 2.4 ANGSTROM, 52M 53Q 54Q 55P 56W DELETED |
Heteromer G1PNR4; L5K3Y9; | 100 | ||||
| 3D1 in complex with 6-mer HR1 peptide from SARS-CoV-2 |
Heteromer | 100 | ||||
| Crystal structure of beta'-COPI-WD40 domain in complex with SARS-CoV-2 clientized spike tail heptap… |
Heteromer P41811; | 100 | 8×EDO; | |||
| Crystal structure of beta'-COPI-WD40 domain in complex with SARS-CoV-2 spike tail hepta-peptide |
Heteromer P41811; | 100 | ||||
| Crystal structure of beta'-COPI-WD40 domain Y33A mutant in complex with SARS-CoV-2 clientized spike… |
Heteromer P41811; | 100 | ||||
| The complex structure of COPI cargo sorting module with SARS-CoV-2 Spike KxHxx sorting motif |
Heteromer P41811; | 100 | ||||
| Crystal structure of neuropilin-1 b1 domain in complex with SARS-CoV-2 S1 C-end rule (CendR) peptide |
Heteromer O14786; | 100 | 1×PEG; | |||
| Cryo-EM structure of SARS-CoV-2 Kappa (B.1.617.1) spike protein | homo-6-mer | 99.04 | 36×NAG; 48×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 Kappa (B.1.617.1) Q484I spike protein | homo-6-mer | 99.04 | 36×NAG; 48×NAG; | |||
| Structure of SARS-CoV-2 3Q-2P full-length dimers of spike trimers | homo-6-mer | 99.82 | 76×NAG; 2×NAG; 2×NAG; 16×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 S-Kappa variant (B.1.617.1), dimer of S trimer conformation 1 | homo-6-mer | 99.13 | 66×NAG; 6×NAG; 24×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 S-Kappa variant (B.1.617.1), dimer of S trimer conformation 3 | homo-6-mer | 99.13 | 66×NAG; 6×NAG; 24×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 S-Kappa variant (B.1.617.1), dimer of S trimer conformation 2 | homo-6-mer | 99.13 | 66×NAG; 6×NAG; 24×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 Kappa (B.1.617.1) spike protein (focused refinement of RBD) | homo-6-mer | 99.25 | 12×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 Kappa (B.1.617.1) Q484I spike protein (focused refinement of RBD) | homo-6-mer | 99.25 | 12×NAG; | |||
| Structure of the SARS-CoV-2 EG.5.1 spike glycoprotein (closed-1 state) | homo-5-mer | 90.91 | 15×NAG; 60×NAG; | |||
| Structure of the 2019-nCoV HR2 Domain | homo-4-mer | 100 | ||||
| Structure of coiled-coil tetramer from SARS-CoV-2 spike stalk region | homo-4-mer | 96.3 | 3×EDO; 2×ZN; | |||
| Closed state of SARS-CoV-2 BA.2 variant spike protein | homo-3-mer | 90.0 | 21×NAG; 6×NAG; 3×NAG; 21×NAG; | |||
| Acidic Omicron Spike Trimer | homo-3-mer | 98.18 | 14×NAG; 5×NAG; 30×NAG; | |||
| Structural and functional impact by SARS-CoV-2 Omicron spike mutations | homo-3-mer | 98.18 | 11×NAG; 3×NAG; 15×NAG; 25×NAG; | |||
| Structural and functional impact by SARS-CoV-2 Omicron spike mutations | homo-3-mer | 98.18 | 9×NAG; 21×NAG; 3×NAG; 21×NAG; | |||
| Middle state of SARS-CoV-2 BA.2 variant spike protein | homo-3-mer | 90.0 | 18×NAG; 8×NAG; 3×NAG; 20×NAG; | |||
| Structural basis for enhanced infectivity and immune evasion of SARS-CoV-2 variants | homo-3-mer | 100 | 20×NAG; 3×NAG; 6×NAG; 28×NAG; | |||
| Distinct conformational states of SARS-CoV-2 spike protein | homo-3-mer | 100.0 | 21×NAG; 9×NAG; 3×NAG; 3×NAG; 21×NAG; | |||
| SARS-CoV-2 C.1.2 variant spike (Close state) | homo-3-mer | 98.17 | 9×NAG; 21×NAG; 3×NAG; 24×NAG; | |||
| Structural basis for enhanced infectivity and immune evasion of SARS-CoV-2 variants | homo-3-mer | 100 | 24×NAG; 3×NAG; 6×NAG; 24×NAG; | |||
| Structural basis for enhanced infectivity and immune evasion of SARS-CoV-2 variants | homo-3-mer | 100 | 20×NAG; 3×NAG; 6×NAG; 28×NAG; | |||
| Structural basis for enhanced infectivity and immune evasion of SARS-CoV-2 variants | homo-3-mer | 100 | 16×NAG; 3×NAG; 6×NAG; 32×NAG; | |||
| SARS-CoV-2 Mu variant spike(close state) | homo-3-mer | 99.27 | ||||
| Structural basis for enhanced infectivity and immune evasion of SARS-CoV-2 variants | homo-3-mer | 98.61 | 19×NAG; 3×NAG; 6×NAG; 29×NAG; | |||
| Closed state of pre-fusion SARS-CoV-2 Kappa variant spike protein | homo-3-mer | 99.46 | 6×NAG; 27×NAG; 3×NAG; 21×NAG; | |||
| Structural basis for enhanced infectivity and immune evasion of SARS-CoV-2 variants | homo-3-mer | 98.63 | 9×NAG; 21×NAG; 3×NAG; 24×NAG; | |||
| Structural impact on SARS-CoV-2 spike protein by D614G substitution | homo-3-mer | 99.91 | 30×NAG; 3×NAG; 3×NAG; 21×NAG; | |||
| Structural basis for enhanced infectivity and immune evasion of SARS-CoV-2 variants | homo-3-mer | 100 | 20×NAG; 3×NAG; 6×NAG; 28×NAG; | |||
| Neutral Omicron Spike Trimer | homo-3-mer | 97.52 | 16×NAG; 5×NAG; 24×NAG; | |||
| One RBD-up 1 of pre-fusion SARS-CoV-2 Delta variant spike protein | homo-3-mer | 97.76 | 10×NAG; 16×NAG; 3×NAG; 25×NAG; | |||
| Structural impact on SARS-CoV-2 spike protein by D614G substitution | homo-3-mer | 99.91 | 9×NAG; 21×NAG; 3×NAG; 24×NAG; | |||
| Structural impact on SARS-CoV-2 spike protein by D614G substitution | homo-3-mer | 99.91 | 20×NAG; 3×NAG; 6×NAG; 28×NAG; | |||
| SARS-CoV-2 lambda variant spike | homo-3-mer | 100.0 | 15×NAG; 15×NAG; 1×NAG; 17×NAG; | |||
| SARS-CoV-2 B.1.620 variant spike (close state) | homo-3-mer | 98.18 | 9×NAG; 21×NAG; 3×NAG; 22×NAG; | |||
| SARS-COV-2 BETA VARIANT SPIKE PROTEIN IN TRANSITION STATE | homo-3-mer | 98.64 | ||||
| One RBD-up 1 of pre-fusion SARS-CoV-2 Kappa variant spike protein | homo-3-mer | 99.45 | 19×NAG; 3×NAG; 11×NAG; 24×NAG; | |||
| One RBD-up 1 of pre-fusion SARS-CoV-2 Gamma variant spike protein | homo-3-mer | 99.01 | 19×NAG; 3×NAG; 6×NAG; 29×NAG; | |||
| SARS-CoV-2 C.1.2 variant spike (Open state) | homo-3-mer | 98.11 | ||||
| SARS-CoV-2 B.1.620 variant spike (open state) | homo-3-mer | 99.09 | 19×NAG; 3×NAG; 6×NAG; 26×NAG; | |||
| SARS-CoV-2 Mu variant spike (open state) | homo-3-mer | 99.26 | 20×NAG; 3×NAG; 6×NAG; 28×NAG; | |||
| One RBD-up 2 of pre-fusion SARS-CoV-2 Delta variant spike protein | homo-3-mer | 97.76 | 10×NAG; 17×NAG; 3×NAG; 24×NAG; | |||
| One RBD-up 2 of pre-fusion SARS-CoV-2 Kappa variant spike protein | homo-3-mer | 99.45 | 19×NAG; 3×NAG; 11×NAG; 24×NAG; | |||
| One RBD-up 2 of pre-fusion SARS-CoV-2 Gamma variant spike protein | homo-3-mer | 99.0 | 17×NAG; 3×NAG; 9×NAG; 28×NAG; | |||
| SARS-CoV-2 Beta variant spike protein in open state | homo-3-mer | 98.64 | ||||
| SARS-CoV-2 Spike protein Beta Variant at 37C structural flexibility / heterogeneity analyses | homo-3-mer | 98.64 | ||||
| SARS-CoV-2 Spike protein Beta Variant at 4C structural flexibility / heterogeneity analyses | homo-3-mer | 98.64 | ||||
| One RBD-up state of SARS-CoV-2 BA.2 variant spike protein | homo-3-mer | 90.0 | 18×NAG; 9×NAG; 3×NAG; 21×NAG; | |||
| Closed state of pre-fusion SARS-CoV-2 Delta variant spike protein | homo-3-mer | 97.76 | 27×NAG; 3×NAG; 3×NAG; 21×NAG; | |||
| BANAL-20-52 Spike trimer | homo-3-mer | 97.9 | 24×NAG; 33×NAG; | |||
| Prototypic SARS-CoV-2 spike (containing K417) in the open conformation | homo-3-mer | 99.45 | 4×NAG; 1×MAN; 21×NAG; | |||
| Prototypic SARS-CoV-2 spike (containing V417) in the open conformation | homo-3-mer | 99.34 | 3×NAG; 15×NAG; 1×MAN; | |||
| Prototypic SARS-CoV-2 G614 spike (open form) | homo-3-mer | 99.72 | 4×NAG; 23×NAG; 1×MAN; | |||
| Delta variant of SARS-CoV-2 Spike protein | homo-3-mer | 99.34 | 12×NAG; 35×NAG; | |||
| Spike of SARS-CoV-2 spike protein(1 up) | homo-3-mer | 99.34 | 31×NAG; | |||
| SARS-CoV-2 Kappa variant spike protein in transition state | homo-3-mer | 99.34 | ||||
| Delta Spike Trimer(3 RBD Down) | homo-3-mer | 98.52 | 6×NAG; 39×NAG; | |||
| Delta Spike Trimer(1 RBD Up) | homo-3-mer | 98.52 | 13×NAG; 35×NAG; | |||
| SARS-CoV-2 spike glycoprotein trimer in closed state | homo-3-mer | 100.0 | 15×NAG; 33×NAG; 3×EIC; 3×BLR; | |||
| SARS-CoV-2-6P-Mut7 S protein (asymmetric) | homo-3-mer | 99.28 | 14×NAG; 34×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 Epsilon (B.1.429) spike protein | homo-3-mer | 99.23 | 18×NAG; 24×NAG; | |||
| Locked Wuhan SARS-CoV2 Prefusion Spike ectodomain with lipid bound | homo-3-mer | 99.54 | 15×NAG; 36×NAG; 3×STE; | |||
| SARS-CoV-2 Kappa variant spike protein in open state | homo-3-mer | 99.34 | ||||
| Open state of SARS-CoV-2 Delta variant spike protein | homo-3-mer | 99.25 | ||||
| Cryo-EM structure of SARS-CoV-2 Alpha (B.1.1.7) spike protein | homo-3-mer | 98.84 | 18×NAG; 24×NAG; | |||
| Double deletion S-2P trimer(3 down) | homo-3-mer | 98.15 | ||||
| Cryo-EM structure of SARS-CoV-2 Gamma (P.1) spike protein | homo-3-mer | 98.36 | 18×NAG; 24×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 Delta (B.1.617.2) spike protein | homo-3-mer | 98.41 | 18×NAG; 20×NAG; | |||
| SARS-CoV-2 S trimer, S-closed | homo-3-mer | 99.82 | 24×NAG; 30×NAG; | |||
| SARS-Cov2 S protein at close state | homo-3-mer | 99.82 | ||||
| Transition state of SARS-CoV-2 Delta variant spike protein | homo-3-mer | 99.25 | ||||
| Cryo-EM structure of SARS-CoV-2 Beta (B.1.351) spike protein | homo-3-mer | 98.65 | 18×NAG; 24×NAG; | |||
| SARS-CoV-2 (D614G) Spike trimer | homo-3-mer | 99.72 | 34×NAG; | |||
| SARS-CoV-2 Omicron S-open-2 | homo-3-mer | 98.18 | ||||
| Cryo-EM structure of the SARS-CoV-2 D614G,L452R mutant spike protein ectodomain | homo-3-mer | 99.23 | 18×NAG; 24×NAG; | |||
| Cryo-EM structure of the SARS-CoV-2 D614G,N501Y,E484K,K417T mutant spike protein ectodomain | homo-3-mer | 99.04 | 18×NAG; 24×NAG; | |||
| Cryo-EM structure of the SARS-CoV-2 N501Y mutant spike protein ectodomain | homo-3-mer | 99.33 | 18×NAG; 24×NAG; | |||
| SARS-CoV-2 Omicron S-open | homo-3-mer | 98.18 | ||||
| Omicron B.1.1.529 2 RBD up conformation | homo-3-mer | 98.18 | ||||
| Cryo-EM structure of the SARS-CoV-2 D614G,N501Y,E484K mutant spike protein ectodomain | homo-3-mer | 99.14 | 18×NAG; 24×NAG; | |||
| Cryo-EM structure of the SARS-CoV-2 D614G,N501Y,E484K,K417N mutant spike protein ectodomain | homo-3-mer | 99.04 | 18×NAG; 24×NAG; | |||
| SARS-CoV-2 Omicron S-close | homo-3-mer | 98.18 | ||||
| SARS-CoV-2 Omicron-XBB.1.16 3-RBD-down Spike Protein Trimer 2 (S-RRAR-Omicron-XBB.1.16) | homo-3-mer | 90.91 | 9×NAG; 26×NAG; | |||
| Cryo-EM structure of the SARS-CoV-2 furin site mutant S-Trimer from a subunit vaccine candidate | homo-3-mer | 100.0 | 39×NAG; 15×NAG; 3×ELA; 3×VCG; | |||
| Cryo-EM structure of SARS-CoV-2 Omicron BA.2 spike protein | homo-3-mer | 90.0 | 18×NAG; 19×NAG; | |||
| Cryo-EM structure of the SARS-CoV-2 D614G mutant spike protein ectodomain | homo-3-mer | 99.33 | 18×NAG; 24×NAG; | |||
| Cryo-EM structure of the SARS-CoV-2 D614G,N501Y mutant spike protein ectodomain | homo-3-mer | 99.23 | 18×NAG; 24×NAG; | |||
| SARS-CoV-2 Omicron S-open | homo-3-mer | 98.18 | ||||
| Cryo-EM structure of SARS-CoV-2 Kappa (B.1.617.1) Q484A spike protein | homo-3-mer | 99.04 | 18×NAG; 20×NAG; | |||
| SARS-CoV-2 S trimer, S-open | homo-3-mer | 99.81 | ||||
| Cryo-EM structure of the SARS-CoV-2 Omicron spike protein | homo-3-mer | 98.18 | 18×NAG; 22×NAG; | |||
| SARS-Cov2 S protein at open state | homo-3-mer | 99.81 | ||||
| Double deletion S-2P trimer(1 Up) | homo-3-mer | 98.15 | ||||
| Spike/Nb2 complex with 1 RBD up | homo-3-mer | 99.35 | 11×NAG; 23×NAG; | |||
| SARS-CoV-2 BA-2.87.1 Spike ectodomain | homo-3-mer | 100 | 9×NAG; 39×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 XBB.1.5 spike protein | homo-3-mer | 90.0 | 18×NAG; 20×NAG; | |||
| SARS-CoV-2 Omicron-XBB.1.16 3-RBD-down Spike Protein Trimer consensus (S-RRAR-Omicron-XBB.1.16) | homo-3-mer | 90.0 | 9×NAG; 28×NAG; | |||
| SARS-CoV-2 Omicron-XBB.1.16 3-RBD-down Spike Protein Trimer 1 (S-RRAR-Omicron-XBB.1.16) | homo-3-mer | 90.91 | 9×NAG; 27×NAG; | |||
| SARS-CoV-2-6P-Mut7 S protein (C3 symmetry) | homo-3-mer | 99.27 | 12×NAG; 30×NAG; | |||
| Cryo-EM structure of the SARS-CoV-2 wild-type S-Trimer from a subunit vaccine candidate | homo-3-mer | 100.0 | 32×NAG; 19×NAG; 3×ELA; | |||
| Cryo-EM structure of SARS-CoV-2 S-Delta variant (B.1.617.2), one RBD-up conformation 5 | homo-3-mer | 97.5 | 33×NAG; 15×NAG; | |||
| Cryo-EM structure of apo SARS-CoV-2 Omicron spike protein (S-2P-GSAS) | homo-3-mer | 98.15 | 16×NAG; 21×NAG; | |||
| Omicron spike at 3.0 A (open form) | homo-3-mer | 98.18 | 12×NAG; 21×NAG; | |||
| Mink Variant SARS-CoV-2 Spike with 2 Erect RBDs | homo-3-mer | 100 | 4×NAG; 30×NAG; | |||
| Furin Cleaved Spike Protein of SARS-CoV-2 in Intermediate Conformation | homo-3-mer | 99.77 | ||||
| Furin Cleaved Spike Protein of SARS-CoV-2 in Closed Conformation | homo-3-mer | 99.82 | 27×NAG; 24×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 S-Gamma variant (P.1), one RBD-up conformation 2 | homo-3-mer | 98.75 | 33×NAG; 1×NAG; 20×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 S-Delta variant (B.1.617.2), one RBD-up conformation 4 | homo-3-mer | 97.5 | 36×NAG; 12×NAG; | |||
| Structure of SARS-CoV-2 3Q-2P full-length prefusion spike trimer (C3 symmetry) | homo-3-mer | 99.82 | 45×NAG; 3×NAG; 3×VCG; 3×EIC; | |||
| Cryo-EM structure of SARS-CoV-2 S-Beta variant (B.1.351), uncleavable form, two RBD-up conformation | homo-3-mer | 98.45 | 30×NAG; 17×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 S-Beta variant (B.1.351), Cleavable form, one RBD-up conformation | homo-3-mer | 98.45 | 29×NAG; 17×NAG; | |||
| Prototypic SARS-CoV-2 G614 spike (closed form) | homo-3-mer | 99.72 | 9×NAG; 24×NAG; | |||
| Mink Variant SARS-CoV-2 Spike with 1 Erect RBD | homo-3-mer | 100 | 8×NAG; 26×NAG; | |||
| SARS-CoV-2 Delta variant spike protein | homo-3-mer | 98.15 | ||||
| Closed conformation of D614G SARS-CoV-2 spike protein | homo-3-mer | 99.72 | 15×NAG; 33×NAG; | |||
| Open conformation of D614G SARS-CoV-2 spike with 2 Erect RBDs | homo-3-mer | 99.72 | 1×NAG; 31×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 S-Kappa variant (B.1.617.1), all RBD-down conformation | homo-3-mer | 99.13 | 34×NAG; 14×NAG; | |||
| Structure of the SARS-CoV-2 A372T spike glycoprotein (open) | homo-3-mer | 99.7 | 35×NAG; | |||
| Open conformation of D614G SARS-CoV-2 spike with 1 Erect RBD | homo-3-mer | 99.72 | 7×NAG; 1×NAG; 33×NAG; | |||
| Mink Variant SARS-CoV-2 Spike in Closed conformation | homo-3-mer | 100 | 6×NAG; 3×NAG; 39×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 S-Kappa variant (B.1.617.1), one RBD-up conformation 1 | homo-3-mer | 99.13 | 34×NAG; 14×NAG; | |||
| Structure of the SARS-CoV-2 A372T spike glycoprotein (closed) | homo-3-mer | 99.71 | 27×NAG; 24×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 S-Gamma variant (P.1), two RBD-up conformation | homo-3-mer | 98.75 | 1×NAG; 31×NAG; 21×NAG; | |||
| Furin Cleaved Spike Protein of SARS-CoV-2 with One RBD Erect | homo-3-mer | 99.81 | ||||
| Prototypic SARS-CoV-2 spike (containing K417) in the closed conformation | homo-3-mer | 99.45 | 7×NAG; 19×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 S-Kappa variant (B.1.617.1), one RBD-up conformation 2 | homo-3-mer | 99.13 | 36×NAG; 12×NAG; | |||
| Prototypic SARS-CoV-2 spike (containing V417) in the closed conformation | homo-3-mer | 99.35 | 5×NAG; 19×NAG; | |||
| S protein of SARS-CoV-2 in the locked conformation | homo-3-mer | 99.82 | 11×NAG; 59×NAG; 3×EIC; | |||
| Cryo-EM structure of SARS-CoV-2 S-Beta variant (B.1.351), uncleavable form, one RBD-up conformation | homo-3-mer | 98.45 | 31×NAG; 15×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 S-Delta variant (B.1.617.2), all RBD-down conformation | homo-3-mer | 97.5 | 1×NAG; 35×NAG; 12×NAG; | |||
| SARS-CoV-2 spike protein in complex with sybody no68 in a 1up/2down conformation | homo-3-mer | 99.53 | ||||
| Cryo-EM structure of SARS-CoV-2 S-Delta variant (B.1.617.2), one RBD-up conformation 2 | homo-3-mer | 97.5 | 36×NAG; 12×NAG; | |||
| Trimeric SARS-CoV-2 spike ectodomain in complex with biliverdin (closed conformation) | homo-3-mer | 99.82 | 30×NAG; 3×BLA; 24×NAG; | |||
| Structure of Covid Spike variant deltaN25 with one erect RBD | homo-3-mer | 100 | 38×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 S-Delta variant (B.1.617.2), two RBD-up conformation 1 | homo-3-mer | 97.5 | 35×NAG; 13×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 S-Delta variant (B.1.617.2), two RBD-up conformation 3 | homo-3-mer | 97.5 | 36×NAG; 12×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 S-Kappa variant (B.1.617.1), two RBD-up conformation | homo-3-mer | 99.13 | 33×NAG; 15×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 S-Delta variant (B.1.617.2), two RBD-up conformation 2 | homo-3-mer | 97.5 | 35×NAG; 13×NAG; | |||
| SARS-CoV-2 Spike Glycoprotein with 2 RBDs Erect | homo-3-mer | 99.81 | ||||
| Trimeric SARS-CoV-2 spike ectodomain in complex with biliverdin (one RBD erect) | homo-3-mer | 99.82 | 25×NAG; 3×BLA; 27×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 S-Gamma variant (P.1), one RBD-up conformation 1 | homo-3-mer | 98.75 | 34×NAG; 1×NAG; 19×NAG; | |||
| Uncleavable Spike Protein of SARS-CoV-2 in Closed Conformation | homo-3-mer | 99.82 | 30×NAG; 21×NAG; | |||
| SARS-CoV-2-6P-Mut2 S protein | homo-3-mer | 99.28 | 18×NAG; 30×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 S-Delta variant (B.1.617.2), one RBD-up conformation 1 | homo-3-mer | 97.5 | 35×NAG; 13×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 S-Delta variant (B.1.617.2), one RBD-up conformation 3 | homo-3-mer | 97.5 | 36×NAG; 12×NAG; | |||
| SARS-CoV-2 BA.1 S-6P-no-RBD | homo-3-mer | 98.18 | 12×NAG; 15×NAG; | |||
| SARS-CoV-2 Delta variant spike protein | homo-3-mer | 98.15 | ||||
| SARS-CoV-2 Omicron-BA.2 3-RBD down Spike Protein Trimer without the P986-P987 stabilizing mutations… | homo-3-mer | 100 | 10×NAG; 30×NAG; | |||
| Cryo-EM structure of the spike of SARS-CoV-2 Omicron variant of concern | homo-3-mer | 98.18 | 15×NAG; 29×NAG; | |||
| SARS-CoV-2 Omicron-BA.2 3-RBD down Spike Protein Trimer without the P986-P987 stabilizing mutations… | homo-3-mer | 100 | 4×NAG; 28×NAG; | |||
| SARS-CoV-2 spike glycoprotein trimer in closed state after treatment with Cathepsin L | homo-3-mer | 100.0 | 15×NAG; 27×NAG; 3×BLR; | |||
| SARS-CoV-2 S protein S:A222V + S:D614G mutant 1-up | homo-3-mer | 99.69 | 10×NAG; 1×NDG; 25×NAG; | |||
| SARS-CoV-2 S-protein:D614G mutant in 1-up conformation | homo-3-mer | 99.84 | 10×NAG; 24×NAG; | |||
| SARS-CoV-2 S protein S:D614G mutant 1-up | homo-3-mer | 99.84 | 10×NAG; 24×NAG; | |||
| SARS-CoV-2 S protein S:D614G mutant in 3-down with binding site of an entry inhibitor | homo-3-mer | 99.84 | 10×NAG; 24×NAG; 3×NA; 1×XIO; | |||
| Alpha Variant SARS-CoV-2 Spike with 2 Erect RBDs | homo-3-mer | 100.0 | 3×NAG; 37×NAG; | |||
| SARS-CoV-2 Omicron Variant SPIKE trimer, all RBDs down | homo-3-mer | 100.0 | 7×NAG; 14×NAG; | |||
| Structure of the Ancestral Scaffold Antigen-5 of Coronavirus Spike protein | homo-3-mer | 51.79 | 9×NAG; 39×NAG; | |||
| Structure of the Ancestral Scaffold Antigen-6 of Coronavirus Spike protein | homo-3-mer | 60.42 | 9×NAG; 45×NAG; | |||
| Cryo-EM structure of S glycoprotein encoded by the Covid-19 mRNA vaccine candidate RQ3013 (Prefusio… | homo-3-mer | 100 | 12×NAG; 21×NAG; | |||
| SARS-CoV-2 Omicron-EG.5 3-RBD down Spike Protein Trimer 1 (S-GSAS-Omicron-EG.5) | homo-3-mer | 100 | 6×NAG; 29×NAG; | |||
| SARS-CoV-2 Omicron BA.2.13 variant spike | homo-3-mer | 100 | 15×NAG; 27×NAG; | |||
| SARS-CoV-2 Omicron BA.2.12.1 variant spike | homo-3-mer | 100 | 18×NAG; 30×NAG; | |||
| SARS-CoV-2 Omicron BA.2 variant spike (state 2) | homo-3-mer | 100 | 18×NAG; 30×NAG; | |||
| SARS-CoV-2 Omicron-XBB.1.16 3-RBD down Spike Protein Trimer 2 (S-GSAS-Omicron-XBB.1.16) | homo-3-mer | 100 | 9×NAG; 29×NAG; | |||
| SARS-CoV-2 S Omicron Spike B.1.1.529 | homo-3-mer | 98.0 | 1×NAG; 3×NAG; 18×NAG; 1×NAG; 14×NAG; | |||
| SARS-CoV-2 Omicron BA.2 variant spike (state 1) | homo-3-mer | 100 | 13×NAG; 30×NAG; | |||
| Structure of SARS-CoV-2 Spike Protein with Engineered x3 Disulfide (x3(D427C, V987C) and single Arg… | homo-3-mer | 99.85 | 14×NAG; 38×NAG; 3×EIC; 3×BLA; | |||
| Structure of SARS-CoV-2 Spike Protein Trimer (K986P, V987P, single Arg S1/S2 cleavage site) in Lock… | homo-3-mer | 99.82 | 15×NAG; 3×BLA; 39×NAG; 3×EIC; | |||
| Structure of SARS-CoV-2 Spike Protein with Engineered x3 Disulfide (x3(D427C, V987C) and single Arg… | homo-3-mer | 99.84 | 15×NAG; 39×NAG; 3×BLA; 3×EIC; | |||
| SARS-CoV-2 XBB 1.0 closed conformation. | homo-3-mer | 80.0 | 36×NAG; | |||
| SARS-CoV-2 Omicron-XBB.1.5 3-RBD down Spike Protein Trimer 2 (S-GSAS-Omicron-XBB.1.5) | homo-3-mer | 100 | 6×NAG; 25×NAG; | |||
| SARS-CoV-2 Omicron-XBB.1.5 3-RBD down Spike Protein Trimer 4 (S-GSAS-Omicron-XBB.1.5) | homo-3-mer | 100 | 6×NAG; 27×NAG; | |||
| Structure of SARS-CoV-2 Spike Protein with Engineered x3 Disulfide (x3(D427C, V987C) and single Arg… | homo-3-mer | 99.85 | 13×NAG; 37×NAG; 3×BLA; 3×EIC; | |||
| Structure of SARS-CoV-2 Spike Protein with Engineered x3 Disulfide (x3(D427C, V987C) and single Arg… | homo-3-mer | 99.85 | 12×NAG; 36×NAG; 3×BLA; 3×EIC; | |||
| Beta Variant SARS-CoV-2 Spike with 1 Erect RBD | homo-3-mer | 99.45 | 6×NAG; 28×NAG; | |||
| SARS-CoV-2 Omicron-XBB.1.16 3-RBD down Spike Protein Trimer 1 (S-GSAS-Omicron-XBB.1.16) | homo-3-mer | 100 | 9×NAG; 30×NAG; | |||
| SARS-CoV-2 Omicron-EG.5.1 3-RBD down Spike Protein Trimer 3 (S-GSAS-Omicron-EG.5.1) | homo-3-mer | 100 | 30×NAG; | |||
| Structure of SARS-CoV-2 D614G Spike Protein with Engineered x3 Disulfide (x3(D427C, V987C) and sing… | homo-3-mer | 99.7 | 12×NAG; 39×NAG; 3×BLA; 3×EIC; | |||
| SARS-CoV-2 Omicron-EG.5 3-RBD down Spike Protein Trimer 2 (S-GSAS-Omicron-EG.5) | homo-3-mer | 100 | 6×NAG; 29×NAG; | |||
| SARS-CoV-2 Omicron-XBB.1.16 3-RBD-down Spike Protein Trimer 3 (S-RRAR-Omicron-XBB.1.16) | homo-3-mer | 100 | 9×NAG; 27×NAG; | |||
| SARS-CoV-2 Omicron-XBB.1.16 3-RBD down Spike Protein Trimer consensus (S-GSAS-Omicron-XBB.1.16) | homo-3-mer | 100 | 9×NAG; 30×NAG; | |||
| SARS-CoV-2 Omicron-EG.5.1 3-RBD down Spike Protein Trimer 2 (S-GSAS-Omicron-EG.5.1) | homo-3-mer | 100 | 30×NAG; | |||
| SARS-CoV-2 Omicron-EG.5 3-RBD down Spike Protein Trimer 3 (S-GSAS-Omicron-EG.5) | homo-3-mer | 100 | 29×NAG; | |||
| SARS-CoV-2 Omicron-XBB.1.16 3-RBD down Spike Protein Trimer 3 (S-GSAS-Omicron-XBB.1.16) | homo-3-mer | 100 | 6×NAG; 30×NAG; | |||
| SARS-CoV-2 Omicron-EG.5.1 3-RBD down Spike Protein Trimer 1 (S-GSAS-Omicron-EG.5.1) | homo-3-mer | 100 | 30×NAG; | |||
| SARS-CoV-2 Omicron-XBB.1.5 3-RBD down Spike Protein Trimer consensus (S-GSAS-Omicron-XBB.1.5) | homo-3-mer | 100 | 27×NAG; | |||
| SARS-CoV-2 Omicron-XBB.1.5 3-RBD down Spike Protein Trimer 3 (S-GSAS-Omicron-XBB.1.5) | homo-3-mer | 100 | 27×NAG; | |||
| SARS-CoV-2 Omicron-EG.5 3-RBD down Spike Protein Trimer consensus (S-GSAS-Omicron-EG.5) | homo-3-mer | 100 | 6×NAG; 29×NAG; | |||
| SARS-CoV-2 Omicron-XBB.1.5 3-RBD down Spike Protein Trimer 1 (S-GSAS-Omicron-XBB.1.5) | homo-3-mer | 100 | 3×NAG; 30×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 Spike Proteins on intact virions: B.1 variant 1 open RBD | homo-3-mer | 99.81 | 26×NAG; 3×NAG; 19×NAG; | |||
| Cryo-EM structure of a biotinylated SARS-CoV-2 spike probe in the prefusion state (RBDs down) | homo-3-mer | 99.8 | 12×NAG; 36×NAG; | |||
| SARS-CoV-2 Spike with ethylbenzamide-tri-iodo Siallyllactose, C3 symmetry | homo-3-mer | 100.0 | 9×NAG; 3×NAG; 36×NAG; 3×GE9; 3×SIA; 3×EIC; | |||
| SARS-CoV-2 Spike, C3 symmetry | homo-3-mer | 100.0 | 9×NAG; 3×NAG; 36×NAG; 3×EIC; | |||
| Structure of Disulphide-stabilized SARS-CoV-2 Spike Protein Trimer (x1 disulphide-bond mutant, S383… | homo-3-mer | 99.84 | 12×NAG; 39×NAG; 3×BLA; | |||
| Structure of the SARS-CoV-2 BA.2.75 spike glycoprotein (closed state 1) | homo-3-mer | 90.0 | 5×NAG; 31×NAG; | |||
| SARS CoV-2 Spike protein, Closed conformation, C3 symmetry | homo-3-mer | 100.0 | 3×NAG; 20×NAG; 3×EIC; | |||
| JN.1 Spike Trimer in complex with heparan sulfate | homo-3-mer | 75.0 | 54×NAG; 1×IDU; | |||
| SARS CoV-2 Spike protein, Closed conformation, C1 symmetry | homo-3-mer | 100.0 | 1×NAG; 25×NAG; 3×EIC; | |||
| Cryo-EM structure of SARS-CoV-2 Spike Proteins on intact virions: 3 Closed RBDs | homo-3-mer | 99.9 | 15×NAG; 33×NAG; | |||
| BA.2.86 Spike Trimer in complex with heparan sulfate | homo-3-mer | 75.0 | 1×NAG; 13×NAG; 34×NAG; 1×IDU; | |||
| Gaussian mixture model based single particle refinement - SARS (SARS-CoV-2 Spike Proteins on intact… | homo-3-mer | 99.9 | 15×NAG; 33×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 Delta variant spike proteins on intact virions: 3 Closed RBD | homo-3-mer | 99.61 | 15×NAG; 33×NAG; | |||
| Cryo-EM structure of bat RaTG13 spike glycoprotein | homo-3-mer | 95.95 | 9×NAG; 36×NAG; | |||
| SARS-CoV-2 spike protein in one-RBD open state | homo-3-mer | 99.81 | ||||
| Structure of the SARS-CoV-2 XBB.1 spike glycoprotein (closed-2 state) | homo-3-mer | 87.5 | 6×NAG; 36×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 Omicron EG.5.1 spike protein(6P), RBD-closed state | homo-3-mer | 83.33 | 27×NAG; | |||
| Structure of the SARS-CoV-2 XBB.1 spike glycoprotein (closed-1 state) | homo-3-mer | 87.5 | 9×NAG; 36×NAG; | |||
| SARS-CoV-2 spike protein in one-RBD weak state after CTSL-treatment | homo-3-mer | 99.81 | ||||
| SARS-CoV-2 Omicron Spike trimer | homo-3-mer | 97.78 | 28×NAG; | |||
| SARS-CoV-2 spike protein in two-RBD weak state after CTSL-treatment | homo-3-mer | 99.77 | ||||
| Structure of the SARS-CoV-2 EG.5.1 spike glycoprotein (closed-2 state) | homo-3-mer | 87.5 | 33×NAG; | |||
| SARS-CoV-2 S (Spike Glycoprotein) D614G with One(1) RBD Up | homo-3-mer | 99.71 | 3×NAG; 45×NAG; | |||
| Structure of SARS-CoV-2 Spike Protein with Engineered x3 Disulfide (x3(D427C, V987C) and single Arg… | homo-3-mer | 99.84 | 12×NAG; 39×NAG; 3×BLA; | |||
| Structure of Covid Spike variant deltaN135 in fully closed form | homo-3-mer | 100.0 | 48×NAG; | |||
| Prefusion-stabilized SARS-CoV-2 spike protein | homo-3-mer | 98.85 | ||||
| Alpha Variant SARS-CoV-2 Spike in Closed conformation | homo-3-mer | 100 | 9×NAG; 39×NAG; | |||
| pH 5.5 SARS-CoV-2 BA.2.75 S Trimer (1 RBD Up) | homo-3-mer | 100 | 9×NAG; 45×NAG; | |||
| SARS-CoV-2 BA.2.75 Spike with K356T mutation (1 RBD up) | homo-3-mer | 100 | 21×NAG; 21×NAG; | |||
| SARS-CoV-2 BA.2.75 S Trimer (1 RBD Up) | homo-3-mer | 100 | 9×NAG; 45×NAG; | |||
| Structure of Covid Spike variant deltaN135 with one erect RBD | homo-3-mer | 100.0 | 48×NAG; | |||
| Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody | homo-3-mer | 99.22 | 15×NAG; 30×NAG; | |||
| SARS-CoV-2 BA.2.75 Spike with K356T mutation (3 RBD down) | homo-3-mer | 100 | 21×NAG; 21×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 Spike Proteins on intact virions: Alpha (B.1.1.7) variant 3 closed … | homo-3-mer | 100.0 | 27×NAG; 3×NAG; 18×NAG; 1×ZN; | |||
| SARS-CoV-2 BA.2.75 S Trimer (3 RBD Down) | homo-3-mer | 100 | 6×NAG; 36×NAG; | |||
| SARS-CoV-2 BA.2.75 S Trimer (3 RBD Down) | homo-3-mer | 100 | 6×NAG; 9×NAG; 33×NAG; | |||
| Alpha Variant SARS-CoV-2 Spike with 1 Erect RBD | homo-3-mer | 100.0 | 7×NAG; 1×NAG; 33×NAG; | |||
| Cryo-EM structure of prefusion SARS-CoV-2 spike omicron B.1.1.529 variant | homo-3-mer | 97.67 | 38×NAG; | |||
| SARS-CoV-2 spike in prefusion state (flexibility analysis, 1-up open conformation) | homo-3-mer | 99.8 | 16×NAG; 4×NAG; 7×NAG; 18×NAG; 2×MAN; 3×DMS; | |||
| BA.2.86 Spike Trimer with ins483V mutation (3 RBD down) | homo-3-mer | 86.96 | 18×NAG; 30×NAG; | |||
| SARS-CoV-2 Omicron BA.3 variant spike | homo-3-mer | 97.5 | 12×NAG; 23×NAG; | |||
| SARS-CoV-2 spike glycoprotein trimer in Intermediate state | homo-3-mer | 100.0 | 8×NAG; 15×NAG; | |||
| BA.2.86 Spike Trimer with T356K mutation (1 RBD up) | homo-3-mer | 86.96 | 15×NAG; 30×NAG; | |||
| SARS-CoV-2 Omicron BA.4 variant spike | homo-3-mer | 100 | 18×NAG; 33×NAG; | |||
| BA.2.86 Spike Trimer with T356K mutation (3 RBD down) | homo-3-mer | 86.96 | 15×NAG; 30×NAG; | |||
| BA.2.86 Spike Trimer with ins483V mutation (1 RBD up) | homo-3-mer | 86.96 | 17×NAG; 31×NAG; | |||
| SARS-CoV-2 JN.1 Spike | homo-3-mer | 86.96 | 18×NAG; 30×NAG; | |||
| Beta Variant SARS-CoV-2 Spike with 2 Erect RBDs | homo-3-mer | 99.42 | 1×NAG; 20×NAG; | |||
| SARS-CoV-2 spike in prefusion state (flexibility analysis, 1-up closed conformation) | homo-3-mer | 99.8 | 16×NAG; 4×NAG; 7×NAG; 18×NAG; 2×MAN; 3×DMS; | |||
| Cryo-EM Structure of Full-Length Spike Protein of Omicron XBB.1.5 | homo-3-mer | 100 | 3×NAG; 19×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 Spike Proteins on intact virions: B.1 variant 3 closed RBDs | homo-3-mer | 99.8 | 27×NAG; 3×NAG; 18×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 Spike Proteins on intact virions: Mu (B.1.621) variant 3 closed RBDs | homo-3-mer | 99.31 | 27×NAG; 3×NAG; 18×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 Spike Proteins on intact virions: Delta (B.1.617.2) variant 3 close… | homo-3-mer | 98.11 | 21×NAG; 3×NAG; 24×NAG; | |||
| Apo spike protein from SARS-CoV2 | homo-3-mer | 99.47 | ||||
| Structure of SARS-CoV-2 Spike Protein Trimer (single Arg S1/S2 cleavage site) in Closed State | homo-3-mer | 100.0 | 12×NAG; 36×NAG; | |||
| Delta (B.1.617.2) SARS-CoV-2 variant spike protein (S-GSAS-Delta) in the 3-RBD-down conformation; S… | homo-3-mer | 99.06 | 14×NAG; 33×NAG; | |||
| SARS-CoV-2 D614G 1-RBD-up Spike Protein Trimer without the P986-P987 stabilizing mutations (S-GSAS-… | homo-3-mer | 99.9 | 12×NAG; 34×NAG; | |||
| SARS-CoV-2 rS2d Down State Spike Protein Trimer | homo-3-mer | 99.59 | ||||
| Cryo-EM structure of SARS-CoV-2 S-UK variant (B.1.1.7), two RBD-up conformation | homo-3-mer | 100.0 | 31×NAG; 16×NAG; | |||
| SARS-CoV-2 Omicron 1-RBD up Spike Protein Trimer without the P986-P987 stabilizing mutations (S-GSA… | homo-3-mer | 97.62 | 11×NAG; 8×NAG; 14×NAG; 15×NAG; | |||
| SARS-CoV-2 D614G 3 RBD down Spike Protein Trimer fully cleaved by furin without the P986-P987 stabi… | homo-3-mer | 99.9 | 15×NAG; 33×NAG; | |||
| S1-S2 deletion S-2P trimer(3 down) | homo-3-mer | 100.0 | ||||
| SARS-CoV-2 D614G 3 RBD down Spike Protein Trimer without the P986-P987 stabilizing mutations (S-GSA… | homo-3-mer | 99.9 | 15×NAG; 33×NAG; | |||
| Cryo-EM structure of a biotinylated SARS-CoV-2 spike probe in the prefusion state (1 RBD up) | homo-3-mer | 99.8 | 12×NAG; 35×NAG; | |||
| SARS-CoV-2 D614G 3 RBD down Spike Protein Trimer without the P986-P987 stabilizing mutations (S-GSA… | homo-3-mer | 99.9 | 15×NAG; 33×NAG; | |||
| Consensus structure of SARS-CoV-2 spike at pH 5.5 | homo-3-mer | 99.81 | 14×NAG; 28×NAG; | |||
| Delta (B.1.617.2) SARS-CoV-2 variant spike protein (S-GSAS-Delta) in the 1-RBD-up conformation; Sub… | homo-3-mer | 99.03 | 12×NAG; 34×NAG; | |||
| SARS-CoV-2 D614G 1RBD up Spike Protein Trimer without the P986-P987 stabilizing mutations (S-GSAS-D… | homo-3-mer | 99.9 | 12×NAG; 35×NAG; | |||
| SARS-CoV-2 u1S2q 1-RBD Up Spike Protein Trimer | homo-3-mer | 99.38 | ||||
| Structure of formaldehyde cross-linked SARS-CoV-2 S glycoprotein | homo-3-mer | 99.79 | 15×NAG; 33×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 S-UK variant (B.1.1.7), one RBD-up conformation 2 | homo-3-mer | 100.0 | 29×NAG; 1×NAG; 18×NAG; | |||
| SARS-CoV-2 RBD down Spike Protein Trimer without the P986-P987 stabilizing mutations (S-GSAS) | homo-3-mer | 100.0 | 15×NAG; 33×NAG; | |||
| Delta (B.1.617.2) SARS-CoV-2 variant spike protein (S-GSAS-Delta) in the 2-RBD-up conformation - D3 | homo-3-mer | 100.0 | 8×NAG; 36×NAG; | |||
| Structure of SARS-CoV-2 spike at pH 5.5, single RBD up, conformation 1 | homo-3-mer | 99.81 | 17×NAG; 26×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 Spike trimer S2D14 with two RBDs in the open conformation | homo-3-mer | 97.72 | 9×NAG; 3×NAG; 3×NAG; 24×NAG; | |||
| Delta (B.1.617.2) SARS-CoV-2 variant spike protein (S-GSAS-Delta) in the 1-RBD-up conformation; Sub… | homo-3-mer | 99.03 | 12×NAG; 34×NAG; | |||
| Structure of the prefusion SARS-CoV-2 spike glycoprotein | homo-3-mer | 99.8 | 11×NAG; 27×NAG; | |||
| Structure of SARS-CoV-2 spike at pH 4.0 | homo-3-mer | 99.81 | 15×NAG; 32×NAG; | |||
| Delta (B.1.617.2) SARS-CoV-2 variant spike protein (S-GSAS-Delta) in the 3-RBD-down conformation; c… | homo-3-mer | 99.06 | 14×NAG; 33×NAG; | |||
| SARS-CoV-2 D614G 3-RBD-down Spike Protein Trimer without the P986-P987 stabilizing mutations (S-GSA… | homo-3-mer | 99.9 | 15×NAG; 33×NAG; | |||
| Structure of SARS-CoV-2 spike at pH 5.5, single RBD up, conformation 2 | homo-3-mer | 99.81 | 18×NAG; 25×NAG; | |||
| SARS-CoV-2 D614G 1-RBD-up Spike Protein Trimer without the P986-P987 stabilizing mutations (S-GSAS-… | homo-3-mer | 99.9 | 12×NAG; 33×NAG; | |||
| SARS-CoV-2 u1S2q 2-RBD Up Spike Protein Trimer | homo-3-mer | 99.38 | ||||
| Delta (B.1.617.2) SARS-CoV-2 variant spike protein (S-GSAS-Delta) in the 1-RBD-up conformation; Sub… | homo-3-mer | 99.03 | 12×NAG; 34×NAG; | |||
| SARS-CoV-2 D614G 3 RBD down Spike Protein Trimer without the P986-P987 stabilizing mutations (S-GSA… | homo-3-mer | 99.9 | 15×NAG; 33×NAG; | |||
| Mink Cluster 5-associated SARS-CoV-2 spike protein (S-GSAS-D614G-delFV) in the 2-RBD up conformation | homo-3-mer | 100.0 | 31×NAG; | |||
| South African (B.1.351) SARS-CoV-2 spike protein variant (S-GSAS-B.1.351) in the 1-RBD-up conformat… | homo-3-mer | 99.4 | 28×NAG; | |||
| Delta (B.1.617.2) SARS-CoV-2 variant spike protein (S-GSAS-Delta) in the 1-RBD-up conformation; Sub… | homo-3-mer | 99.03 | 12×NAG; 34×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 Spike trimer S2D14 with two RBDs exposed | homo-3-mer | 97.73 | 11×NAG; 4×NAG; 32×NAG; | |||
| SARS-CoV-2 spike ectodomain structure (open state) | homo-3-mer | 99.69 | 12×NAG; 35×NAG; | |||
| SARS-CoV-2 spike protein in closed state | homo-3-mer | 99.8 | ||||
| SARS-CoV-2 Spike H655Y variant, One RBD Open | homo-3-mer | 99.63 | ||||
| Delta (B.1.617.2) SARS-CoV-2 variant spike protein (S-GSAS-Delta) in the 3-RBD-down conformation; S… | homo-3-mer | 99.06 | 14×NAG; 33×NAG; | |||
| SARS-CoV-2 spike glycoprotein trimer in open state | homo-3-mer | 100.0 | 5×NAG; 15×NAG; | |||
| Structure of SARS-CoV-2 spike at pH 5.5, all RBDs down | homo-3-mer | 99.81 | 16×NAG; 26×NAG; | |||
| SARS-CoV-2 Spike Glycoprotein, prefusion with one RBD up conformation | homo-3-mer | 99.79 | 12×NAG; 35×NAG; | |||
| Down-state locked rS2d SARS-CoV-2 spike ectodomain in the RBD-down conformation, State 1 | homo-3-mer | 99.59 | ||||
| South African (B.1.351) SARS-CoV-2 spike protein variant (S-GSAS-B.1.351) in the 1-RBD-up conformat… | homo-3-mer | 99.4 | 38×NAG; | |||
| SARS-CoV-2 D614G 3 RBD down Spike Protein Trimer without the P986-P987 stabilizing mutations (S-GSA… | homo-3-mer | 99.9 | 15×NAG; 33×NAG; | |||
| Mink Cluster 5-associated SARS-CoV-2 spike protein (S-GSAS-D614G-delFV) in the 1-RBD up conformation | homo-3-mer | 100 | 3×NAG; 30×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 Spike trimer S2D14 in the 3-RBD Down conformation | homo-3-mer | 97.69 | 18×NAG; 15×NAG; 15×NAG; | |||
| Triple mutant (K417N-E484K-N501Y) SARS-CoV-2 spike protein in the 3-RBD-Down conformation (S-GSAS-D… | homo-3-mer | 99.6 | ||||
| Delta (B.1.617.2) SARS-CoV-2 variant spike protein (S-GSAS-Delta) in the 1-RBD-up conformation; Sub… | homo-3-mer | 99.03 | 12×NAG; 34×NAG; | |||
| South African (B.1.351) SARS-CoV-2 spike protein variant (S-GSAS-B.1.351) in the 1-RBD-up conformat… | homo-3-mer | 99.4 | 38×NAG; | |||
| SARS-CoV-2 D614G 1-RBD-up Spike Protein Trimer without the P986-P987 stabilizing mutations (S-GSAS-… | homo-3-mer | 99.9 | 12×NAG; 35×NAG; | |||
| UK (B.1.1.7) SARS-CoV-2 spike protein variant (S-GSAS-B.1.1.7) in the 1-RBD-up conformation | homo-3-mer | 100 | 35×NAG; | |||
| UK (B.1.1.7) SARS-CoV-2 S-GSAS-D614G variant spike protein in the 3-RBD-down conformation | homo-3-mer | 100 | 18×NAG; 27×NAG; | |||
| Triple mutant (K417N-E484K-N501Y) SARS-CoV-2 spike protein in the 1-RBD-up conformation (S-GSAS-D61… | homo-3-mer | 99.6 | 12×NAG; 26×NAG; | |||
| Delta (B.1.617.2) SARS-CoV-2 variant spike protein (S-GSAS-Delta) in the 1-RBD-up conformation; con… | homo-3-mer | 99.03 | 12×NAG; 34×NAG; | |||
| Delta (B.1.617.2) SARS-CoV-2 variant spike protein (S-GSAS-Delta) in the 1-RBD-up conformation; Sub… | homo-3-mer | 99.03 | 12×NAG; 34×NAG; | |||
| Delta (B.1.617.2) SARS-CoV-2 variant spike protein (S-GSAS-Delta) in the 3-RBD-down conformation; S… | homo-3-mer | 99.06 | 14×NAG; 33×NAG; | |||
| Delta (B.1.617.2) SARS-CoV-2 variant spike protein (S-GSAS-Delta) in the 3-RBD-down conformation; S… | homo-3-mer | 99.06 | 14×NAG; 32×NAG; | |||
| Down-state locked rS2d SARS-CoV-2 spike ectodomain in the RBD-down conformation, State 2 | homo-3-mer | 99.59 | ||||
| Mink Cluster 5-associated SARS-CoV-2 spike protein (S-GSAS-D614G-delFV) in the 3-RBD down conformat… | homo-3-mer | 100 | 30×NAG; | |||
| South African (B.1.351) SARS-CoV-2 spike protein variant (S-GSAS-B.1.351) in the 2-RBD-up conformat… | homo-3-mer | 99.4 | 25×NAG; | |||
| Mink Cluster 5-associated SARS-CoV-2 spike protein (S-GSAS-D614G-delFV) in the 3-RBD down conformat… | homo-3-mer | 100 | 30×NAG; | |||
| Mink Cluster 5-associated SARS-CoV-2 spike protein (S-GSAS-D614G-delFV) in the 1-RBD up conformation | homo-3-mer | 100 | 3×NAG; 31×NAG; | |||
| South African (B.1.351) SARS-CoV-2 spike protein variant (S-GSAS-B.1.351) in the RBD-down conformat… | homo-3-mer | 99.3 | 33×NAG; | |||
| South African (B.1.351) SARS-CoV-2 spike protein variant (S-GSAS-B.1.351) in the 1-RBD-up conformat… | homo-3-mer | 99.4 | 40×NAG; | |||
| Mink Cluster 5-associated SARS-CoV-2 spike protein (S-GSAS-D614G-delFV) in the 1-RBD up conformation | homo-3-mer | 100 | 5×NAG; 27×NAG; | |||
| UK (B.1.1.7) SARS-CoV-2 spike protein variant (S-GSAS-B.1.1.7) in the 1-RBD-up conformation | homo-3-mer | 100 | 9×NAG; 30×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 S-UK variant (B.1.1.7), one RBD-up conformation 1 | homo-3-mer | 100.0 | 32×NAG; 1×NAG; 15×NAG; | |||
| UK (B.1.1.7) SARS-CoV-2 spike protein variant (S-GSAS-B.1.1.7) in the 1-RBD-up conformation | homo-3-mer | 100 | 34×NAG; | |||
| Delta (B.1.617.2) SARS-CoV-2 variant spike protein (S-GSAS-Delta) in the 3-RBD-down conformation; S… | homo-3-mer | 99.06 | 14×NAG; 33×NAG; | |||
| Structure of the SARS-CoV-2 spike glycoprotein (closed state) | homo-3-mer | 99.79 | 15×NAG; 33×NAG; | |||
| Structure of SARS-CoV-2 spike at pH 4.5 | homo-3-mer | 99.81 | 17×NAG; 30×NAG; | |||
| Delta (B.1.617.2) SARS-CoV-2 variant spike protein (S-GSAS-Delta) in the 1-RBD-up conformation; Sub… | homo-3-mer | 99.03 | 12×NAG; 34×NAG; | |||
| SARS-CoV-2 u1S2q All Down RBD State Spike Protein Trimer - asymmetric refinement | homo-3-mer | 99.38 | ||||
| Mink Cluster 5-associated SARS-CoV-2 spike protein (S-GSAS-D614G-delFV) in the 3-RBD down conformat… | homo-3-mer | 100 | 30×NAG; | |||
| Down-state locked, S2 stabilized rS2d-HexaPro SARS-CoV-2 spike ectodomain in the RBD-down conformat… | homo-3-mer | 99.18 | ||||
| Cryo-EM structure of a prefusion stabilized SARS-CoV-2 Spike (D614N, R682S, R685G, A892P, A942P and… | homo-3-mer | 99.58 | 3×NAG; 15×NAG; | |||
| Mink Cluster 5-associated SARS-CoV-2 spike protein (S-GSAS-D614G-delFV) in the 3-RBD down conformat… | homo-3-mer | 100 | 30×NAG; | |||
| South African (B.1.351) SARS-CoV-2 spike protein variant (S-GSAS-B.1.351) in the RBD-down conformat… | homo-3-mer | 99.3 | 28×NAG; | |||
| Characterization of the SARS-CoV-2 S Protein: Biophysical, Biochemical, Structural, and Antigenic A… | homo-3-mer | 99.8 | 12×NAG; 33×NAG; | |||
| Delta (B.1.617.2) SARS-CoV-2 variant spike protein (S-GSAS-Delta) in the 3-RBD-down conformation; S… | homo-3-mer | 99.06 | 14×NAG; 33×NAG; | |||
| SARS-CoV-2 Omicron 3-RBD down Spike Protein Trimer without the P986-P987 stabilizing mutations (S-G… | homo-3-mer | 97.62 | 4×NAG; 1×NAG; 26×NAG; | |||
| SARS-CoV-2 Omicron 3-RBD down Spike Protein Trimer without the P986-P987 stabilizing mutations (S-G… | homo-3-mer | 97.62 | 6×NAG; 3×NAG; 4×NAG; 3×NAG; 25×NAG; | |||
| Cryo-EM structure of the SARS-CoV-2 spike glycoprotein in complex with all-trans retinoic acid | homo-3-mer | 99.79 | 27×NAG; 3×REA; | |||
| Down-state locked, S2 stabilized rS2d-HexaPro SARS-CoV-2 spike ectodomain in the RBD-down conformat… | homo-3-mer | 99.18 | ||||
| SARS-CoV-2 u1S2q All Down RBD State Spike Protein Trimer | homo-3-mer | 99.38 | ||||
| SARS-CoV-2 B.1.1.7 Spike Glycoprotein trimer | homo-3-mer | 100 | 9×NAG; 23×NAG; | |||
| SARS-CoV-2 Omicron 1-RBD up Spike Protein Trimer without the P986-P987 stabilizing mutations (S-GSA… | homo-3-mer | 97.62 | 15×NAG; 2×NAG; 1×NAG; 21×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 S-UK variant (B.1.1.7), one RBD-up conformation 3 | homo-3-mer | 100.0 | 29×NAG; 1×NAG; 16×NAG; | |||
| SARS-CoV-2 RBD up Spike Protein Trimer without the P986-P987 stabilizing mutations (S-GSAS) | homo-3-mer | 100.0 | 58×NAG; | |||
| SARS-CoV-2 Omicron 1-RBD down Spike Protein Trimer without the P986-P987 stabilizing mutations (S-G… | homo-3-mer | 97.62 | 9×NAG; 22×NAG; | |||
| SARS-CoV-2 D614G 1-RBD-up Spike Protein Trimer fully cleaved by furin without the P986-P987 stabili… | homo-3-mer | 99.79 | 12×NAG; 35×NAG; | |||
| SARS-CoV-2 D614G 1-RBD up Spike Protein Trimer without the P986-P987 stabilizing mutations (S-GSAS-… | homo-3-mer | 99.9 | 12×NAG; 35×NAG; | |||
| Cryo-EM structure of Brazil (P.1) SARS-CoV-2 spike glycoprotein variant in the prefusion state (1 R… | homo-3-mer | 99.02 | 11×NAG; 29×NAG; | |||
| Cryo-EM structure of a prefusion stabilized SARS-CoV-2 Spike (D614N, R682S, R685G, A892P, A942P and… | homo-3-mer | 99.58 | 10×NAG; 10×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 Spike Proteins on intact virions: Alpha (B.1.1.7) variant 1 open RBD | homo-3-mer | 100 | 26×NAG; 3×NAG; 18×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 Spike Proteins on intact virions: Gamma (P.1) variant 3 closed RBDs | homo-3-mer | 99.29 | 27×NAG; 3×NAG; 18×NAG; | |||
| Cryo-EM structure of the Sars-Cov2 S trimer without RBDs | homo-3-mer | 100.0 | ||||
| VAS5 Spike (3 RBD down) | homo-3-mer | 100.0 | 14×NAG; 29×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 Spike D614G variant, one RBD-up conformation 1 | homo-3-mer | 99.7 | 2×NAG; 30×NAG; 16×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 Spike D614G variant, one RBD-up conformation 3 | homo-3-mer | 99.7 | 1×NAG; 29×NAG; 18×NAG; | |||
| S protein of SARS-CoV-2 D614G mutant | homo-3-mer | 99.69 | 22×NAG; 27×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 Spike D614G variant, one RBD-up conformation 2 | homo-3-mer | 99.7 | 3×NAG; 26×NAG; 19×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 Spike D614G variant, two RBD-up conformation 1 | homo-3-mer | 99.7 | 1×NAG; 28×NAG; 16×NAG; | |||
| SARS-CoV-2 HexaPro S One RBD up | homo-3-mer | 99.38 | 11×NAG; 28×NAG; | |||
| Trypsin-digested S protein of SARS-CoV-2 D614G mutant | homo-3-mer | 99.69 | 22×NAG; 27×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 Spike D614G variant, two RBD-up conformation 2 | homo-3-mer | 99.71 | 27×NAG; 20×NAG; | |||
| CryoEM structure of del68-76/del679-688 prefusion-stabilized spike | homo-3-mer | 100.0 | 9×NAG; 28×NAG; | |||
| S protein of SARS-CoV-2 bound with PD of ACE2 in the conformation 1 (1 up RBD and no PD bound) | homo-3-mer | 99.79 | 22×NAG; 27×NAG; | |||
| S protein of SARS-CoV-2 in the active conformation | homo-3-mer | 99.8 | 22×NAG; 27×NAG; | |||
| Trypsin-digested S protein of SARS-CoV-2 | homo-3-mer | 99.79 | 22×NAG; 27×NAG; | |||
| Cryo-EM structure of protein encoded by vaccine candidate BNT162b2 | homo-3-mer | 99.79 | ||||
| Prefusion 2019-nCoV spike glycoprotein with a single receptor-binding domain up | homo-3-mer | 99.79 | 17×NAG; 27×NAG; | |||
| SARS-CoV-2 E406W mutant Spike ectodomain | homo-3-mer | 99.27 | 6×NAG; 42×NAG; | |||
| Complex structure of a small molecule (SPC-14) bound SARS-CoV-2 spike protein, closed state | homo-3-mer | 99.81 | 3×Q83; 15×NAG; | |||
| Structure of freshly purified SARS-CoV-2 S2P spike at pH 7.4 | homo-3-mer | 99.78 | 14×NAG; 14×NAG; | |||
| XBB.1.5 Spike Trimer in complex with heparan sulfate | homo-3-mer | 100 | 48×NAG; 1×IDU; | |||
| Structure of aged SARS-CoV-2 S2P spike at pH 7.4 | homo-3-mer | 99.75 | 14×NAG; 13×NAG; | |||
| Structure of SARS-CoV-2 S2P spike at pH 7.4 refolded by low-pH treatment | homo-3-mer | 99.78 | 14×NAG; 14×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 Omicron JN.1 spike protein | homo-3-mer | 100 | 3×NAG; 1×NAG; 26×NAG; | |||
| Structure of apo SARS-CoV-2 spike protein with one RBD up | homo-3-mer | 99.8 | 13×NAG; | |||
| Spike Trimer of BA.2.86 with three RBDs down | homo-3-mer | 97.56 | 18×NAG; 30×NAG; | |||
| Spike Trimer of BA.2.86 with single RBD up | homo-3-mer | 97.56 | 17×NAG; 31×NAG; | |||
| Prefusion SARS-CoV-2 S ectodomain trimer covalently stabilized in the closed conformation | homo-3-mer | 99.58 | 9×NAG; 33×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 Spike ectodomain | homo-3-mer | 99.8 | 8×NAG; 1×NAG; 2×NAG; 2×NAG; 23×NAG; | |||
| Structure of Disulphide-stabilized SARS-CoV-2 Spike Protein Trimer (x1 disulphide-bond mutant, S383… | homo-3-mer | 99.83 | 12×NAG; 36×NAG; | |||
| Structure of Disulphide-stabilized SARS-CoV-2 Spike Protein Trimer (x2 disulphide-bond mutant, G413… | homo-3-mer | 99.83 | 15×NAG; 33×NAG; | |||
| Structural and biochemical rationale for Beta variant protein booster vaccine broad cross-neutraliz… | homo-3-mer | 99.33 | 1×NAG; 27×NAG; | |||
| Structure of SARS-CoV-2 Spike Protein with Engineered x3 Disulfide (x3(D427C, V987C) and single Arg… | homo-3-mer | 99.83 | 9×NAG; 3×BLA; 27×NAG; | |||
| Structural and biochemical rationale for Beta variant protein booster vaccine broad cross-neutraliz… | homo-3-mer | 99.68 | 35×NAG; | |||
| Structure of SARS-CoV-2 Spike Protein Trimer (K986P, V987P, single Arg S1/S2 cleavage site) in Clos… | homo-3-mer | 100.0 | 15×NAG; 33×NAG; | |||
| Structure of SARS-CoV-2 D614G Spike Protein with Engineered x3 Disulfide (x3(D427C, V987C) and sing… | homo-3-mer | 99.61 | 6×NAG; 3×BLA; 30×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 Omicron BA.2.86 spike protein(6P), 1-RBD-up state | homo-3-mer | 97.37 | 6×NAG; 24×NAG; | |||
| SARS CoV-2 Spike protein, Bristol UK Deletion variant, Closed conformation, C3 symmetry | homo-3-mer | 100.0 | 3×EIC; 33×NAG; | |||
| One RBD up state of Spike glycoprotein, SARS-CoV-2 | homo-3-mer | 100.0 | 15×NAG; 1×NAG; 5×NAG; 21×NAG; | |||
| SARS CoV-2 Spike protein, Bristol UK Deletion variant, Closed conformation, C1 symmetry | homo-3-mer | 100.0 | 3×EIC; 30×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 Omicron HV.1 spike protein(6P), RBD-closed state | homo-3-mer | 97.17 | 38×NAG; | |||
| Cryo-EM structure of SARS-CoV-2 Omicron EG.5 spike protein(6P), RBD-closed state | homo-3-mer | 98.09 | 27×NAG; | |||
| Structure of the SARS-CoV-2 XBB.1.5 spike glycoprotein (closed state 2) | homo-3-mer | 98.0 | 6×NAG; 36×NAG; | |||
| Structure of the SARS-CoV-2 BA.2.86 spike protein (1-up state) | homo-3-mer | 97.44 | 7×NAG; 35×NAG; | |||
| Structure of the SARS-CoV-2 BA.2.86 spike glycoprotein (closed state) | homo-3-mer | 97.5 | 6×NAG; 39×NAG; | |||
| Structure of the SARS-CoV-2 XBB.1.5 spike glycoprotein (closed state 1) | homo-3-mer | 98.11 | 9×NAG; 36×NAG; | |||
| SARS-CoV-2 Spike D614G variant, minus RBD | homo-3-mer | 99.72 | ||||
| Cryo-EM structure of SARS-CoV-2 postfusion spike in membrane | homo-3-mer | 100.0 | 6×NAG; 3×NAG; 6×NAG; 3×MAN; 9×NAG; | |||
| Nanometer resolution in situ structure of SARS-CoV-2 post-fusion spike | homo-3-mer | 100.0 | 3×NAG; 9×NAG; 9×NAG; | |||
| Cryo-EM structure of S glycoprotein encoded by the Covid-19 mRNA vaccine candidate RQ3013 (Postfusi… | homo-3-mer | 100.0 | 6×NAG; 6×NAG; 3×NAG; 9×NAG; 3×MAN; | |||
| Distinct conformational states of SARS-CoV-2 spike protein | homo-3-mer | 100.0 | 6×NAG; 6×NAG; 3×NAG; 9×NAG; 3×MAN; | |||
| Structure of the SARS-CoV-2 spike glycoprotein S2 subunit | homo-3-mer | 98.2 | 18×NAG; | |||
| Prefusion stabilized structure of the SARS-CoV-2 fusion machinery | homo-3-mer | 96.99 | 12×NAG; 6×NAG; | |||
| Prefusion stabilized structure of the SARS-CoV-2 fusion machinery | homo-3-mer | 98.12 | 9×NAG; 9×NAG; | |||
| Prefusion stabilized structure of the SARS-CoV-2 fusion machinery | homo-3-mer | 96.05 | 12×NAG; 6×NAG; | |||
| Prefusion-stabilized SARS-CoV-2 S2 subunit | homo-3-mer | 98.28 | ||||
| Simulation-driven design of prefusion stabilized SARS-CoV-2 spike S2 antigen | homo-3-mer | 97.48 | 9×NAG; | |||
| Structure of post fusion core of SARS-CoV-2 S2 subunit | homo-3-mer | 100.0 | ||||
| Structure of post fusion core of 2019-nCoV S2 subunit | homo-3-mer | 100 | 2×PG4; 4×ZN; | |||
| Crystal structure of post fusion core of 2019-nCoV S2 subunit | homo-3-mer | 100 | ||||
| Crystal Structure of SARS-CoV-2 HR1 motif in complex with pan-CoVs inhibitor EK1 | homo-3-mer | 100.0 | ||||
| SARS-CoV-2 spike Protein TM domain | homo-3-mer | 76.19 | ||||
| Crystal structure of the recombinant protein HR121 from the S2 protein of SARS-CoV-2 | homo-2-mer | 100.0 | ||||
| Cryo-EM structure of S protein trimer of SARS-CoV2 | monomer | 100 | ||||
| BA.2.86-T356K Spike Trimer in complex with heparan sulfate (Local refinement) | monomer | 75.0 | 1×NAG; 6×NAG; 1×IDU; | |||
| Crystal structure of SARS-CoV-2 spike protein N-terminal domain in complex with biliverdin | monomer | 100 | 1×BLA; 7×NAG; 2×PG4; 3×PEG; 3×PGE; 1×1PE; | |||
| Cryo-EM structure of SARS-CoV-2 Omicron BA.2 spike protein (focused refinement of NTD) | monomer | 90.0 | 1×NAG; 4×NAG; | |||
| Local CryoEM structure del68-76/del679-688 prefusion-stabilized spike | monomer | 100 | ||||
| SARS-CoV-2 Omicron BA.3 variant spike (local) | monomer | 94.38 | 2×NAG; | |||
| Crystal structure of SARS-CoV-2 S RBD in complex with a stapled peptide | monomer | 100 | 3×GOL; 1×KZ0; | |||
| Crystal structure of the SARS-CoV-2 receptor binding domain | monomer | 100 | 1×NAG; 2×NAG; 1×FUC; 5×GOL; | |||
| SARS-CoV-2 E406W mutant RBD - Local Refinement | monomer | 99.48 | 1×NAG; | |||
| Membrane bound structure of HR1 domain of SARS-CoV-2 spike protein | monomer | 100 | ||||
| Fusion Peptide of SARS-CoV-2 Spike Rearranges into a Wedge Inserted in Bilayered Micelles | monomer | 97.62 | ||||
| NMR structure of a peptide deriving from SARS-CoV-2 S RBD 482-506 fragment in HFIP/H2O | monomer | 100 | ||||
| NMR structure of a peptide deriving from SARS-CoV-2 Lineages P.1 and B.1.351 S RBD 482-506 fragment… | monomer | 92.0 | ||||
| NMR structure of a peptide deriving from SARS-CoV-2 Lineage B.1.1.7 S RBD 482-506 fragment in HFIP/… | monomer | 96.0 | ||||
3 SWISS-MODEL models
| Template | Oligo-state | QMEAN | Range | Ligands | Trg-Tpl Seq id (%) | |
|---|---|---|---|---|---|---|
| 7mjm.1 |
Heteromer P0DTC2; Q9BYF1; | 0.77 | 99.45 | |||
| 6xr8.1.A | homo-3-mer | 0.74 | 6×NAG; 2×NAG; 1×NAG; 2×NAG; | 100.00 | ||
| 7kj2.1 |
Heteromer P0DTC2; Q9BYF1; | 0.72 | 4×NAG; 10×NAG; | 99.67 | ||